<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006478" GROUP_ID="WOUNDS" ID="333906013012561352" MERGED_FROM="" MODIFIED="2010-02-16 17:10:02 +0100" MODIFIED_BY="Sally Bell-Syer" REVIEW_NO="120" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-02-16 17:10:02 +0100" MODIFIED_BY="Sally Bell-Syer">
<TITLE MODIFIED="2008-06-10 16:12:06 +0100" MODIFIED_BY="[Empty name]">Topical silver for preventing wound infection</TITLE>
<CONTACT MODIFIED="2010-02-16 17:10:02 +0100" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="62EBE90E82E26AA20003EB8A563D84C8" ROLE="AUTHOR"><FIRST_NAME>Marja</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Storm-Versloot</LAST_NAME><EMAIL_1>m.n.storm@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>Academic Medical Centre at the University of Amsterdam</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1105 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5662767</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-02-16 17:10:02 +0100" MODIFIED_BY="Sally Bell-Syer"><PERSON ID="62EBE90E82E26AA20003EB8A563D84C8" ROLE="AUTHOR"><FIRST_NAME>Marja</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Storm-Versloot</LAST_NAME><EMAIL_1>m.n.storm@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>Academic Medical Centre at the University of Amsterdam</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1105 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5662767</PHONE_1></ADDRESS></PERSON><PERSON ID="D860C1AF82E26AA201E74FE9CE641862" ROLE="AUTHOR"><FIRST_NAME>Cornelis</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Vos</LAST_NAME><EMAIL_1>niels_vos15@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>Academic Medical Centre at the University of Amsterdam</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1105 AZ</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5662767</PHONE_1></ADDRESS></PERSON><PERSON ID="15807" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dirk</FIRST_NAME><MIDDLE_INITIALS>T</MIDDLE_INITIALS><LAST_NAME>Ubbink</LAST_NAME><POSITION>Physician and Clinical Epidemiologist</POSITION><EMAIL_1>d.ubbink@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Quality Assurance &amp; Process Innovation</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam</ORGANISATION><ADDRESS_1>J1b-215 Academic Medical Centre</ADDRESS_1><ADDRESS_2>Meibergdreef 9, PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1100 DE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON><PERSON ID="15812" ROLE="AUTHOR"><FIRST_NAME>Hester</FIRST_NAME><LAST_NAME>Vermeulen</LAST_NAME><POSITION>Senior Research Nurse</POSITION><EMAIL_1>h.vermeulen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Quality Assurance &amp; Process Innovation</DEPARTMENT><ORGANISATION>Academic Medical Centre, University of Amsterdam</ORGANISATION><ADDRESS_1>Meibergdreef 9</ADDRESS_1><ADDRESS_2>PO Box 22700</ADDRESS_2><CITY>Amsterdam</CITY><ZIP>1100 DE</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-02-16 15:08:38 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="2" MONTH="11" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="5" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-28 15:29:06 +0000" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2009-10-28 15:29:06 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-28 15:29:06 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-21 08:48:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-06-03 17:02:57 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="1" YEAR="2007"/>
<DESCRIPTION>
<P>protocol published</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-09-17 17:55:04 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-09-17 17:55:04 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-09-17 17:55:04 +0100" MODIFIED_BY="[Empty name]">
<NAME>Academic Medical Center; Amsterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-02-16 13:54:07 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-02-02 13:52:27 +0000" MODIFIED_BY="Elizabeth Royle">Probable that silver-containing dressings and creams do not prevent wound infection or promote healing </TITLE>
<SUMMARY_BODY MODIFIED="2010-02-16 13:54:07 +0000" MODIFIED_BY="[Empty name]">
<P>Wound dressings and creams containing silver are widely used. It is thought that silver may help wounds to heal faster and prevent infection, but we did not know if this was true. This review identified 26 trials (involving 2066 participants) comparing silver-containing dressings or creams against dressings or creams that did not contain silver. Twenty of the trials were on burn wounds, while the other trials were on a mixture of wound types. Most studies were small and of poor quality. After examining them all, the authors concluded that there is not enough evidence to support the use of silver-containing dressings or creams, as generally these treatments did not promote wound healing or prevent wound infections. Some evidence from a number of small, poor-quality studies suggested that one silver-containing compound (silver sulphadiazine) has no effect on infection, and actually slows down healing in patients with partial-thickness burns.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-02-16 14:21:25 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-02-02 13:30:38 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Silver-containing treatments are popular and used in wound treatments to combat a broad spectrum of pathogens, but evidence of their effectiveness in preventing wound infection or promoting healing is lacking.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-02-16 13:53:54 +0000" MODIFIED_BY="[Empty name]">
<P>To establish the effects of silver-containing wound dressings and topical agents in preventing wound infection and healing of wounds.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-02-02 13:31:02 +0000" MODIFIED_BY="Elizabeth Royle">
<P>We searched the Cochrane Wounds Group Specialised Register (6 May 2009); The Cochrane Central Register of Controlled Trials (CENTRAL) (2009 Issue 2); Ovid MEDLINE (1950 to April Week 4 2009); Ovid EMBASE (1980 to 2009 Week 18); EBSCO CINAHL (1982 to April Week 4 2009) and Digital Dissertations (to May 2009) for relevant trials. We contacted manufacturers and distributors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-02-02 13:31:12 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomised controlled trials (RCTs) comparing silver-containing wound dressings and topical agents with silver-containing and non silver-containing comparators on uninfected wounds.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-02-02 13:31:22 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Two authors independently selected trials, assessed risk of bias, and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-02-16 14:21:25 +0000" MODIFIED_BY="[Empty name]">
<P>We identified 26 RCTs (2066 patients). Heterogeneity of treatments and outcomes precluded meta-analysis. We grouped results according to wound type, and silver preparation.</P>
<P>
<B>Burns</B>
</P>
<P>Thirteen trials compared topical silver (in a variety of formulations - including silver sulphadiazine (SSD) cream) with non-silver dressings. One trial showed fewer infections with silver nitrate when compared with a non-silver dressing, but three trials showed significantly more infection with SSD than with the non-silver dressing.</P>
<P>Six trials compared SSD cream with silver-containing dressings. One showed significantly fewer infections with the silver-containing dressing (Hydron AgSD) compared with SSD, the remaining five found no evidence of a difference. </P>
<P>One trial compared two silver-containing dressings, and showed a significantly lower infection rate with silver-coated gauze (Acticoat®) than with silver nitrate gauze.</P>
<P>
<B>Other wounds</B>
</P>
<P>Six trials compared SSD/silver-containing dressings with non-silver dressings (nine dressings in total). Most comparisons (seven) found no significant differences in infection rates; one trial in a variety of wounds exhibited significantly fewer infections with SSD/hydrocolloid, but another, in acute wounds, found significantly more infections with SSD. Only one comparison showed a significant reduction in healing time associated with a silver-containing hydrofibre dressing in diabetic foot ulcers. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-02-02 13:37:14 +0000" MODIFIED_BY="Elizabeth Royle">
<P>There is insufficient evidence to establish whether silver-containing dressings or topical agents promote wound healing or prevent wound infection; some poor quality evidence for SSD suggests the opposite.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-02-16 13:54:11 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2010-02-02 13:59:40 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Wounds are a prevalent clinical problem and a burden to many patients, resulting in pain, discomfort, longer hospital stay, and considerable economic costs for the healthcare system. Wounds are either acute or chronic, and can result from venous or arterial insufficiency, diabetes, burns, trauma, chronic pressure or surgery (<LINK REF="REF-O_x0027_Meara-2001" TYPE="REFERENCE">O'Meara 2001</LINK>; <LINK REF="REF-O_x0027_Meara-2008" TYPE="REFERENCE">O'Meara 2008</LINK>). If wounds become contaminated with bacteria or clinically infected, wound healing is likely to be impaired (<LINK REF="REF-Ovington-2003" TYPE="REFERENCE">Ovington 2003</LINK>). This holds true for both acute and chronic wounds. In addition, wound infection is one of the most common surgical complications (<LINK REF="REF-Wilson-2004" TYPE="REFERENCE">Wilson 2004</LINK>), and leads to significant mortality and morbidity. The focus in wound care, therefore, is to prevent wound infection and to promote wound healing.</P>
<P>Prevention of wound infection has always been a challenge. It was not until the late eighteenth century that micro-organisms were recognised as the cause of infectious diseases, and the principles of asepsis and hygiene began to be more fully understood (germ theory, as developed by Pasteur during the period 1860 to 1863, and Lister's development of antiseptic surgery) (<LINK REF="REF-Abedon-1998" TYPE="REFERENCE">Abedon 1998</LINK>). Good hygiene and use of antiseptics were initially considered effective strategies for the prevention of infection, including wound infection. Nurses developed stringent hygiene rules for dressing changes (<LINK REF="REF-Arrowsmith-2001" TYPE="REFERENCE">Arrowsmith 2001</LINK>; <LINK REF="REF-Fernandez-2008" TYPE="REFERENCE">Fernandez 2008</LINK>; <LINK REF="REF-Lethaby-2008" TYPE="REFERENCE">Lethaby 2008</LINK>; <LINK REF="REF-Moore-2005" TYPE="REFERENCE">Moore 2005</LINK>), and physicians experimented with various antiseptics. Some of these preventative actions have been investigated for their effectiveness in various types of wounds, including aseptic dressing techniques (<LINK REF="REF-Lawson-2003" TYPE="REFERENCE">Lawson 2003</LINK>; <LINK REF="REF-Stotts-1997" TYPE="REFERENCE">Stotts 1997</LINK>), hand-rubbing (<LINK REF="REF-Kac-2005" TYPE="REFERENCE">Kac 2005</LINK>; <LINK REF="REF-Moralejo-2003" TYPE="REFERENCE">Moralejo 2003</LINK>; <LINK REF="REF-Rossoff-1995" TYPE="REFERENCE">Rossoff 1995</LINK>; <LINK REF="REF-Rotter-1997" TYPE="REFERENCE">Rotter 1997</LINK>; <LINK REF="REF-Tanner-2008" TYPE="REFERENCE">Tanner 2008</LINK>), sterile gloving (<LINK REF="REF-Adeyemo-2005" TYPE="REFERENCE">Adeyemo 2005</LINK>; <LINK REF="REF-Perelman-2004" TYPE="REFERENCE">Perelman 2004</LINK>), shaving (<LINK REF="REF-Balthazar-1982" TYPE="REFERENCE">Balthazar 1982</LINK>; <LINK REF="REF-Tang-2001" TYPE="REFERENCE">Tang 2001</LINK>; <LINK REF="REF-Tanner-2006" TYPE="REFERENCE">Tanner 2006</LINK>), and skin disinfection (<LINK REF="REF-Edwards-2004" TYPE="REFERENCE">Edwards 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-02-16 13:54:11 +0000" MODIFIED_BY="[Empty name]">
<P>Several antiseptic dressings or agents are available, each claiming advantages regarding wound healing or prevention of wound infection. The effectiveness of antiseptics such as povidone iodine, chlorhexidine, alcohol, and silver-based compounds against microorganisms has been studied in vitro as well as in vivo (<LINK REF="REF-Brooks-2001" TYPE="REFERENCE">Brooks 2001</LINK>; <LINK REF="REF-Kucan-1981" TYPE="REFERENCE">Kucan 1981</LINK>; <LINK REF="REF-Lammers-1990" TYPE="REFERENCE">Lammers 1990</LINK>; <LINK REF="REF-Nagl-2003" TYPE="REFERENCE">Nagl 2003</LINK>; <LINK REF="REF-Vogt-2001" TYPE="REFERENCE">Vogt 2001</LINK>; <LINK REF="REF-Wilson-1986" TYPE="REFERENCE">Wilson 1986</LINK>). In particular, silver-based compounds (e.g. silver sulphadiazine cream (SSD)) have been widely used on burns since the 1960s in an attempt to overcome the problem of wound infection (<LINK REF="REF-Hartford-1981" TYPE="REFERENCE">Hartford 1981</LINK>), and increasingly, silver-containing dressings and topical applications are being used to prevent infection in non-burn wounds such as leg ulcers (<LINK REF="REF-Karlsmark-2003" TYPE="REFERENCE">Karlsmark 2003</LINK>), diabetic foot ulcers (<LINK REF="REF-Bergin-2006" TYPE="REFERENCE">Bergin 2006</LINK>), fingertips (<LINK REF="REF-Jakobsen-1993" TYPE="REFERENCE">Jakobsen 1993</LINK>), and pressure ulcers (<LINK REF="REF-Dowsett-2004" TYPE="REFERENCE">Dowsett 2004</LINK>). There is a growing number of silver-containing dressings and topical agents available for the treatment of skin wounds, including creams such as SSD, silver salts such as silver nitrate, alginates (e.g. Silvercel®), foams (e.g. Avance, Contreet Ag), hydrofibres (e.g. Aquacel® Ag), hydrocolloids (e.g. SSD/hydrocolloid, Contreet Ag) and polymeric films and meshes (e.g. Arglaes), including metallic, nanocrystalline (e.g. Acticoat®) or ionic silver (Aquacel® Ag).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-02-02 14:07:51 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Silver ions bind to the DNA of bacteria and bacterial spores, thus reducing their ability to replicate (<LINK REF="REF-Ballard-2002" TYPE="REFERENCE">Ballard 2002</LINK>; <LINK REF="REF-Cooper-2004" TYPE="REFERENCE">Cooper 2004</LINK>). Furthermore, silver is reported to be effective against all known bacteria, fungi and some viruses (<LINK REF="REF-Ovington-2001" TYPE="REFERENCE">Ovington 2001</LINK>). Few bacteria have been shown to develop resistance to silver (resistance is a major problem associated with use of antibiotics). Silver has also been described as effective against malodour (<LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>). The various silver-containing dressings differ in the way the Ag<SUP>+</SUP> ions are released. Mostly, Ag<SUP>+</SUP> ions are released from the dressing through oxidation when the silver atoms come into contact with fluid. The silver can be incorporated as complex silver molecules in creams, ointments, hydrocolloids, hydrogels or foam dressings, which regulate the speed of delivery. Recent products have been produced in an attempt to ensure a more controlled and prolonged release of small (nanocrystalline) silver particles into the wound area. This nanocrystalline form releases silver ions faster than the normal silver materials, and, therefore, is claimed to have increased antimicrobial activity (<LINK REF="REF-Dunn-2004" TYPE="REFERENCE">Dunn 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-02-03 10:01:21 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Silver-containing dressings have become popular despite the absence of a robust summary of the evidence for their role in preventing wound infection, and encouraging wound healing (<LINK REF="REF-Brett-2006" TYPE="REFERENCE">Brett 2006</LINK>). The effect of silver-containing wound dressings and topical applications as treatments for infected wounds is the subject of a related review (<LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK>), which identified little evidence of effectiveness. It is timely, therefore, to conduct a systematic review of the effects of silver-containing dressings and topical agents for the prevention of wound infection and the promotion of wound healing in uninfected wounds.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-10-28 16:31:45 +0000" MODIFIED_BY="[Empty name]">
<P>To summarise the evidence for the effects of silver-containing dressings and topical agents compared with non-silver dressings and topical agents in terms of preventing of wound infections and/or promoting wound healing.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-02-16 13:54:12 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-02-10 18:00:09 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-12-04 11:42:09 +0000" MODIFIED_BY="Elizabeth Royle">
<P>We considered all randomised controlled trials (RCTs), both published and unpublished, that evaluated the effects of silver-containing dressings and topical agents (used alone or in combination with other dressings/agents), in preventing infection or promoting the healing, or both, of uninfected wounds of any aetiology (cause) and in any care setting.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-09-17 12:17:44 +0100" MODIFIED_BY="[Empty name]">
<P>Men and women aged 18 years and over with any type of wound (not diagnosed as infected at baseline) in any care setting.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-02-10 18:00:09 +0000" MODIFIED_BY="[Empty name]">
<P>Wound dressings and topical applications containing silver.</P>
<P>Eligible comparisons were:</P>
<OL>
<LI>topical silver-containing agents compared with topical agents without silver;</LI>
<LI>dressings containing silver compared with any dressings without silver (including dressings containing other antiseptics);</LI>
<LI>comparisons between alternative topical preparations of silver (e.g. SSD cream);</LI>
<LI>comparisons between alternative silver-containing dressings, including dose comparisons.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-02-03 10:54:25 +0000" MODIFIED_BY="Elizabeth Royle">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-02-03 10:54:25 +0000" MODIFIED_BY="Elizabeth Royle">
<OL>
<LI>Wound infection rate (<LINK REF="REF-Cutting-2005" TYPE="REFERENCE">Cutting 2005</LINK>; <LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>; <LINK REF="REF-McLaws-2000" TYPE="REFERENCE">McLaws 2000</LINK>): infection was defined as localised pain and swelling, spreading erythema (redness), appearance of a purulent exudate, odour, and the presence of a positive bacterial culture with more than 10<SUP>5 </SUP>colony-forming units per mm<SUP>3</SUP> tissue (<LINK REF="REF-Mangram-1999" TYPE="REFERENCE">Mangram 1999</LINK>). Trial authors' definitions of infection (e.g. critical colonisation) were also accepted.</LI>
<LI>Wound healing: this was measured as time to complete healing, rate of change in wound area or volume, or both, or time to skin grafting.</LI>
</OL>
<P>We decided to promote the outcome of wound healing from a secondary to a primary outcome after publication of the review protocol, since it is the most important outcome for patients.</P>
<P>The outcome of time to skin grafting was also added post-protocol. Although the appropriateness of a wound for skin graft is a subjective judgement, skin grafting is only undertaken on clean and granulating wounds. We judged these post-protocol changes to be unlikely to introduce bias to the review.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-12-04 11:50:09 +0000" MODIFIED_BY="Elizabeth Royle">
<UL>
<LI>Adverse events;</LI>
<LI>rate of use of systemic antibiotics;</LI>
<LI>pain;</LI>
<LI>patient satisfaction;</LI>
<LI>health related quality of life (HRQoL);</LI>
<LI>length of hospital stay (LOS);</LI>
<LI>costs.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-02-10 14:42:56 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-02-10 14:42:56 +0000" MODIFIED_BY="[Empty name]">
<P>The following electronic databases were searched:</P>
<OL>
<LI>Cochrane Wounds Group Specialised Register (Searched 6 May 2009);</LI>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2009);</LI>
<LI>Ovid MEDLINE (1950 to April Week 4 2009);</LI>
<LI>Ovid EMBASE (1980 to 2009 Week 18);</LI>
<LI>EBSCO CINAHL (1982 to April Week 4 2009);</LI>
<LI>Digital dissertations at http://www.umi.com (to October 2008).</LI>
</OL>
<P>The following search strategy was used in the Cochrane Central Register of Controlled Trials (CENTRAL):<BR/>#1 MeSH descriptor Wound Infection explode all trees<BR/>#2 (wound* NEAR/5 infect*):ti,ab,kw<BR/>#3 (#1 OR #2)<BR/>#4 MeSH descriptor Skin Ulcer explode all trees<BR/>#5 MeSH descriptor Diabetic Foot explode all trees<BR/>#6 MeSH descriptor Pressure Ulcer explode all trees<BR/>#7 MeSH descriptor Wounds, Penetrating explode all trees<BR/>#8 MeSH descriptor Lacerations explode all trees<BR/>#9 MeSH descriptor Burns explode all trees<BR/>#10 MeSH descriptor Bites and Stings explode all trees<BR/>#11 MeSH descriptor Surgical Wound Dehiscence explode all trees<BR/>#12 MeSH descriptor Wound Healing explode all trees<BR/>#13 (skin NEXT ulcer*) or (foot NEXT ulcer*) or (feet NEAR/5 ulcer*) or (diabetic NEXT foot) or (diabetic NEXT ulcer*) or (leg NEXT ulcer*) or (varicose NEXT ulcer*) or (varicose NEAR/5 wound*) or (venous NEXT ulcer*) or (stasis NEXT ulcer*) or (arterial NEXT ulcer*):ti,ab,kw<BR/>#14 ((ischaemic or ischemic) NEXT (wound* or ulcer*)):ti,ab,kw<BR/>#15 (bed NEXT sore*) or (pressure NEXT sore*) or (pressure NEXT ulcer*) or (decubitus NEXT ulcer*):ti,ab,kw<BR/>#16 (surgical NEXT wound*):ti,ab,kw<BR/>#17 ("gun" or guns or gunshot):ti,ab,kw<BR/>#18 ("stab" or stabs or stabbing):ti,ab,kw<BR/>#19 (burn or burns or scald*):ti,ab,kw<BR/>#20 (bite or bites or biting):ti,ab,kw<BR/>#21 laceration*:ti,ab,kw<BR/>#22 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)<BR/>#23 (infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital*):ti,ab,kw<BR/>#24 (positive NEAR/5 culture*):ti,ab,kw<BR/>#25 (pain* NEAR/5 wound*):ti,ab,kw<BR/>#26 (dirty NEAR/5 wound*):ti,ab,kw<BR/>#27 (#23 OR #24 OR #25 OR #26)<BR/>#28 MeSH descriptor Silver explode all trees<BR/>#29 MeSH descriptor Silver Sulfadiazine explode all trees<BR/>#30 (silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina):ti,ab,kw<BR/>#31 (#28 OR #29 OR #30)<BR/>#32 (#22 AND #27 AND #31)<BR/>#33 (#3 AND #31)<BR/>#34 (#32 OR #33)<BR/>
<BR/>The Ovid MEDLINE, Ovid EMBASE and EBSCO CINAHL search strategies can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> respectively. The MEDLINE search was combined with the Cochrane Highly Sensitive Search Strategy for identifying reports of randomised controlled trials in MEDLINE ( the sensitivity- and precision-maximising version (2008 revision)) Ovid format (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). The EMBASE and CINAHL searches were combined with the trial filters developed by the Scottish Intercollegiate Guidelines Network (<LINK REF="REF-SIGN-2008" TYPE="REFERENCE">SIGN 2008</LINK>). No date or language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-21 14:03:36 +0100" MODIFIED_BY="[Empty name]">
<P>We also contacted companies, manufacturers and distributors of silver dressings for details of unpublished and ongoing trials and scrutinised citations within all obtained trials and major review articles to identify any additional trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-02-16 13:54:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-12-04 12:16:38 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Two review authors (HV and DU) independently assessed the titles and abstracts of studies identified from the search in terms of their relevance and design. Full text versions of articles were obtained if, from the initial assessment, it was suggested they might meet the inclusion criteria. Another review author (either CV or MS) assessed those studies where there was disagreement.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-02-03 10:19:22 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Details of selected trials were extracted and summarised using a data extraction sheet. Data from trials published in duplicate were included only once. Data extraction was undertaken by one review author (CV), and checked for accuracy by a second (MS). Any discrepancy was resolved by discussion.<BR/>
<BR/>We extracted the following data.<BR/>
</P>
<UL>
<LI>Characteristics of the trial (method of randomisation, setting, location of care, country, source of funding).</LI>
<LI>Participants (number, type of wound(s), definition used to determine infection, wound size, duration of wound, length of follow-up, co-morbidities).</LI>
<LI>Intervention (type of silver dressing or topical silver, dose of silver, frequency of dressing changes, co-interventions).</LI>
<LI>Comparative intervention (type of dressing or topical application, dose of silver (where applicable), number of dressing changes, co-interventions).</LI>
<LI>Primary outcomes: rate of wound infection; wound healing.</LI>
<LI>Secondary outcomes: number and proportion of adverse events; rate of use of systemic antibiotics; pain; patient satisfaction; quality of life (QoL); length of hospital stay (LOS), and cost of treatment.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-02-16 13:54:12 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (CV and MS) independently assessed the risk of bias of each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Any disagreement was referred to a third review author (DU) for adjudication.</P>
<P>The following criteria were applied, and graded, as follows:</P>
<P>1. Sequence generation: was the allocation sequence randomly generated? Yes/No/Unclear</P>
<P>2. Allocation concealment: was allocation adequately concealed? Yes/No/Unclear</P>
<P>3. Blinding: was knowledge of the allocated interventions prevented adequately during the study?</P>
<UL>
<LI>Was the participant blinded to the intervention? Yes/No/Unclear</LI>
<LI>Was the care provider blinded to the intervention?  Yes/No/Unclear</LI>
<LI>Was the outcome assessor blinded to the intervention? Yes/No/Unclear</LI>
</UL>
<P>4. Incomplete outcome data: were incomplete outcome data adequately addressed?</P>
<UL>
<LI>Was the drop-out rate described and acceptable (i.e. &lt; 20%) Yes/No/Unclear</LI>
<LI>Were all randomised participants analysed in the group to which they were allocated? (i.e. using intention-to-treat (ITT) analysis) Yes/No/Unclear</LI>
</UL>
<P>Other sources of potential bias:</P>
<UL>
<LI>Were the groups similar at baseline for the most important prognostic indicators? Yes/No/Unclear</LI>
<LI>Was the trial sponsored by a manufacturer who had a potential interest in the results? Yes/No/Unclear</LI>
<LI>Were co-interventions avoided or given to all groups? Yes/No/Unclear</LI>
</UL>
<P>
<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
<B> </B>outlines the criteria on which the judgements were based in detail. We completed the risk of bias table for each eligible study and present an assessment of risk of bias using a 'risk of bias summary figure'. This display of internal validity indicates the weight readers may give the results of each study.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-02-03 10:24:17 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Quantitative data were entered into RevMan 5 by one review author (CV) and were checked by a second (MS).</P>
<P>Summary estimates of treatment effect (with 95% confidence intervals (CI)) were calculated for each outcome and every comparison. For continuous outcomes, the mean difference (MD) is presented. For dichotomous outcomes, the risk difference (RD) is presented; this is an absolute effect measure that expresses the difference between the experimental and control event rates, and allows calculation of the number needed to treat (NNT). We refrained from a sensitivity analysis because of the lack of replication of comparisons.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-12-04 12:29:05 +0000" MODIFIED_BY="Elizabeth Royle">
<P>We conducted prespecified subgroup analyses for different wound types: burns, acute (e.g. surgical), chronic (e.g. ulcers) and mixed wound types.</P>
<P>Where studies evaluated similar interventions in a similar population we assessed statistical heterogeneity using the Chi<SUP>2</SUP> test and estimated the amount of heterogeneity using I<SUP>2</SUP>. Where pooling seemed appropriate in view of clinical and methodological similarities between studies, we planned to use a fixed-effect model where I<SUP>2</SUP> was below 25%. We did not intend to pool studies where inter-study heterogeneity was high (I<SUP>2</SUP> greater than 75%), and we intended to use a random-effects model when I<SUP>2</SUP> was between 25% and 75% (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We constructed a funnel plot to test for publication bias (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-02-16 13:54:14 +0000" MODIFIED_BY="[Empty name]">
<P>The search identified 313 titles of potential relevance. Discrepancy in judgement regarding suitability occurred in approximately 10% of all abstracts, but was resolved after adjudication by a third review author. After the first screening, 59 citations were considered potentially relevant. Full text articles were obtained and screened by two review authors independently against the inclusion criteria (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). One ongoing trial (two citations) was identified (<LINK REF="STD-Serena-2008" TYPE="STUDY">Serena 2008</LINK>) (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>), and four trials are awaiting assessment (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Hirsch-2008" TYPE="STUDY">Hirsch 2008</LINK>; <LINK REF="STD-Li-2006" TYPE="STUDY">Li 2006</LINK>; <LINK REF="STD-Wang-2008" TYPE="STUDY">Wang 2008</LINK>) (<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>).</P>
<P>Trials were excluded if no infection or healing parameters were reported; or if silver-containing agents were not used in one of the treatment arms; if the trials were not RCTs; or if trials were published in abstract form only and no additional information could be retrieved from the trial authors to allow a decision regarding eligibility for inclusion to be made. </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-02-16 13:54:16 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty-six trials (33 citations) met the inclusion criteria (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All 26 were published between 1980 and 2008. Study sizes ranged from 14 to 465 participants, and a total of 2066 participants were enrolled. The majority of trials (i.e. 21 of the 26 (81%)) included fewer than 80 participants.</P>
<P>Burns were the most frequently studied wound type (20 out of 26 (77%)), and there was substantial variation between trials in the percentage of total body surface area (TBSA) and depth of burn studied (14 trials studied partial-thickness or superficial burns, six studied full-thickness burns). One trial included a range of types of wound (i.e. venous leg ulcers, partial-thickness burns and donor sites) (<LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>). The remaining trials included minor soft tissue injuries (<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>), open surgical or traumatic wounds (<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), venous leg ulcers (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>), and diabetic foot ulcers (<LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>).</P>
<P>Around half of the trials (14 out of 26 (54%)) compared 1% silver sulphadiazine (SSD) cream with another topical agent or dressing without silver (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>). Six trials (23%) compared 1% SSD with other silver-containing topical agents or dressings such as Acticoat®, Aquacel® Ag, Hydron® AgSD, Sildimac®, SSD-cerium nitrate, and SSD with chlorhexidine digluconate cream (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>; <LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>; <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>; <LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK>). One trial compared a silver-coated gauze dressing (Acticoat®) with another topical agent or dressing without silver (<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>), and one trial compared a silver-coated gauze dressing (Acticoat®) with 0.5% silver nitrate solution (<LINK REF="STD-Tredget-1998" TYPE="STUDY">Tredget 1998</LINK>). One trial compared an activated charcoal dressing containing silver (Actisorb Plus®) with other topical agents (<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>). Two trials compared a hydrofibre dressing, containing ionic silver (Aquacel®), with other topical agents (<LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>). One trial compared a 0.5% silver nitrate solution with two other agents (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>).<BR/>
<BR/>While most of the trials had two treatment arms, two trials had three treatment arms (<LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), and one trial had four treatment arms (<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>).</P>
<P>All but two trials reported infection rates (<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>), but the definitions of infection varied. Four trials (15%) defined infection as the presence of more than 10<SUP>5</SUP> organisms per gram of tissue (<LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>; <LINK REF="STD-Tredget-1998" TYPE="STUDY">Tredget 1998</LINK>); 15 trials (58%) accepted positive wound swabs or clinical signs of infection as evidence of infection. Seven trials (27%) provided no definition of infection (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>). Twenty-one trials (81%) reported healing rates predominantly in terms of days to complete healing, or time to complete re-epithelialisation.</P>
<P>Pain was the secondary outcome measure most frequently reported. Three trials reported a sample size calculation (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>). It was not clear whether informed consent was obtained in 11 trials, and in 13 trials the ethics review board approval was not reported.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<P>The <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>
<I> </I>table provides details<I> </I>of<I> </I>the 18 trials (20 citations) that did not meet the inclusion criteria. Six trials were not RCTs (<LINK REF="STD-De-Boer-1981" TYPE="STUDY">De Boer 1981</LINK>; <LINK REF="STD-Hadjiiski-1999" TYPE="STUDY">Hadjiiski 1999</LINK>; <LINK REF="STD-Munster-1980" TYPE="STUDY">Munster 1980</LINK>; <LINK REF="STD-Silver-2007" TYPE="STUDY">Silver 2007</LINK>; <LINK REF="STD-Stair-1986" TYPE="STUDY">Stair 1986</LINK>; <LINK REF="STD-Verd_x00fa_-2004" TYPE="STUDY">Verdú 2004</LINK>), five trials were only published in abstract form with no further information forthcoming from the study authors (<LINK REF="STD-Lanzara-2008" TYPE="STUDY">Lanzara 2008</LINK>; <LINK REF="STD-Molnar-2004" TYPE="STUDY">Molnar 2004</LINK>; <LINK REF="STD-Planinsek-2007" TYPE="STUDY">Planinsek 2007</LINK>; <LINK REF="STD-Riesinger-2006" TYPE="STUDY">Riesinger 2006</LINK>; <LINK REF="STD-Yue-Seng-2005" TYPE="STUDY">Yue Seng 2005</LINK>), in four trials wounds were already infected (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>; <LINK REF="STD-Jorgensen-2006" TYPE="STUDY">Jorgensen 2006</LINK>; <LINK REF="STD-M_x00fc_nter-2006" TYPE="STUDY">Münter 2006</LINK>; <LINK REF="STD-Subrahmanyam-1991" TYPE="STUDY">Subrahmanyam 1991</LINK>). The three remaining trials were excluded because they did not compare dressings (<LINK REF="STD-Ganai-2002" TYPE="STUDY">Ganai 2002</LINK>); no data was reported on the effect of silver (<LINK REF="STD-Guilbaud-1993" TYPE="STUDY">Guilbaud 1993</LINK>); and the silver compound was not the comparator under investigation rather it was the type of bag covering the hand (<LINK REF="STD-Terrill-1991" TYPE="STUDY">Terrill 1991</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-02-03 13:29:14 +0000" MODIFIED_BY="Elizabeth Royle">
<P>A summary of the assessment of risk of bias based on the criteria outlined in <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK> is given in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. Additionally, a brief descriptive analysis of the studies is provided below. In general, the overall methodological quality of the included trials was relatively poor, although a few trials were at low risk of bias.</P>
<ALLOCATION MODIFIED="2009-12-08 12:23:56 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Treatment allocation was reported as random in all included studies, but the method of generating the randomisation sequence was not always clear. Only three trials reported their method of allocation sufficiently clearly to determine that allocation was concealed (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>).</P>
<P>In sixteen trials the unit of allocation was the individual patient (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>; <LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>; <LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>), and in the remaining ten trials the unit of allocation was the wound (<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Tredget-1998" TYPE="STUDY">Tredget 1998</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-02-03 10:44:35 +0000" MODIFIED_BY="Elizabeth Royle">
<P>One trial reported double-blinding with regard to the treatment given (<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>), and two trials reported blinding of outcome assessors (<LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>). All other trials did not report blinding sufficiently.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-02-03 13:29:14 +0000" MODIFIED_BY="Elizabeth Royle">
<SUBSECTION>
<HEADING LEVEL="4">Drop-out rate described and acceptable?</HEADING>
<P>Follow-up was less than 80% in three trials (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>), and unclear in two trials (<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>; <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>). In the remaining 21 trials there were either no dropouts, or the proportion of dropouts was less than 20%.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">ITT analysis</HEADING>
<P>We defined intention-to-treat (ITT) analysis as occurring when all randomised participants were reported or analysed in the group to which they were allocated for the most important time point of outcome measurement, irrespective of non-compliance and co-interventions<B>. </B>Thirteen trials conducted an ITT analysis, but thirteen either did not (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>; <LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>), or it was unclear whether this principle was applied (<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>).</P>
</SUBSECTION>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2010-02-03 10:51:53 +0000" MODIFIED_BY="Elizabeth Royle">
<SUBSECTION>
<HEADING LEVEL="4">Financial support</HEADING>
<P>Twelve trial groups reported that they had received financial support from one or more companies. One trial reported that it did not received financial support (<LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>), while the remaining 13 trials did not report this aspect at all.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparability</HEADING>
<P>In 22 trials the treatment groups appeared to be broadly comparable at baseline for wound size, aetiology and duration. Baseline comparability was unclear in one trial (<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>), and in the remaining three trials the treatment groups were not comparable at baseline (<LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>). In <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK> scald burns were more frequent in the SSD group than in the SSD/chlorhexidine digluconate cream group; no adjustments in the analysis were made to compensate for this imbalance. In the trials <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK> and <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> the wound size at baseline seemed different between both groups, although their authors had stated no differences.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Co-interventions</HEADING>
<P>The intervention of interest appeared to be the only systematic difference in the management of treatment groups within 23 of the included trials. In three trials it was unclear whether there was any imbalance in co-interventions delivered (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis of time to healing as a continuous variable</HEADING>
<P>It is not appropriate to analyse time-to-event data - such as time to healing - using methods for continuous outcomes (e.g. using mean times-to-event) as the relevant times are only known for the subset of participants who have experienced the event (e.g. healing). The most appropriate way of summarising time-to-event data is to use methods of survival analysis and express the intervention effect as a hazard ratio. A hazard ratio is interpreted in a similar way to a risk ratio, as it describes how many times more (or less) likely a participant is to experience the event at a particular point in time if they receive the experimental rather than the control intervention. Inappropriate analysis of outcome data can introduce bias in the interpretation of the results.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-02-16 15:02:34 +0000" MODIFIED_BY="[Empty name]">
<P>Diverse interventions were evaluated in the 26 included trials, and, as a result, pooling was possible for only two trials. We have presented the results according to wound type, i.e. acute wounds (first burns and then other wounds), chronic wounds, and mixed wounds. Within each wound type we investigated the following comparisons:</P>
<OL>
<LI>topical silver-containing agents compared with topical agents or dressings without silver (SSD versus no silver);</LI>
<LI>dressings containing silver compared with any dressings without silver (silver versus no silver);</LI>
<LI>comparisons between alternative topical preparations of silver, e.g. SSD cream (SSD versus silver);</LI>
<LI>comparisons between alternative silver-containing dressings including dose comparisons (silver versus silver).</LI>
</OL>
<P>For each outcome and comparison the results are presented below. Trial details are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>We were only able to assess the possibility of publication bias for one comparison, SSD/silver versus no silver, where we performed a funnel plot for the outcome of infection rate (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). The funnel plot included 10 trials with 11 comparisons demonstrating symmetry, indicating no publication bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Acute wounds: burns</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Topical silver-containing agents compared with topical agents without silver (silver sulphadiazine (SSD) versus no silver)</HEADING>
<P>Eleven trials compared a topical application containing silver (1% silver sulphadiazine cream, SSD) with another topical agent or dressing not containing silver. Only two trials compared similar interventions and were pooled (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>), while the remainder were considered separately.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1 SSD cream compared with biosynthetic dressing (Biobrane®) (two trials)</HEADING>
<P>
<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK> enrolled 43 patients with 50 acute partial-thickness burns, and <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK> enrolled 52 patients with 56 acute partial-thickness thermal wounds in two trials comparing 1% SSD cream with a biosynthetic dressing.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>
<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK> defined wound infection on clinical grounds in conjunction with semi-quantitative surface swab cultures. In this trial a mixture of paired and unpaired data were presented; seven patients were used as matched controls by randomising the paired wounds to treatment with opposite modalities. <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK> defined wound infection on clinical grounds, but did not give a detailed description. In <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK> 4/23 wounds in the SSD group, and 4/27 in the biosynthetic dressing group were judged to be infected. While in <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>, 2/26 wounds in the SSD group and 3/30 in the biosynthetic dressing group were judged to be infected. Pooling these two trials (I<SUP>2</SUP> = 0%) using a fixed-effect model showed no statistically significant difference between groups (RD 0.00; 95% CI -0.12 to 0.12) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Both Gerding trials reported the standard error of the mean; the standard deviation (SD) was calculated for our analysis. In both trials, healing was defined as complete re-epithelialisation. <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK> reported the mean time to complete healing as 21.3 days (SD 11.03) in the SSD group, and 13.7 days (SD 6.75) in the biosynthetic dressing group, while <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK> reported the mean time to complete healing as 15.0 days (SD 6.12) in the SSD group and 10.6 days (SD 4.38) in the biosynthetic dressing group. Both trials reported a statistically significant difference in favour of the biosynthetic dressing, however, these original trials analysed time to healing (a time-to-event outcome) as a continuous variable, which is inappropriate and potentially misleading (since it cannot take account of people who did not heal). We did not have access to the original data and therefore could not re-analyse it.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Both trials measured pain on a scale from one (none) to five (severe). The pain score was statistically significantly lower in the biosynthetic dressing groups (pooled, fixed-effect, MD 1.41; 95% CI 0.99 to 1.83). Both trials reported standard error of the mean, we calculated the SD for the purposes of analysis (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: costs</HEADING>
<P>
<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK> reported no statistically significant differences in the mean material costs, based on the total cost of topical cream, dressing materials and medications used in each case. Nursing costs were $238 in the SSD group and $71 in the biosynthetic dressing group (P value &lt; 0.001). No SDs were reported; therefore no mean difference could be calculated. <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK> reported that mean costs, based on hospital charges, were significantly lower in the biosynthetic dressing group (MD 70; 95% CI 15.5 to 124.5) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2 SSD cream compared with biosynthetic dressing with human fibroblast skin substitute (Transcyte on Biobrane mesh) (one trial)</HEADING>
<P>
<LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK> enrolled 14 patients, each with two partial-thickness burns of similar size, and compared SSD cream on one burn with a biosynthetic dressing combined with human fibroblasts on the other.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>The trial report defined wound infection as cellulitis. Six of the 14 burns in the SSD group, and none in the biosynthetic dressing group developed cellulitis. The number of burns that developed cellulitis was significantly lower in the biosynthetic dressing group (RD 0.43; 95% CI 0.16 to 0.70). (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The number needed to treat (NNT) with biosynthetic dressings was two, in order to prevent one additional patient developing cellulitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>The report defined healing as 90% re-epithelialisation. The mean time to 90% healing in the SSD group was 18.14 days, compared to 11.14 days in the biosynthetic dressing group. The mean time to healing was significantly shorter in the biosynthetic dressing group. Time to healing is a time-to-event outcome, however, the trialists did not analyse it as such and, therefore, this effect estimate may be inaccurate.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.3 SSD cream with chlorhexidine-impregnated gauze (Bactigras®) compared with hydrocolloid dressing (Duoderm® Hydroactive) (one trial)</HEADING>
<P>
<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK> enrolled 48 patients with partial-thickness burns and compared a layer of SSD cream covered by chlorhexidine-impregnated gauze (Bactigras) with a hydrocolloid dressing (Duoderm Hydroactive).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was not defined in this trial, but was based on the unblinded, subjective opinion of the investigator or the plastic surgeon, and, therefore, was subject to bias. One participant out of 24 in the SSD with chlorhexidine-impregnated gauze group developed an infection, and 2/24 in the hydrocolloid dressing group. There was no statistically significant difference in the number of patients that developed a wound infection (RD: -0.04, 95% CI -0.18 to 0.09) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>The trialists defined healing as complete re-epithelialisation. The mean time to complete healing was 11.2 days in the SSD with chlorhexidine-impregnated gauze group, and 10.7 days in the hydrocolloid group. There was no statistically significant difference in the mean time to complete healing. Again, this time-to-event outcome had been inappropriately analysed as a continuous variable rather than by survival analysis, and, therefore, was inaccurate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>The pain scores at baseline and the second visit (24 hours after the initial visit) were assessed. Pain was measured on a scale from 1 to 10. There was no statistically significant difference in the groups for the median pain score at baseline or at the second visit.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: patient satisfaction</HEADING>
<P>Overall satisfaction was reported as excellent or satisfactory for all patients, and there was no statistically significant difference between the groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.4 SSD cream compared with hydrocolloid dressing (DuoDerm® Hydroactive) (one trial)</HEADING>
<P>
<LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK> enrolled 50 patients with minor, second-degree burn injuries in order to compare the effects of SSD cream with hydrocolloid dressings.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined on clinical grounds, but how exactly was unclear. None of the patients developed a wound infection (RD 0.00; 95% CI -0.09 to 0.09) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as complete healing. The mean time to complete healing was 15.59 days in the SSD group, and 10.23 days in the hydrocolloid dressing group. The mean time to complete healing was significantly shorter in the hydrocolloid group. Again, this time-to-event outcome was inappropriately analysed as a continuous variable, and is, therefore, inaccurate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured on a scale from one (no pain) to 10 (maximum pain). The mean pain score was 2.28 in the SSD group, and 1.09 in the hydrocolloid dressing group. The mean reported pain score was significantly lower in the hydrocolloid group (MD 1.19; 95% CI 0.56 to 1.82) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.5 SSD cream compared with honey (two trials)</HEADING>
<P>
<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> enrolled 50 patients with superficial and partial-thickness burns. <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK> enrolled 50 patients with superficial thermal burns. Both compared the effects of SSD cream with pure, unprocessed, undiluted honey. <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> described it as 'traditional medicine honey' and <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK> stated only that the honey was obtained from hives.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>While <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> defined wound infection on clinical grounds, and via swabs for bacterial density and culture, infection rate was not reported. For <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK> wound infection was defined clinically (presence of pus or slough), and by means of bacterial cultures. There was no statistically significant difference between the two groups in this trial with respect to clinical evidence of wound infection in the short term (day 7), but in the longer term (day 21), the honey group demonstrated significantly fewer infections (RD 0.20; 95% CI 0.03 to 0.37) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). The NNT with honey was five, in order to prevent one wound infection.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>In the <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> trial healing was defined as 100% epithelialisation. The number of wounds completely healed was reported after two, four and six weeks' treatment. At the two and four weeks' treatment time-points, the honey group did significantly better. The number of wounds completely healed after two weeks was 5/25 in the SSD group and 13/25 in the honey treated group (RD -0.32; 95% CI -0.57 to -0.07) (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). The number of wounds completely healed after four weeks was 15/25 in the SSD group and 25/25 in the honey treated group (RD -0.40; 95% CI -0.60 to -0.20). The NNT with honey was three, in order to promote the healing of one extra wound. All wounds were completely healed after six weeks.</P>
<P>In the <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK> trial healing was defined as "patients with clinical and histological evidence of epithelialisation". The number of patients with clinical evidence of wound healing was reported on days 21 and 30, with histological evidence of wound healing reported for days 7 and 21. There was no statistically significant difference between the two groups for the clinical evidence on day 30. For the other time points, the honey group performed significantly better than the SSD group. The number of patients with clinical evidence of wound healing on day 21 was 21/25 in the SSD group and 25/25 in the honey group (RD -0.16; 95% CI -0.31 to -0.01) (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). The NNT with honey was six, in order to promote the healing of one extra wound.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>
<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> reported pain on the basis of the number of participants who were free of pain after one, two, three and four weeks of treatment. While there was no statistically significant difference between the two groups at the start and end of the trial (i.e. weeks 1 and 4), there was a statistically significant difference between groups in the middle (i.e. weeks 2 and 3), with more patients free of pain in the honey group (RD -0.36; 95% CI -0.61 to -0.11) (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>). We calculated the Mann-Whitney U test: z = -2.823, P value = 0.005.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: costs</HEADING>
<P>
<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK> reported the cost of dressing material for one percent of body surface area burnt. The cost of dressing material for each percent of body surface area burnt was PKR 0.10/2 g for SSD, and PKR 0.75/5 ml for honey. No SDs were reported, so no mean difference could be calculated.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.6 SSD cream compared with liposome hydrogel containing polyvinyl-pyrrolidone iodine (PVP-I) (one trial)</HEADING>
<P>
<LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK> enrolled 47 patients with 94 partial-thickness burns (degree IIa).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined using clinical criteria such as inflammation. When wound infection was suspected, wound swabs were taken for microbiological investigation. None of the patients developed a wound infection (RD 0.00; 95% CI -0.04 to 0.04) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as 95% to 100% re-epithelialisation. There was no statistically significant difference in the mean time to complete healing (11.3 days for the SSD group, 9.9 days for the liposome hydrogel containing polyvinyl-pyrrolidone iodine (PVP-I) group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable rather than by means of survival analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>There was no statistically significant difference between the groups with respect to wound necrosis and wound itching (RD 0.02; 95% CI -0.05 to 0.10) (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured, but the method the trialists used was not reported. There was no statistically significant difference in the number of patients reporting wound pain (RD -0.02; 95% CI -0.16 to 0.12) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.7 SSD cream compared with collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®) (two trials)</HEADING>
<P>
<LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> enrolled 15 patients with 30 partial-thickness burns. <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK> enrolled 79 patients with 158 partial-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>
<LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> did not report infection rate. <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK> did not define wound infection, but the number of patients with cellulitis were reported. There was no statistically significant difference in the number of patients who developed cellulitis between the groups (11/79 in the SSD group; 12/79 in the collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®) group), (RD -0.01; 95% CI -0.12 to 0.10) (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>
<LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> defined healing as complete re-epithelialisation and time to a clean wound bed (determined by the disappearance of injured dermis), while <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK> defined healing as complete re-epithelialisation and time to a clean wound bed (determined by the absence of retained dermis). In both trials, healing was significantly better in the Santyl® group. In <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> the median time to complete epithelialisation was 15 days in the SSD group and 10 days in the Santyl® group (P value 0.00007). In the <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK> trial, the mean time to epithelial closure was 22.1 days in the SSD group, and 19.0 days in the Santyl® group (no SD was reported) (P value &lt; 0.001). Again, this time-to-event outcome was inappropriately analysed as a continuous variable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain and adverse events</HEADING>
<P>
<LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK> reported pain as an adverse event and described it as burning or stinging. The number of patients reporting pain was significantly lower in the SSD group (RD -0.19; 95% CI -0.31 to -0.07) (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>). The NNT with SSD was five, in order to prevent one patient from experiencing pain. <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK> reported three patients who described a burning sensation at the wound site in the Santyl® group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.8 SSD cream/chlorhexidine (Silverex) compared with diphenyldantoin (Phenytoin) (one trial)</HEADING>
<P>
<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK> enrolled 64 patients with second degree burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome:infection rate</HEADING>
<P>Bacterial cultures were obtained on days 5 and 10. Negative cultures were defined as the absence of pathogens. The number of positive bacterial cultures on both days was significantly lower in the diphenyldantoin group. At day 10 15/32 cultures were positive in the SSD/chlorhexidine group compared with 3/32 in the diphenyldantoin group (RD 0.38; 95% CI 0.17 to 0.58) (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK>).The NNT with diphenyldantoin was three, in order to prevent one additional positive culture.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Wound healing was defined as complete healing. There was no statistically significant difference between the groups in the rate of complete healing; 24/32 wounds in the SSD/chlorhexidine group were completely healed, and 29/32 in the diphenyldantoin group (RD -0.16; 95% CI -0.34 to 0.02) (<LINK REF="CMP-008.02" TYPE="ANALYSIS">Analysis 8.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured in categories: moderate to severe pain or discomfort; mild; or no pain or discomfort. Statistically significantly more patients reported moderate to severe pain or discomfort in the SSD/chlorhexidine group (17/32), than in the diphenyldantoin group (7/32) (RD 0.31; 95% CI 0.09 to 0.54) (<LINK REF="CMP-008.03" TYPE="ANALYSIS">Analysis 8.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: length of hospital stay</HEADING>
<P>The mean length of hospital stay was 16.3 days in the SSD/chlorhexidine group and 14.2 days in the diphenyldantoin group (not statistically significant). No SDs were reported; therefore no mean difference could be calculated.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for burns: SSD versus no silver</HEADING>
<P>Eleven trials compared SSD with a range of non-silver comparators in participants with superficial or partial-thickness burns. Only four of the eleven trials reported adequate sequence generation (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>), and only two described allocation concealment (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>), therefore these trials were generally of at least moderate, (or unknown), risk of bias and the findings should be interpreted with this in mind.</P>
<UL>
<LI>Infection rate was reported in nine trials. Six trials found no statistically significant differences (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>), and three trials found a statistically significant increase in infection with SSD compared with the non-silver comparators (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>).</LI>
<LI>Time to complete healing was reported in eight trials, though in each trial this had been inappropriately analysed as a continuous variable ("mean time") rather than as a time-to-event outcome. Six trials showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>), and two trials showed no differences (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>), however, these data would be inaccurate if not all the participants were followed to complete healing.</LI>
<LI>The proportions of wounds healed and unhealed at specific time points were reported in three trials. Two trials showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>), and one trial showed no difference (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>).</LI>
<LI>Pain was reported in eight trials. While one trial showed a statistically significant difference in favour of SSD (<LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>), five trials showed a statistically significant difference is favour of non-silver dressings (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>), and two trials showed no difference (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Dressings containing silver compared with any dressings without silver (silver versus no silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Nanocrystalline silver coated dressing (Acticoat®) compared with hydrophilic polyurethane dressing (Allevyn®) (one trial)</HEADING>
<P>
<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK> enrolled 17 patients, with 18 paired adjacent burn sites, who required a split-thickness skin graft.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined clinically by criteria such as erythema, induration, purulent discharge, and malodour. Every third day, swabs were taken and were rated as 1 (light growth), 2 (medium growth), or 3 (heavy bacterial growth). There was no statistically significant difference in the number of patients who developed an infection, or in the number of positive cultures at any time point. None of the patients developed a wound infection (RD 0.00; 95% CI -0.11 to 0.11) (<LINK REF="CMP-009.01" TYPE="ANALYSIS">Analysis 9.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as 90% or more re-epithelialisation. Healing was significantly faster in the hydrophilic polyurethane dressing group (Allevyn®) (14.5 days for the nanocrystalline silver coated dressing (Acticoat®) group, and 9.1 days for the Allevyn® group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable. The number of wounds healed by day of discharge showed a statistical significance in favour of Allevyn® (RD -0.69; 95% CI -0.92 to -0.45) (<LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>). The NNT with Allevyn® was six, in order to promote one additional wound to heal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: cost</HEADING>
<P>The mean cost per cm<SUP>2</SUP> was USD 0.088 in the Acticoat® group and USD 0.059 in the Allevyn® group. No SDs were reported, so no mean difference could be calculated.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Silver nitrate (0.5%) compared with Ringer's lactate (one trial)</HEADING>
<P>
<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK> enrolled 52 patients with burns who required skin grafting. The trial had three treatment groups; silver nitrate (0.5%) (19 participants), Ringer's lactate (15 participants), and neomycin with bacitracin (18 participants).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined as present when there were more than 10<SUP>5</SUP> organisms per gram of tissue. The silver nitrate group showed significantly fewer infections (2/19 infections in the silver nitrate group; 8/15 in the Ringer's lactate group) (RD -0.43; 95% CI -0.72 to -0.14) (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>). The NNT with silver nitrate was two, in order to prevent one wound infection. Mean time to development of wound infection was significantly shorter in the Ringer's lactate group (13.7 days in the silver nitrate group, versus 5.5 days in the Ringer's lactate group). Again, the outcome was inappropriately analysed as a continuous variable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: length of hospital stay</HEADING>
<P>Length of hospital stay was only reported for subgroups, and was reported as being significantly shorter for patients in the silver nitrate group with wounds covering 20% to 40% TBSA.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Silver nitrate (0.5%) compared with neomycin with bacitracin (one trial)</HEADING>
<P>In the same trial (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), the comparison arm of silver nitrate (0.5%) (19 participants) was compared with the neomycin with bacitracin arm (18 participants).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined as present when there were more than 10<SUP>5</SUP> organisms per gram of tissue. There was no statistically significant difference in the number of patients who developed an infection (2/19 in the silver nitrate group and 6/18 in the neomycin with bacitracin group) (RD -0.23; 95% CI -0.49 to 0.03) (<LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>). Mean time to development of wound infection was significantly shorter in the neomycin with bacitracin group (13.7 days in the silver nitrate group versus 5.5 days in the neomycin with bacitracin group). Again, this time-to-event outcome was inappropriately analysed as a continuous variable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: length of hospital stay</HEADING>
<P>Length of hospital stay was only reported for subgroups, and there were no statistically significant differences between them.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">
<I>Summary for burns: </I>silver versus no silver</HEADING>
<P>Both trials investigated burns requiring skin grafting. Only one of the trials reported adequate sequence generation (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), and neither trial reported adequate allocation concealment.</P>
<UL>
<LI>Infection rate was reported in both trials with a total of three dressing comparisons. Two comparisons showed no differences (<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>; <LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), and one comparison showed a statistically significant difference in favour of silver nitrate (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>).</LI>
<LI>Time to complete healing was reported in one trial (<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>), which showed a statistically significant difference in favour of non-silver dressings however it had been wrongly analysed as a continuous variable (with mean healing time calculated) whereas time to healing is a time-to-event outcome which should be subject to analysis by survival methods.</LI>
<LI>The number of wounds healed was reported in one trial (<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>), which showed a statistically significant difference in favour of non-silver dressings.</LI>
</UL>
<P>An overview of the number of patients who developed a wound infection for all trials comparing SSD/silver versus no silver is given in <LINK REF="CMP-012.01" TYPE="ANALYSIS">Analysis 12.1</LINK>. A funnel plot (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) revealed no evidence of publication bias for wound infection.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Comparisons between alternative topical preparations of silver, e.g. SSD cream (SSD versus silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.3.1 SSD cream compared with nanocrystalline silver-coated dressing (Acticoat®) (one trial)</HEADING>
<P>
<LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK> enrolled 50 patients, with partial-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined as the presence of erythema, induration, purulent discharge and malodour. There was no statistically significant difference in the number of patients who developed an infection (4/25 in the SSD group; 3/25 in the nanocrystalline silver-coated dressing (Acticoat®) group) (RD 0.04; 95% CI -0.15 to 0.23) (<LINK REF="CMP-013.01" TYPE="ANALYSIS">Analysis 13.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured on a visual analogue pain scale from 1 (no pain) to 10 (extreme pain). Background pain, between dressings, was significantly lower in the Acticoat® group (5 in the SSD group, 4 in the Acticoat® group) (MD 1.00; 95% CI 0.64 to 1.36) (<LINK REF="CMP-013.02" TYPE="ANALYSIS">Analysis 13.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: length of hospital stay</HEADING>
<P>The mean length of hospital stay was 21 days in both groups (MD 0.00; 95% CI -6.43 to 6.43) (<LINK REF="CMP-013.03" TYPE="ANALYSIS">Analysis 13.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.2 SSD cream compared with hydrofibre dressing containing ionic silver (Aquacel® Ag) (one trial)</HEADING>
<P>
<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK> enrolled 82 patients, with superficial, mid-dermal or mixed partial-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was not defined. There was no statistically significant difference in the number of patients who developed an infection (6/40 in the SSD group; 8/42 in the hydrofibre dressing containing ionic silver (Aquacel® Ag) group) (RD -0.04; 95% CI -0.20 to 0.12) (<LINK REF="CMP-014.01" TYPE="ANALYSIS">Analysis 14.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as either 100% re-epithelialisation, including open areas; less than 1 cm fully re-epithelialised area; or re-epithelialisation less than 100% but to the extent that surgical interventions were not required. There were no differences in healing within 21 days (24/40 in the SSD group; 31/42 in the Aquacel® Ag group) (RD -0.14; 95% CI -0.34 to 0.06) (<LINK REF="CMP-014.02" TYPE="ANALYSIS">Analysis 14.2</LINK>). For the time to complete re-epithelialisation only median values were given: 17 days in the SSD group and 16 days in the Aquacel® Ag group (P value 0.517). No MD could be calculated. The time to complete re-epithelialisation was analyzed using life table methods. Kaplan Meier survival curves for each treatment group were plotted.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>Adverse events were defined as any untoward medical occurrence that was new or worsened during the trial. There were no statistically significant differences between SSD and Aquacel® Ag for adverse events (RD -0.03; 95% CI -0.24 to 0.19) (<LINK REF="CMP-014.03" TYPE="ANALYSIS">Analysis 14.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: use of systemic antibiotics</HEADING>
<P>There was no statistically significant difference between groups in the number of patients that used antibiotics (RD -0.04; 95% CI -0.20 to 0.12) (<LINK REF="CMP-014.04" TYPE="ANALYSIS">Analysis 14.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured on a visual analogue scale from 1 (no pain) to 10 (extreme pain). The mean pain score per week was 4.77 in the SSD group and 3.63 in the Aquacel® Ag group (P value 0.003). No SDs were reported, so no mean difference could be calculated. Pain was also measured on an observational scale. Patients were able to grade the extent to which the dressings reduced pain from "extremely well" to "not very well at all". Patients reported statistically significantly less pain associated with the Aquacel® Ag dressing (P value 0.002).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: costs</HEADING>
<P>Different components of costs were measured and combined later to be able to calculate cost effectiveness. For most components no SDs were reported, so no mean difference could be calculated. All costs were expressed as US dollars. There was no statistically significant difference in the mean total costs of clinical care ($1181 for the SSD group and $1040 for the Aquacel® Ag group) (MD $141; 95% CI -216 to 498) (<LINK REF="CMP-014.05" TYPE="ANALYSIS">Analysis 14.5</LINK>). The average cost effectiveness, calculated from the total cost of clinical care, divided by the proportion of patients with full epithelialisation, was $1968 (95% CI $1483 to $2690) in the SSD group and $1409 (95% CI $1050 to $1858) in the Aquacel® Ag group.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.3 SSD cream compared with synthetic dressing containing silver (Hydron-AgSD) (one trial)</HEADING>
<P>
<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK> enrolled 27 patients with 54 second degree burns, with areas of similar size and injury matched.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was determined by taking swabs for bacterial colonisation and reporting on the number of positive cultures. The time-point(s) at which the swabs were taken was not reported. The number of positive culture swabs was significantly higher in the SSD group (46/98 swabs in the SSD group; 32/98 in the synthetic dressing containing silver (Hydron-AgSD) group) (RD 0.14; 95% CI 0.01 to 0.28) (<LINK REF="CMP-015.01" TYPE="ANALYSIS">Analysis 15.1</LINK>). The NNT with Hydron-AgSD was seven, in order to prevent one positive culture.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>No definition of healing was reported. <LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK> stated that wounds healed equally in both groups, no data were reported to support this statement.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.4 SSD cream (Flamazine®) compared with 1% SSD plus 0.2% chlorhexidine digluconate cream (Silvazine®) (one trial)</HEADING>
<P>
<LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK> enrolled 121 patients with fresh, full-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined by clinical criteria such as softening of eschar, erythema, or colour change accompanied with a quantitative culture with 10<SUP>5</SUP> or more organisms per gram of burn tissue. There was no statistically significant difference between the groups in the number of patients that developed an infection (12/67 in the SSD group; 10/54 in the SSD with chlorhexidine digluconate cream group) (RD -0.01; 95% CI -0.14 to 0.13) (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: use of systemic antibiotics</HEADING>
<P>There was no statistically significant difference between groups in the use of antibiotics during the in-hospital period (RD 0.10; 95% CI -0.03 to 0.24) (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was not defined. There was no statistically significant difference between groups in the number of patients who experienced extreme pain at the time when cream was being applied (RD -0.02; 95% CI -0.07 to 0.03) (<LINK REF="CMP-016.03" TYPE="ANALYSIS">Analysis 16.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.5 SSD cream compared with SSD cream containing cerium nitrate (SSD-CN) (one trial)</HEADING>
<P>
<LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK> enrolled 60 patients with moderate and severe burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>In the <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK> trial, wound sepsis was defined as wound deterioration with severe inflammation. Wound biopsies were taken and bacterial growth on culture media was reported. <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK> found no statistically significant difference between the groups for any infection outcome. The number of patients developing sepsis after ten days was 3/30 in the SSD group and 0/30 in the SSD-cerium nitrate (SSD-CN) group (RD 0.10; 95% CI -0.02 to 0.22) (<LINK REF="CMP-017.01" TYPE="ANALYSIS">Analysis 17.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>The <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK> trial defined healing as complete re-epithelialisation, or wounds being ready for skin grafting. Re-epithelialisation was categorised into four groups: 'quick' (0 to 14 days), 'moderate' (15 to 21 days), 'slow' (22 to 35 days), and 'very slow' (more than 35 days). We calculated the Chi<SUP>2 </SUP>statistic as 5.233, and the P value as 0.155. There were no statistically significant differences between the groups.</P>
<P>The mean number of days until complete re-epithelialisation was significantly shorter in the SSD-CN nitrate group (25.1 days in the SSD group; 17.2 days in the SSD-CN group). The mean time to readiness to accept a skin graft was significantly shorter in the SSD-CN group (24.6 days in the SSD group (17 participants); 13.6 days in the SSD-CN group (nine participants). Once again, these were time-to-event outcomes that had been inappropriately analysed as continuous data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>In the <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK> trial skin rashes were observed in both groups, but did not differ significantly between the groups. A subjective stinging effect was significantly higher in the SSD-CN group (RD -0.37; 95% CI -0.58 to -0.15) (<LINK REF="CMP-017.02" TYPE="ANALYSIS">Analysis 17.2</LINK>). The NNT with SSD was three, in order to prevent one participant experiencing a stinging effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: use of systemic antibiotics</HEADING>
<P>There was no statistically significant difference between groups in the number of patients who received oral antibiotics for at least seven days (RD -0.03; 95% CI -0.20 to 0.13) (<LINK REF="CMP-017.03" TYPE="ANALYSIS">Analysis 17.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: length of hospital stay</HEADING>
<P>There was no statistically significant difference between groups in the mean length of hospital stay (MD 7.4; 95% CI -1.69 to 16.49) (<LINK REF="CMP-017.04" TYPE="ANALYSIS">Analysis 17.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3.6 SSD cream compared with Dimac containing SSD (Sildimac®) (one trial)</HEADING>
<P>
<LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK> enrolled 59 patients with two separate, comparable, sustained full-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined as present when there were more than10<SUP>5</SUP> organisms per gram of tissue. Wound biopsies were obtained before treatment, and every seven days thereafter until the last day of treatment. Positive cultures were defined as any growth of any organism. Wound infection was based on clinical judgement. There was no statistically significant difference between the groups in the number of patients who developed an infection at any time point. Clinical wound infection occurred in 2/51 patients in the SSD group and 1/51 patients in the Dimac SSD group (RD 0.02; 95% CI -0.05 to 0.09) (<LINK REF="CMP-018.01" TYPE="ANALYSIS">Analysis 18.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>There was no statistically significant difference between groups in the number of patients reporting local adverse effects (such as burning and stinging) (RD 0.03; 95% CI -0.10 to 0.16) (<LINK REF="CMP-018.02" TYPE="ANALYSIS">Analysis 18.2</LINK>). Six patients reported adverse effects at both the SSD site and the Dimac SSD site.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for burns: SSD versus silver</HEADING>
<P>Two trials investigated partial-thickness burns and four trials full-thickness or severe burns. Only two out of six trial reports described adequate sequence generation (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>), and none described adequate allocation concealment.</P>
<UL>
<LI>Infection rates were reported in six trials. No statistically significant differences were found in five trials (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>; <LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>; <LINK REF="STD-Miller-1990" TYPE="STUDY">Miller 1990</LINK>; <LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK>), though one trial showed a statistically significant difference for the number of positive-culture swabs in favour of the synthetic silver dressings (<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>).</LI>
<LI>Time to complete healing was reported in two trials. One trial used appropriate analysis methods and showed no statistically significant differences (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>), and the second trial analysed a time-to-event outcome (time to complete healing) inappropriately as a continuous variable (<LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>) and showed a statistical significance in favour of the SSD-cerium nitrate group.</LI>
<LI>The number of wounds healed was reported in three trials. None of the trials showed statistically significant differences (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-De-Gracia-2001" TYPE="STUDY">De Gracia 2001</LINK>; <LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>).</LI>
<LI>Pain was reported in three trials. One trial showed no statistically significant differences (<LINK REF="STD-Inman-1984" TYPE="STUDY">Inman 1984</LINK>), while two trials showed a statistically significant difference in favour of the silver-containing dressings Acticoat® and Aquacel® Ag (<LINK REF="STD-Caruso-2006" TYPE="STUDY">Caruso 2006</LINK>; <LINK REF="STD-Muangman-2006" TYPE="STUDY">Muangman 2006</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Comparisons between alternative silver-containing dressings including dose comparisons (silver versus silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.4.1 Nanocrystalline silver-coated dressing (Acticoat®) compared with fine-mesh gauze with silver nitrate (0.5%) (one trial)</HEADING>
<P>
<LINK REF="STD-Tredget-1998" TYPE="STUDY">Tredget 1998</LINK> enrolled 30 patients with 60 deep partial- and full-thickness burns.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined as present when there were more than 10<SUP>5</SUP> organisms per gram of tissue present. Bacteraemia was defined as the presence of the same bacterium isolated from the blood and the burn wound at concentrations of more than 10<SUP>5</SUP> organisms per gram of tissue. Significantly fewer patients developed a wound infection in the nanocrystalline silver-coated (Acticoat®) group (5/17 in the Acticoat® group; 16/17 in the fine-mesh gauze with silver nitrate group) (RD -0.65; 95% CI -0.89 to -0.40) (<LINK REF="CMP-019.01" TYPE="ANALYSIS">Analysis 19.1</LINK>). The NNT with nanocrystalline silver was two, in order to prevent one infection. There was no statistically significant difference between groups in the number of patients who developed bacteraemia (1/17 in the Acticoat® group and 5/17 fine-mesh gauze with silver nitrate group) (RD -0.24; 95% CI -0.48 to 0.01) (<LINK REF="CMP-019.02" TYPE="ANALYSIS">Analysis 19.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as complete re-epithelialisation; the authors reported there was no difference between the treatments, but no data were reported to support this statement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured on a visual analogue scale from 1 (not painful) to 5 (very painful). Only the mean pain score on dressing removal was significantly lower in the Acticoat® group, but not the mean overall pain score (MD -0.28; 95% CI -0.93 to 0.37) (<LINK REF="CMP-019.03" TYPE="ANALYSIS">Analysis 19.3</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Acute wounds: other wounds</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)</HEADING>
<P>
<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK> enrolled 465 patients with minor, uncomplicated, soft-tissue wounds requiring sutures into a study that compared three antimicrobial regimens with paraffin-impregnated gauze. Data from 39 enrolled participants were excluded for protocol violations, so only 426 participants were included in the analysis (i.e. not analysed by intention-to-treat). The trial had four treatment groups in which the following numbers of participants completed the trial; SSD cream (99 participants), bacitracin zinc ointment (109 participants), neomycin sulphate (110 participants), and petrolatum (108 participants). We compared each of these antimicrobial alternatives with SSD cream.</P>
<P>Wound infection was defined as any subjective or objective sign or symptom of infection, e.g. fever, erythema, oedema, induration, tenderness, heat, exudate, adenopathy, and lymphangitis. Wounds were classified into one of five categories based upon clinical assessment, ranging from no signs of infection (384 participants), simple stitch abscess (25 participants), surrounding cellulitis (14 participants), accompanying lymphangitis (three participants), and systemic symptoms (no participants).</P>
<SUBSECTION>
<HEADING LEVEL="5">2.1.1 SSD cream compared with bacitracin zinc ointment</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>There was no statistically significant difference between groups in the number of patients who developed wound infections (12/99 in the SSD group; 6/109 in the bacitracin zinc group) (RD 0.07; 95% CI -0.01 to 0.14) (<LINK REF="CMP-020.01" TYPE="ANALYSIS">Analysis 20.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.2 SSD cream compared with neomycin sulphate</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Significantly fewer patients developed wound infections in the neomycin sulphate group (12/99 in the SSD group; 5/110 in the neomycin sulphate group) (RD 0.08; 95% CI 0.00 to 0.15) (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>). The NNT with neomycin sulphate was 13, in order to prevent one infection.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.1.3 SSD cream compared with petrolatum</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>There was no statistically significant difference between groups in the number of patients who developed wound infections (12/99 in the SSD group; 19/108 in the petrolatum group) (RD -0.05; 95% CI -0.15 to 0.04) (<LINK REF="CMP-022.01" TYPE="ANALYSIS">Analysis 22.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.2 Dressings containing silver compared with dressings without silver (silver versus no silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.2.1 Hydrofibre dressing containing ionic silver (Aquacel® Ag) compared with povidone iodine gauze (one trial)</HEADING>
<P>
<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK> enrolled 67 patients with open surgical wounds or open traumatic wounds all healing by secondary intention to a randomised controlled trial comparing silver-containing hydrofibre (hydrofibre-Ag) with povidone iodine gauze.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined on clinical criteria such as warmth, redness, increased tenderness, swelling, increased exudate or purulent discharge, and malodour. There was no statistically significant difference in the number of patients who developed a wound infection during the trial period (4/35 in the Aquacel® Ag group; 4/32 in the povidone iodine group) (RD -0.01; 95% CI -0.17 to 0.14) (<LINK REF="CMP-023.01" TYPE="ANALYSIS">Analysis 23.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as epithelialisation, but also reduction in wound area in mm<SUP>2</SUP>, and reduction in wound depth in mm were reported. The mean time to complete healing was 14.1 days in the Aquacel® Ag group and 13.9 days in the povidone iodine group (log-rank test: not statistically significant). There was no statistically significant difference in the number of patients with complete wound healing at two weeks (8/35 in the Aquacel® Ag group; 3/32 in the povidone iodine group) (RD 0.13; 95% CI -0.04 to 0.31) (<LINK REF="CMP-023.02" TYPE="ANALYSIS">Analysis 23.2</LINK>).<BR/>The authors stated that the adjusted mean reduction in wound area was 551 mm<SUP>2</SUP> in the Aquacel® Ag group and 401 mm<SUP>2</SUP> in the povidone iodine group. The adjusted mean reduction in wound depth was 9 mm in the Aquacel® Ag group and 10 mm in the povidone iodine group. How, and why, the adjustment was made was not reported. The authors stated that both reductions were statistically significant when compared with baseline, but, when compared with each other, no statistically significant difference was found. No SDs were reported; therefore the mean difference could not be calculated.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>Adverse events were defined as any event that occurred during the trial period, e.g. allergy, skin burn, haemorrhage. There was no statistically significant difference between the groups (RD -0.09; 95% CI -0.21 to 0.02) (<LINK REF="CMP-023.03" TYPE="ANALYSIS">Analysis 23.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: pain</HEADING>
<P>Pain was measured on a visual analogue scale from 1 (no pain) to 10 (worst pain imaginable). Although no statistically significant differences were found for the pain score at dressing removal and application, the decrease in mean pain score from baseline when the dressings were in place was<B> </B>-0.7 for Aquacel® Ag versus 0 for povidone iodine gauze, though no SD was given. The overall ability to manage pain could be scored as excellent, good, fair or poor. The pain management was evaluated at the final visit (i.e. when the wound was completely healed or at week 2). Overall 70.6% of participants rated pain management as excellent in the Aquacel® Ag group compared with 22.6% in the povidone iodine gauze group. There was a statistically significant difference in the ability to manage pain in favour of the Aquacel® Ag group; P value &lt; 0.001.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for acute<I> wounds:</I> SSD/silver versus no silver</HEADING>
<P>One of the two trials reported adequate sequence generation and adequate allocation concealment (<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>).</P>
<UL>
<LI>Infection rate was reported in both trials with a total of four different dressing comparisons. Three comparisons (<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>) were not statistically significantly different, and one comparison (<LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>) showed a statistically significant difference in favour of neomycin sulphate.</LI>
<LI>Time to complete healing was reported in one trial (<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), and was not statistically significant.</LI>
<LI>The number of wounds healed was reported in one trial (<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), and was not statistically significant.</LI>
<LI>Pain was reported in one trial (<LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), and showed a statistically significant difference in favour of hydrofibre dressing containing ionic silver.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Chronic wounds</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1.1 SSD cream compared with Bensal HP with QRB7 (one trial)</HEADING>
<P>
<LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK> enrolled 40 patients with Wagner grade 1 or 2 diabetic foot ulcers in a trial comparing SSD with Bensal HP with QRB7, which is a mixture of 6% benzoic acid, 3% salicylic acid and 3% extract of Q rubra (an extract of oak (<I>Quercus rubra) </I>bark).</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined on the basis of clinical signs (foul odour, exudate, or erythema) and bacterial cultures. None of the treated wounds demonstrated growth of pathogenic bacteria at six weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as the percentage reduction in total wound size (derived by adding the individual wound areas for each participant in each group) at two, four and six weeks. Complete healing was not defined. The "collective" wound diameter of the Bensal HP-treated patients had decreased by 72.5%, whereas the collective diameter of the SSD group had reduced by 54.7% (Student t test: P value 0.059).</P>
<P>There was no statistically significant difference in the number of patients with complete wound healing within six weeks (6/20 in the SSD group; 8/20 in the Bensal HP group) (RD -0.10; 95% CI -0.39 to 0.19) (<LINK REF="CMP-024.01" TYPE="ANALYSIS">Analysis 24.1</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>None of the patients experienced adverse effects.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Dressings containing silver compared with non-silver dressings (silver versus no silver)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.2.1 Activated-charcoal dressing containing silver (Actisorb Plus®) compared with conventional phase-adapted therapy using diverse topical modalities (one trial)</HEADING>
<P>
<LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK> enrolled 40 patients with venous leg ulcers of whom 38 were followed to study completion.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Every two weeks swabs were taken and were rated as 0 (no bacterial growth), 1 (light bacterial growth), 2 (medium bacterial growth), or 3 (heavy bacterial growth). The authors reported no differences in infection rates, but no actual data were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as granulation (on an ordinal scale from 0 to 3), epithelialisation (on an ordinal scale from 0 to 3), and also as the reduction of the mean ulcer area in cm<SUP>2</SUP>. There was no statistically significant difference in the number of patients healed after six weeks of treatment (6/19 patients in the charcoal-silver group; 2/19 patients in the conventional phase-adapted therapy using diverse topical modalities group) (RD 0.21; 95% CI -0.04 to 0.46) (<LINK REF="CMP-025.01" TYPE="ANALYSIS">Analysis 25.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2.2 Hydrofibre dressing containing ionic silver (Aquacel® Ag) compared with calcium alginate dressing (Algosteril®) (one trial)</HEADING>
<P>
<LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK> enrolled 434 patients with diabetic foot ulcers (Wagner grade 1 and 2). Although, at baseline, the calcium alginate dressing group (Algosteril®) seemed to have larger ulcers, and more patients in the hydrofibre dressing containing ionic silver (Aquacel® Ag) group were receiving antibiotics, the authors stated that the groups were comparable.</P>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Wound infection was defined on the basis of clinical signs and/or bacterial cultures. There was no statistically significant difference in the number of patients who developed wound infection (11/67 in the Aquacel® Ag group; 8/67 in the Algosteril® group) (RD 0.04; 95% CI -0.07 to 0.16) (<LINK REF="CMP-026.01" TYPE="ANALYSIS">Analysis 26.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: wound healing rate</HEADING>
<P>Healing was defined as complete re-epithelialisation, and as the reduction of the mean ulcer area in percentage and ulcer depth. Healing speed was defined as a weekly reduction in absolute and percentage ulcer area. Only the mean time to complete healing was significantly lower in the Aquacel® Ag group (52.6 days +/- 1.8 days (SD) Aquacel® Ag group; 57.7 days +/- 1.7 days (SD) Algosteril® group) (MD -5.1; 95% CI -5.69 to -4.51) (<LINK REF="CMP-026.02" TYPE="ANALYSIS">Analysis 26.2</LINK>). Time in days to 100% healing was estimated by Kaplan-Meier survival analysis.</P>
<P>The number of patients with complete wound healing within eight weeks was 21/67 in the Aquacel® Ag group and 15/67 in the Algosteril® group (RD 0.09; 95% CI -0.06 to 0.24) (<LINK REF="CMP-026.03" TYPE="ANALYSIS">Analysis 26.3</LINK>). The mean percentage ulcer area reduction by eight weeks was 58.1% in the Aquacel® Ag group and 60.5% in the Algosteril® group (MD -2.4; 95% CI -18.72 to 13.92) (<LINK REF="CMP-026.04" TYPE="ANALYSIS">Analysis 26.4</LINK>). The reduction in mean ulcer depth at eight weeks was 0.25 cm in the Aquacel® Ag group and 0.13 cm in the Algosteril® group (MD 0.12; 95% CI -0.05 to 0.29) (<LINK REF="CMP-026.05" TYPE="ANALYSIS">Analysis 26.5</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Secondary outcome: adverse events</HEADING>
<P>Adverse events were not clearly defined. One of the events mentioned was infection. There was no statistically significant difference in the number of patients who experienced adverse effects (25/67 in the Aquacel® Ag group; 26/67 in the Algosteril® group) (RD -0.01; 95% CI -0.18 to 0.15) (<LINK REF="CMP-026.06" TYPE="ANALYSIS">Analysis 26.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for chronic wounds: SSD/silver versus no silver</HEADING>
<P>Two of the three trials reported adequate sequence generation (<LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>), and none adequate allocation concealment.</P>
<UL>
<LI>Infection rate was reported in three trials (<LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>), and showed no statistically significant differences.</LI>
<LI>Time to complete healing was reported in one trial (<LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>), and was significantly faster with the silver hydrofibre (Aquacel® Ag) dressing. Time to healing was appropriately analysed using survival analysis.</LI>
<LI>The number of wounds healed was reported in all three trials, and showed no statistically significant difference.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Mixed wounds</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Topical silver-containing agents compared with topical agents without silver (SSD versus no silver)</HEADING>
<P>
<LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK> enrolled 292 patients with venous leg ulcers, partial-thickness burns or partial-thickness donor sites. The trial had three treatment groups; SSD cream/hydrocolloid (58 participants), hydrocolloid alone (108 participants), and non-occlusive paraffin impregnated gauze (126 participants). The results are presented comparing SSD cream to each of the comparators.</P>
<P>Wound infection was defined using clinical criteria such as erythema, oedema, pain and purulent discharge.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1.1 SSD cream/hydrocolloid compared with hydrocolloid alone (one trial)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>There was no statistically significant difference in the number of patients who developed a wound infection (0/58 in the SSD/hydrocolloid group, and 2/108 in the hydrocolloid group) (RD -0.02; 95% CI -0.06 to 0.02) (<LINK REF="CMP-027.01" TYPE="ANALYSIS">Analysis 27.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.1.2 SSD cream/hydrocolloid compared with non-occlusive paraffin impregnated gauze</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Primary outcome: infection rate</HEADING>
<P>Significantly fewer patients in the SSD/hydrocolloid group developed a wound infection when compared with the non-occlusive paraffin impregnated gauze group (0/58 in the SSD/hydrocolloid group; 7/126 in the non-occlusive paraffin impregnated gauze group) (RD -0.06; 95% CI -0.10 to -0.01) (<LINK REF="CMP-028.01" TYPE="ANALYSIS">Analysis 28.1</LINK>). The NNT with SSD/hydrocolloid was 18, in order to prevent one infection.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for mixed wounds: SSD versus no silver</HEADING>
<P>This trial did not report adequate sequence generation, nor adequate allocation concealment, therefore effect estimates may be biased.</P>
<UL>
<LI>Infection rate was reported in this trial with a total of two different dressing comparisons. One comparison showed a statistically significant difference in favour of SSD/hydrocolloid, and the other showed no differences.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary for all wounds: SSD/silver versus no silver</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Infection rate</HEADING>
<P>Infection rates were reported in 17 trials with a total of 21 different dressing comparisons. One comparison showed a statistically significant difference in favour of silver nitrate dressings (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), 15 comparisons showed no differences, and five comparisons using SSD showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Dire-1995" TYPE="STUDY">Dire 1995</LINK>; <LINK REF="STD-Hutchinson-1993" TYPE="STUDY">Hutchinson 1993</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Wound healing rate</HEADING>
<P>Time to complete wound healing was reported in eleven trials. One trial showed a statistically significant difference in favour of hydrofibre dressing with ionic silver (<LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>), three trials showed no differences (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), and seven trials showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>). In most cases, time to complete wound healing was inappropriately regarded as a continuous outcome and the analysis of these outcomes was, therefore, flawed, leading to potentially misleading results.</P>
<P>Eight trials reported the number of wounds completely healed. Five trials showed no differences (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>; <LINK REF="STD-Wunderlich-1991" TYPE="STUDY">Wunderlich 1991</LINK>), and three trials showed a statistically significant difference in favour of non-silver dressings(<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Subrahmanyam-1998" TYPE="STUDY">Subrahmanyam 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse events</HEADING>
<P>Adverse events were reported in four trials. None of them showed statistically significant differences (<LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Jacobs-2008" TYPE="STUDY">Jacobs 2008</LINK>; <LINK REF="STD-Jude-2007" TYPE="STUDY">Jude 2007</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pain</HEADING>
<P>Pain was reported in nine trials, but was expressed in different ways, e.g. the need for analgesia, or on a visual analogue scale (VAS). Overall, the reported pain scores were low in the majority of these trials, and the absolute differences in pain scores between the studied interventions were minimal. Two trials showed a statistically significant difference in favour of silver-containing dressings (<LINK REF="STD-Hansbrough-1995" TYPE="STUDY">Hansbrough 1995</LINK>; <LINK REF="STD-Jurczak-2007" TYPE="STUDY">Jurczak 2007</LINK>), two trials found no differences (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>; <LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>), and five trials showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>; <LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient satisfaction</HEADING>
<P>Patient satisfaction was reported in one trial (<LINK REF="STD-Afilalo-1992" TYPE="STUDY">Afilalo 1992</LINK>), and showed no statistically significant differences.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Length of hospital stay</HEADING>
<P>Length of hospital stay was reported in two trials, with a total of three dressing comparisons. Only one patient group treated with silver nitrate for burns covering 20% to 40% of the total body surface area experienced significantly shorter hospital stay compared with participants who received Ringer's lactate (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>). No statistically significant differences were present for any of the other groups (<LINK REF="STD-Livingston-1990" TYPE="STUDY">Livingston 1990</LINK>), or trial (<LINK REF="STD-Carneiro-2002" TYPE="STUDY">Carneiro 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Costs</HEADING>
<P>Costs were reported in four trials. One trial (<LINK REF="STD-Innes-2001" TYPE="STUDY">Innes 2001</LINK>), found that the mean costs per cm<SUP>2</SUP> of dressing - based on price lists supplied by the manufacturers - were lower in the non-silver dressings group, compared with the silver-containing dressing group. One trial reported costs of dressings per percent of body surface burnt (<LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>), but differences were not reported. Both of the remaining two trials showed a statistically significant difference in favour of non-silver dressings (<LINK REF="STD-Gerding-1988" TYPE="STUDY">Gerding 1988</LINK>; <LINK REF="STD-Gerding-1990" TYPE="STUDY">Gerding 1990</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-02-16 13:56:45 +0000" MODIFIED_BY="[Empty name]">
<P>This review highlights the lack of conclusive evidence on the effects of silver-containing dressings or agents to prevent wound infection and to promote wound healing. In particular, there was no evidence to support the use of silver sulphadiazine (SSD) for prevention of wound infection in patients with partial-thickness burns. None of the trials indicated a beneficial effect for SSD for other outcomes when compared with other silver-containing or non-silver dressings. Furthermore, there was evidence that SSD may delay wound healing, may be more expensive, and may be more painful when applied to burns. The few trials on full-thickness burns and acute, chronic, or mixed wounds showed insufficient evidence for a beneficial effect of silver-containing dressings to decrease infection rates and to aid wound healing.</P>
<P>Only one trial showed significantly better results in terms of infection rates when another agent was added to the silver-containing dressing: infection rates were significantly lower than with SSD cream alone when a synthetic dressing was added to silver sulphadiazine cream (Hydron-SSD) (<LINK REF="STD-Fang-1987" TYPE="STUDY">Fang 1987</LINK>). The nanocrystalline form of silver present in the Hydron-SSD dressing, which releases silver ions faster, might explain the better results in burns. Furthermore, most trials used 1% SSD cream, but its effect might be dose-related (<LINK REF="REF-Fuller-1994" TYPE="REFERENCE">Fuller 1994</LINK>). On the other hand, higher doses could also result in higher toxicity and more adverse effects (<LINK REF="REF-Lansdown-2002" TYPE="REFERENCE">Lansdown 2002</LINK>).</P>
<P>Recently published literature had already suggested the lack of evidence of effectiveness for silver-containing dressings and topical agents in burns. <LINK REF="REF-Hussain-2006" TYPE="REFERENCE">Hussain 2006</LINK> published a Best Evidence Topic report on burns, including evidence from RCTs and CCTs. The authors concluded that there was little evidence for using silver-containing dressings to prevent wound infection, and that such products tend to delay wound healing. Furthermore, silver may have serious cytotoxic activity on various host cells (<LINK REF="REF-Atiyeh-2007" TYPE="REFERENCE">Atiyeh 2007</LINK>). In minor thermal burns (less than 15% TBSA) SSD cream was found to delay healing time and increase pain when compared with other treatments (<LINK REF="REF-Wasiak-2006" TYPE="REFERENCE">Wasiak 2006</LINK>). <LINK REF="REF-Wasiak-2008" TYPE="REFERENCE">Wasiak 2008</LINK> also evaluated different dressings for burn wounds and found evidence for a delayed healing time for SSD. Similarly, <LINK REF="REF-Bergin-2006" TYPE="REFERENCE">Bergin 2006</LINK> found no RCTs that evaluated the effects of silver-containing dressings for the treatment of diabetic foot ulcers, and <LINK REF="REF-Vermeulen-2007" TYPE="REFERENCE">Vermeulen 2007</LINK> found three RCTs and concluded that there was insufficient evidence of effectiveness for silver-containing dressings as a treatment for infected wounds.</P>
<SUBSECTION>
<HEADING LEVEL="2">The following limitations of this review should be noted</HEADING>
<P>Firstly, the methodological quality of the 26 included trials was relatively low, and a large proportion of the evidence presented here is accrued from trials which demonstrate a high or uncertain risk of bias. Most of the studies had small sample sizes and were, therefore, at risk of not detecting any existing differences, and of incurring chance baseline imbalances for important prognostic factors. Only one-third of the trials reported adequate sequence generation, and even fewer reported allocation concealment. Blinding of participants and care providers was not really possible, but outcome assessors could have been blinded, or healing confirmed by blinded assessment of photographs. This was almost never achieved or reported. Similarly the drop-out rate or reasons for drop-out were not always described.</P>
<P>The duration of follow-up of the included studies ranged from a few days to more than three months, whilst in only five studies was follow-up continued until complete wound re-epithelialisation was achieved (<LINK REF="STD-Homann-2007" TYPE="STUDY">Homann 2007</LINK>; <LINK REF="STD-Mashhood-2006" TYPE="STUDY">Mashhood 2006</LINK>; <LINK REF="STD-Noordenbos-1999" TYPE="STUDY">Noordenbos 1999</LINK>; <LINK REF="STD-Soroff-1994" TYPE="STUDY">Soroff 1994</LINK>; <LINK REF="STD-Wyatt-1990" TYPE="STUDY">Wyatt 1990</LINK>). In some trials the length of follow-up was unclear, or too short, and almost half of the trials were supported financially by a single manufacturer. If this caused publication bias - which was shown to be present in studies on negative pressure wound therapy (<LINK REF="REF-Peinemann-2008" TYPE="REFERENCE">Peinemann 2008</LINK>) - the real effect is likely to be even less favourable.</P>
<P>Secondly, one strength of a systematic review is the ability to pool data from several - often small - trials to achieve greater statistical power and a more precise overall effect size estimate. In this review few data could be pooled because the trials did not compare similar interventions, and there was considerable heterogeneity in the wounds being compared. Therefore, the lack of conclusive evidence for the effects of silver-containing dressings remains.<BR/>
<BR/>Thirdly, some trials used repeated measurements, for example, healing rate or swabs taken (e.g. at three, six, or nine days for one endpoint). This may illustrate the eagerness of the investigators (or the sponsors) to identify any sign of a treatment difference, at the cost of an increased chance of false positive results, while the shorter intervals are not relevant to patients. Furthermore, outcome parameters were measured in different ways and on different scales. Many secondary outcomes were based on subjective concepts such as "ease of use", "comfortable to wear". These subjective findings can hardly help in clinical practice and should be measured with standardised objective measurements whenever possible. Also, some trials measured "time per dressing", or "costs per cm<SUP>2"</SUP>. These measures alone are meaningless and should be reported in combination with other aspects of costs.</P>
<P>Fourthly, the majority of studies that reported outcomes such as time to healing or time to skin grafting, incorrectly reported and analysed these outcomes as continuous - rather than time-to-event - variables. The problem with this approach is that the time to the event is only known for those people who actually experienced it (in this case healing, or grafting), and no information is obtained from those who were observed, but did not experience the event. This approach may introduce bias. Time-to-event data, such as time to wound healing, should be analysed using survival analysis in which the treatment effect is expressed as a hazard ratio.</P>
<P>Finally, eight trials did not attempt to define infection. Some trials defined infection only on clinical grounds and others merely on the presence of bacterial cultures. It is clearly difficult to interpret the results of studies that do not define their main outcomes. We reported the definition of infection and healing as used by the study authors and were unable to conduct any pooling due to heterogeneity.</P>
<P>Apart from the definition used, <LINK REF="REF-Sibbald-2005" TYPE="REFERENCE">Sibbald 2005</LINK> stated that chronic wounds always contain bacteria and a diagnosis of infection should be based on clinical signs and not solely on bacterial cultures.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-02-16 13:56:46 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-02-16 13:56:46 +0000" MODIFIED_BY="[Empty name]">
<P>There is currently insufficient evidence that silver-containing dressings prevent wound infection or promote wound healing; the available evidence is low both in volume and quality. There is some evidence from small, poor-quality trials, that silver sulphadiazine does not reduce wound infection and slows down wound healing in people with partial-thickness burns.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-02-03 12:53:56 +0000" MODIFIED_BY="Elizabeth Royle">
<P>More studies, and particularly studies with a low risk of bias, are needed to confirm any effect of silver-containing dressings in full-thickness burns and other wound groups. Future research must develop clear, valid, and reliable measures of wound infection. The use of common, quantifiable, and clinically-relevant endpoints (time to complete wound healing, number and time to wound infection, pain, adverse events, costs, and, preferably, a validated scale for patient satisfaction) should always be used. Whilst it is very difficult to blind patients and medical professionals with regard to the intervention, it is possible to blind outcome assessors, or to use computer programmes to measure wound size. Future research must adopt a survival approach for the analysis of time-to-event data, such as time to healing.<BR/>
</P>
<P>Finally, a sufficiently long follow-up period of at least six months is essential if treatment effects in chronic wounds are to be detected. Interventions under evaluation should be thoroughly, and clearly, described. For this purpose use of the revised CONSORT statement is recommended in order to report these trials adequately.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-02-10 17:11:53 +0000" MODIFIED_BY="[Empty name]">
<P>We express our gratitude to the people who refereed the protocol and review for readability, relevance, and methodological rigour: Editors David Margolis, Joan Webster and Gill Worthy, and Peer referees Charlotte Ives and Amy Zelmer and in particular thanks to Elizabeth Royle for copy editing the review.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-02-16 14:14:39 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Marja N Storm-Versloot</HEADING>
<UL>
<LI>Co-ordinated the review.</LI>
<LI>Extracted and checked data and performed the statistical analysis.</LI>
<LI>Undertook and checked the quality assessment.</LI>
<LI>Analysed and interpreted the data.</LI>
<LI>Completed the first draft of the review and contributed to the writing and editing of further drafts.</LI>
<LI>Made an intellectual contribution to the review.</LI>
<LI>Performed previous work that was the foundation of the current review and approved the final review prior to submission</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Cornelis G Vos</HEADING>
<UL>
<LI>Extracted and checked data and performed the statistical analysis.</LI>
<LI>Undertook and checked the quality assessment.</LI>
<LI>Analysed and interpreted the data.</LI>
<LI>Contributed to the writing and editing of the review. </LI>
<LI>Wrote to study author, experts, and companies. </LI>
<LI>Performed previous work that was the foundation of the current review and approved the final review prior to submission.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Dirk T Ubbink</HEADING>
<UL>
<LI>Conceived, designed and coordinated the review.</LI>
<LI>Checked data extraction.</LI>
<LI>Undertook and checked the quality assessment.</LI>
<LI>Analysed and interpreted the data.</LI>
<LI>Contributed to the writing and editing of the review and made an intellectual contribution to the review.</LI>
<LI>Performed previous work that was the foundation of the current review and approved the final review prior to submission</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hester Vermeulen</HEADING>
<UL>
<LI>Conceived, designed and co-ordinated the review.</LI>
<LI>Checked data extraction and quality assessment.</LI>
<LI>Analysed and interpreted the data.</LI>
<LI>Contributed to the writing and editing of the review and made an intellectual contribution to the review.</LI>
<LI>Performed previous work that was the foundation of the current review and approved the final review prior to submission.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Contributions of editorial base</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Nicky Cullum</HEADING>
<UL>
<LI>Edited the review, advised on methodology, interpretation and review content.</LI>
<LI>Approved the final review prior to submission.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sally Bell-Syer</HEADING>
<UL>
<LI>Co-ordinated the editorial process.</LI>
<LI>Advised on methodology, interpretation and content.</LI>
<LI>Edited the review.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Ruth Foxlee</HEADING>
<UL>
<LI>Designed the search strategy, ran the searches and edited the search methods and reference sections.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-02-16 13:56:47 +0000" MODIFIED_BY="[Empty name]">
<P>We have added 'promoting healing' to the objective, indicating that the wound is not infected. Therefore the primary outcomes have been changed accordingly. A priori we did not identify time to grafting as an outcome, but in severe burns the goal is to prevent infection by grafting the wound as soon as possible. Therefore we have added time to grafting as it is a subjective indication of healing in the sense that the wound has become clean and is granulating, and thus ready for secondary closure. Study selection was based on one of these primary outcomes. Duration of wound infection was deleted, because this endpoint suggests treating an infected wound rather than preventing infection.</P>
<P>We planned to conduct subgroup analysis for each wound type. Due to the few studies identified for wound types other than burns, we categorised these wounds as acute, chronic or mixed wounds in order to evaluate the studies.</P>
<P>The search strategy was refined after consulting the Wounds Group Trial Search Co-ordinator.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-12 16:28:39 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-02-12 16:28:39 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-02-12 16:28:39 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Afilalo-1992" NAME="Afilalo 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Afilalo M, Dankoff J, Guttman A, and Lloyd J&lt;br&gt;Article Title:          DuoDERM hydroactive dressing versus silver sulphadiazine/Bactigras in the emergency treatment of partial skin thickness burns&lt;br&gt;Journal Detail:      Burns  92  18  4  313-6&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Afilalo M, Dankoff J, Guttman A, Lloyd J</AU>
<TI>DuoDERM hydroactive dressing versus silver sulphadiazine/Bactigras in the emergency treatment of partial skin thickness burns</TI>
<SO>Burns</SO>
<YR>1992</YR>
<VL>18</VL>
<NO>4</NO>
<PG>313-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carneiro-2002" NAME="Carneiro 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Carneiro PM, Rwanyuma LR, Mkony CA. A comparison of topical Phenytoin with Silverex in the treatment of superficial dermal burn wounds. Central African Journal of Medicine 48(9-10):105-8, 2002;-Oct.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carneiro PM, Rwanyuma LR, Mkony CA</AU>
<TI>A comparison of topical Phenytoin with Silverex in the treatment of superficial dermal burn wounds</TI>
<SO>Central African Journal of Medicine</SO>
<YR>2002</YR>
<VL>48</VL>
<NO>9/10</NO>
<PG>105-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caruso-2006" MODIFIED="2008-11-04 22:25:40 +0000" MODIFIED_BY="[Empty name]" NAME="Caruso 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-04 22:25:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Caruso DM, Foster KN, Blome-Eberwein SA, Twomey JA, Herndon DN, Luterman A, Silverstein P, Antimarino JR, Bauer GJ&lt;br&gt;Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial-thickness burns.J Burn Care Res. 2006 May-Jun;27(3):298-309. PMID: 16679897 [PubMed - indexed for MEDLINE]&lt;/p&gt;" NOTES_MODIFIED="2008-11-04 22:25:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caruso DM, Foster KN, Blome-Eberwein SA, Twomey JA, Herndon DN, Luterman A, et al</AU>
<TI>Randomized clinical study of Hydrofiber dressing with silver or silver sulfadiazine in the management of partial-thickness burns</TI>
<SO>Journal of Burn Care and Research</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>3</NO>
<PG>298-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Gracia-2001" MODIFIED="2009-12-04 12:41:12 +0000" MODIFIED_BY="Elizabeth Royle" NAME="De Gracia 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-12-04 12:41:01 +0000" MODIFIED_BY="Elizabeth Royle" NOTES="&lt;p&gt;Record Number:    31490&lt;br&gt;Author, Analytic:  de Gracia CG&lt;br&gt;Article Title:          An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns&lt;br&gt;Journal Detail:      Burns  2001  27  1  67-74&lt;/p&gt;" NOTES_MODIFIED="2009-12-04 12:41:01 +0000" NOTES_MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Gracia CG</AU>
<TI>An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns</TI>
<SO>Burns</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>1</NO>
<PG>67-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dire-1995" NAME="Dire 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Dire DJ, Coppola M, Dwyer DA, Lorette JJ, and Karr JL&lt;br&gt;Article Title:          Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED [see comments]&lt;br&gt;Journal Detail:      Academic Emergency Medicine  95  2  1  4-10&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dire DJ, Coppola M, Dwyer DA, Lorette JJ, Karr JL</AU>
<TI>Prospective evaluation of topical antibiotics for preventing infections in uncomplicated soft-tissue wounds repaired in the ED</TI>
<SO>Academic Emergency Medicine</SO>
<YR>1995</YR>
<VL>2</VL>
<NO>1</NO>
<PG>4-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-1987" MODIFIED="2010-02-10 14:50:51 +0000" MODIFIED_BY="[Empty name]" NAME="Fang 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-02-10 14:50:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author, Analytic:  Fang CH, Nathan P, Robb EC, Alexander JW, and MacMillan BG &lt;br&gt;Article Title:          Prospective clinical study of Hydron, a synthetic dressing, in delivery of an antimicrobial drug to second-degree burns&lt;br&gt;Journal Detail:      Journal of Burn Care and Rehabilitation  87   8  3   206-9&lt;/p&gt;" NOTES_MODIFIED="2010-02-10 14:50:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang CH, Nathan P, Robb EC, Alexander JW, MacMillan BG</AU>
<TI>Prospective clinical study of Hydron, a synthetic dressing, in delivery of an antimicrobial drug to second-degree burns</TI>
<SO>Journal of Burn Care and Rehabilitation</SO>
<YR>1987</YR>
<VL>8</VL>
<NO>3</NO>
<PG>206-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerding-1988" NAME="Gerding 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerding RL, Imbembo AL, Fratianne RB</AU>
<TI>Biosynthetic Skin Substitute vs. 1% Silver Sulfadiazine for Treatment of Inpatient Partial-thickness Thermal Burns</TI>
<SO>The Journal of Trauma</SO>
<YR>1988</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1265-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerding-1990" MODIFIED="2008-11-04 18:46:23 +0000" MODIFIED_BY="[Empty name]" NAME="Gerding 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-11-04 18:46:23 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Record Number:    9665&lt;br&gt;Author, Analytic:  Gerding RL, Emerman CL, Effron D, Lukens T, Imbembo AL, and Fratianne RB &lt;br&gt;Article Title:          Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine&lt;br&gt;Journal Detail:      Annals of Emergency Medicine  90  19  2  121-124&lt;/p&gt;" NOTES_MODIFIED="2008-11-04 18:46:23 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerding RL, Emerman CL, Effron D, Lukens T, Imbembo AL, Fratianne RB</AU>
<TI>Outpatient management of partial-thickness burns: Biobrane versus 1% silver sulfadiazine</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>2</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansbrough-1995" MODIFIED="2009-12-10 14:38:41 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Hansbrough 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-12-10 14:38:41 +0000" MODIFIED_BY="Elizabeth Royle" NOTES="&lt;p&gt;Author, Analytic:  Hansbrough JF, Achauer B, Dawson J, Himel H, Luterman A, Slater H, Levenson S, Salzberg CA, Hansbrough WB, and Dore C&lt;br&gt;Article Title:          Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream&lt;br&gt;Journal Detail:      Journal of Burn Care and Rehabilitation  95   16  3 (pt 1)  241-7&lt;/p&gt;" NOTES_MODIFIED="2009-12-10 14:38:41 +0000" NOTES_MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansbrough JF, Achauer B, Dawson J, Himel H, Luterman A, Slater H, et al</AU>
<TI>Wound healing in partial-thickness burn wounds treated with collagenase ointment versus silver sulfadiazine cream</TI>
<SO>The Journal of Burn Care and Rehabilitation</SO>
<YR>1995</YR>
<VL>16</VL>
<NO>3 Pt 1</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homann-2007" MODIFIED="2009-12-10 14:30:29 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Homann 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-04 22:27:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hauser J, Rossbach O, Langer S, Vogt P, Germann G, Steinau HU, et al</AU>
<TI>Local therapy of grade IIa burns: Efficacy and tolerability of a new hydrosome wound gel for the local treatment of grade IIa burns as compared with silver sulfadiazine ointment</TI>
<TO>Lokale Behandlung von Grad-IIa-Verbrennungen. Wirksamkeit und Verträglichkeit eines neuartigen hydrosomalen Wundgels im Vergleich zu Silbersulfadiazin-Creme</TO>
<SO>Unfallchirurg  2007</SO>
<YR>2007</YR>
<VL>110</VL>
<NO>11</NO>
<PG>988-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-12-10 14:30:29 +0000" MODIFIED_BY="Elizabeth Royle" NOTES="&lt;p&gt;Homann HH, Rosbach O, Moll W, Vogt PM, Germann G, Hopp M, Langer-Brauburger B, Reimer K, Steinau HU.A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds.Ann Plast Surg. 2007 Oct;59(4):423-7.&lt;/p&gt;" NOTES_MODIFIED="2009-12-10 14:30:29 +0000" NOTES_MODIFIED_BY="Elizabeth Royle" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Homann HH, Rosbach O, Moll W, Vogt PM, Germann G, Hopp M, et al</AU>
<TI>A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds</TI>
<SO>Annals of Plastic Surgery</SO>
<YR>2007</YR>
<VL>59</VL>
<NO>4</NO>
<PG>423-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-28 15:37:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rossbach O, Vogt P, Germann G et al</AU>
<TI>Repithel® in comparison with Flammazine® for IIa degree burns</TI>
<SO>European Wound Management Association Conference; 2005, 15-17 September; Stuttgart, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchinson-1993" MODIFIED="2009-04-28 15:42:37 +0100" MODIFIED_BY="[Empty name]" NAME="Hutchinson 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-04-28 15:41:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Allen RB, Kerstein M, Klassen H, Friedmann PS, Pryce DW, Lawrence JC, et al</AU>
<TI>Prospective study of clinical infections in wounds dressed with occlusive versus conventional dressings</TI>
<SO>9th Annual Symposium on Advanced Wound Care and 6th Annual Medical Research Forum on Wound Repair; April 20-24; Atlanta</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-28 15:42:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Hutchinson JJ</AU>
<TI>A prospective clinical trial of wound dressings to investigate the rate of infection under occlusion</TI>
<SO>3rd European Conference on Advances in Wound Management; 19-22 October; Harrogate, UK</SO>
<YR>1993</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-28 15:42:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hutchinson JT</AU>
<TI>Influence of occlusive dressings on wound microbiology - interim results of a multi-centre clinical trial of an occlusive hydrocolloid dressing</TI>
<SO>1st European Conference on Advances in Wound Management; 4-6 September; Cardiff, UK</SO>
<YR>1992</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inman-1984" NAME="Inman 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Inman RJ, Snelling CF, Roberts FJ, Shaw K, and Boyle JC&lt;br&gt;Article Title:          Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 02 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection&lt;br&gt;Journal Detail:      Burns, Including Thermal Injury  84  11  1  35-40&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inman RJ, Snelling CF, Roberts FJ, Shaw K, Boyle JC</AU>
<TI>Prospective comparison of silver sulfadiazine 1 per cent plus chlorhexidine digluconate 0.2 per cent (Silvazine) and silver sulfadiazine 1 per cent (Flamazine) as prophylaxis against burn wound infection</TI>
<SO>Burns</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>1</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Innes-2001" NAME="Innes 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Innes ME, Umraw N, Fish JS, Gomez M, and Cartotto RC&lt;br&gt;Article Title:          The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study&lt;br&gt;Journal Detail:      Burns  2001  27  6  621-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Innes ME, Umraw N, Fish JS, Gomez M, Cartotto RC</AU>
<TI>The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study</TI>
<SO>Burns</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>6</NO>
<PG>621-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-2008" MODIFIED="2009-01-17 17:41:46 +0000" MODIFIED_BY="[Empty name]" NAME="Jacobs 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-01-17 17:41:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs AM, Tomczak R</AU>
<TI>Evaluation of Bensal HP for the treatment of diabetic foot ulcers</TI>
<SO>Advances in Skin and Wound Care</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>10</NO>
<PG>461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jude-2007" MODIFIED="2009-12-10 14:33:47 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Jude 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-10 14:33:47 +0000" MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jude E, Apelqvist J, Spraul M, Martini J</AU>
<TI>Randomized controlled study of diabetic foot ulcers dressed with hydrofiber® containing ionic silver or calcium alginate dressings</TI>
<SO>European Wound Management Association Conference,15-17 September, Stuttgart, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-28 16:08:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jude E</AU>
<TI>Non-ischemic diabetic foot ulcers: Effects of Aquacel Ag with hydrofiber versus alginate dressing</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-21 18:57:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Jude EB, Apelqvist J, Spraul M, Martini J; Silver Dressing Study Group.Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers.Diabet Med. 2007 Mar;24(3):280-8.&lt;/p&gt;" NOTES_MODIFIED="2008-06-21 18:57:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jude EB, Apelqvist J, Spraul M, Martini J, and the Silver Dressing Study Group</AU>
<TI>Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers</TI>
<SO>Diabetic Medicine</SO>
<YR>2007</YR>
<VL>24</VL>
<NO>3</NO>
<PG>280-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jurczak-2007" MODIFIED="2009-04-28 15:45:58 +0100" MODIFIED_BY="[Empty name]" NAME="Jurczak 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-04-28 15:45:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dugré T, Jurczak F, Offori T et al</AU>
<TI>Randomized multi-center study comparing open surgical wound outcomes using silver or iodine dressings</TI>
<SO>European Wound Management Association Conference,15-17 September, Stuttgart, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-21 18:56:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Jurczak F, Dugr&amp;#233; T, Johnstone A, Offori T, Vujovic Z, Hollander D; AQUACEL Ag Surgical/Trauma Wound Study Group.&lt;br&gt;Randomised clinical trial of Hydrofiber dressing with silver versus povidone-iodine gauze in the management of open surgical and traumatic wounds.Int Wound J. 2007 Mar;4(1):66-76. PMID: 17425549 [PubMed - indexed for MEDLINE]&lt;/p&gt;" NOTES_MODIFIED="2008-06-21 18:56:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jurczak F, Dugré T, Johnstone A, Offori T, Vujovic Z, Hollander D, on behalf of the AQUACEL Ag Surgical/Trauma Wound Study Group</AU>
<TI>Randomised clinical trial of Hydrofiber dressing with silver versus povidone-iodine gauze in the management of open surgical and traumatic wounds</TI>
<SO>International Wound Journal</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>1</NO>
<PG>66-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Livingston-1990" MODIFIED="2009-04-28 15:46:29 +0100" MODIFIED_BY="[Empty name]" NAME="Livingston 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-04-28 15:46:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author, Analytic:  Livingston DH, Cryer HG, Miller FB, Malangoni MA, Polk HC, and Weiner LJ&lt;br&gt;Article Title:          A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury&lt;br&gt;Journal Detail:      Plastic and reconstructive surgery  90  86  6  1059-64; discussion 1065&lt;/p&gt;" NOTES_MODIFIED="2009-04-28 15:46:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livingston DH, Cryer HG, Miller FB, Malangoni MA, Polk HC, Weiner LJ</AU>
<TI>A randomized prospective study of topical antimicrobial agents on skin grafts after thermal injury</TI>
<SO>Plastic and Reconstructive Surgery</SO>
<YR>1990</YR>
<VL>86</VL>
<NO>6</NO>
<PG>1059-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mashhood-2006" NAME="Mashhood 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mashhood AA, Khan TA, Sami AN</AU>
<TI>Honey compared with 1% silver sulfadiazine cream in the treatment of superficial and partial thickness burns</TI>
<SO>Journal of Pakistan Association of Dermatologists</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>14-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1990" MODIFIED="2008-11-04 22:28:22 +0000" MODIFIED_BY="[Empty name]" NAME="Miller 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-11-04 22:28:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author, Analytic:  Miller L, Hansbrough J, Slater H, Goldfarb IW, Kealey P, Saffle J, Kravitz M, and Silverstein P&lt;br&gt;Article Title:          Sildimac: a new delivery system for silver sulfadiazine in the treatment of full-thickness burn injuries&lt;br&gt;Journal Detail:      Journal of Burn Care and Rehabilitation  90  11  1  35-41&lt;/p&gt;" NOTES_MODIFIED="2008-11-04 22:28:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller L, Hansbrough J, Slater H, Goldfarb IW, Kealey P, Saffle J, et al</AU>
<TI>Sildimac: a new delivery system for silver sulfadiazine in the treatment of full-thickness burn injuries</TI>
<SO>Journal of Burn Care &amp; Rehabilitation</SO>
<YR>1990</YR>
<VL>11</VL>
<NO>1</NO>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muangman-2006" MODIFIED="2008-11-04 22:29:16 +0000" MODIFIED_BY="[Empty name]" NAME="Muangman 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-04 22:29:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Muangman P, Chuntrasakul C, Silthram S, Suvanchote S, Benjathanung R, Kittidacha S, Rueksomtawin S.Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial-thickness burn wounds.J Med Assoc Thai. 2006 Jul;89(7):953-8. PMID: 16881426 [PubMed - indexed for MEDLINE]&lt;/p&gt;" NOTES_MODIFIED="2008-11-04 22:29:16 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muangman P, Chuntrasakul C, Silthram S, Suvanchote S, Benjathanung R, Kittidacha S, et al</AU>
<TI>Comparison of efficacy of 1% silver sulfadiazine and Acticoat for treatment of partial-thickness burn wounds</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2006</YR>
<VL>89</VL>
<NO>7</NO>
<PG>953-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noordenbos-1999" MODIFIED="2008-11-04 22:29:37 +0000" MODIFIED_BY="[Empty name]" NAME="Noordenbos 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-04 22:29:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noordenbos J, Doré C, Hansbrough JF</AU>
<TI>Safety and efficacy of TransCyte for the treatment of partial-thickness burns</TI>
<SO>Journal of Burn Care and Rehabilitation</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>4</NO>
<PG>275-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soroff-1994" MODIFIED="2010-02-10 14:53:27 +0000" MODIFIED_BY="[Empty name]" NAME="Soroff 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-02-10 14:53:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soroff HS, Sasvary DH</AU>
<TI>Collagenase ointment and polymyxin B sulfate/bacitracin spray versus silver sulfadiazine cream in partial-thickness burns: a pilot study</TI>
<SO>Journal of Burn Care and Rehabilitation</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subrahmanyam-1998" NAME="Subrahmanyam 1998" YEAR="1998)">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Subrahmanyam M &lt;br&gt;Article Title:          A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine&lt;br&gt;Journal Detail:      Burns  98  24  2  157-61&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subrahmanyam M</AU>
<TI>A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine</TI>
<SO>Burns</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>2</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tredget-1998" MODIFIED="2010-02-10 14:53:45 +0000" MODIFIED_BY="[Empty name]" NAME="Tredget 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-02-10 14:53:45 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Author, Analytic:  Tredget EE, Shankowsky HA, Groeneveld A, and Burrell R&lt;br&gt;Article Title:          A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds&lt;br&gt;Journal Detail:      Journal of Burn Care and Rehabilitation  98  19  6  531-7&lt;/p&gt;" NOTES_MODIFIED="2010-02-10 14:53:45 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tredget EE, Shankowsky HA, Groeneveld A, Burrell R</AU>
<TI>A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds</TI>
<SO>Journal of Burn Care and Rehabilitation</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>6</NO>
<PG>531-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wunderlich-1991" NAME="Wunderlich 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Wunderlich U and Orfanos CE&lt;br&gt;Article Title:          [Treatment of venous ulcera cruris with dry wound dressings Phase overlapping use of silver impregnated activated charcoal xero-dressing]&lt;br&gt;Journal Detail:      Hautarzt  91  42  7  446-50&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wunderlich U, Orfanos CE</AU>
<TI>Treatment of venous ulcera cruris with dry wound dressings Phase overlapping use of silver impregnated activated charcoal xero-dressing</TI>
<SO>Hautarzt</SO>
<YR>1991</YR>
<VL>42</VL>
<NO>7</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wyatt-1990" NAME="Wyatt 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Wyatt D, McGowan DN, Najarian MP.Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second-degree burns.J Trauma. 1990 Jul;30(7):857-65.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wyatt D, McGowan DN, Najarian MP</AU>
<TI>Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second-degree burns</TI>
<SO>The Journal of Trauma</SO>
<YR>1990</YR>
<VL>30</VL>
<NO>7</NO>
<PG>857-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-12-10 14:46:44 +0000" MODIFIED_BY="Elizabeth Royle">
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boer-1981" MODIFIED="2009-12-10 14:40:53 +0000" MODIFIED_BY="Elizabeth Royle" NAME="De Boer 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-12-10 14:40:53 +0000" MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boer P, Collinson PO</AU>
<TI>The use of silver sulphadiazine occlusive dressings for finger-tip injuries</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>1981</YR>
<VL>63-B</VL>
<NO>4</NO>
<PG>545-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ganai-2002" NAME="Ganai 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Ganai AA, Darzi MA, Chowdri NA, Iqbal S, and Zaroo MI&lt;br&gt;Article Title:          Prospective randomized comparative study of early surgical excision and conservative treatment for deep burns of hand&lt;br&gt;Journal Detail:      JK Practitioner  2002  9  1  24-27&lt;br&gt;Design:                   RCT&lt;br&gt;Trial Cross Reference: &lt;br&gt;Notes:                     Full journal name is JK Practitioner in OVID&lt;br&gt;Abstract:                A prospective randomized comparative study was carried in 50 patients (72 hands) with deep dorsal hand burns, over a period of 3 years. Twenty five patients (35 hands) were treated conservatively by local antimicrobial cream (silver sulfadiazine) and late grafting when needed, while 25 patients (37 hands) were treated by early surgical excision and skin grafting at a mean of sixth post burn day (range 3 to 12 days). Physiotherapy was the same for both the groups. Patients were followed for a period of 12 to 24 months. We have observed that early surgical excision and immediate skin grafting shorten healing time, morbidity and lessens hospital stay. The number of anatomic deformities and the total number of reconstructive procedures were much reduced in the primarily excised group. Long term functional and cosmetic results in the excision group were also superior to those obtained in the conservatively managed group. These results encourage the routine use of primary excision and immediate for all deep dorsal burns of hand in patients with burn size of less than 40% of total body surface area. Number of References 21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ganai AA, Darzi MA, Chowdri NA, Iqbal S, Zaroo MI</AU>
<TI>Prospective randomized comparative study of early surgical excision and conservative treatment for deep burns of hand</TI>
<SO>JK Practitioner</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>1</NO>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guilbaud-1993" NAME="Guilbaud 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Guilbaud J and Honde C&lt;br&gt;Article Title:          Multicentre comparative clinical study of a new wound dressing: PA286 (Inerpan)&lt;br&gt;Journal Detail:      European Journal of Plastic Surgery  93  16  2  73-76&lt;br&gt;Design:                   &lt;br&gt;Trial Cross Reference: &lt;br&gt;Notes:                     &lt;br&gt;Abstract:                10 French burn centres participated in a prospective, randomised clinical trial comparing a new wound dressing, PA286 (trademark Inerpan) with the dressings commonly used in each centre, such as vaseline gauze, vaseline gauze with antibiotics, silver sulphadiazine cream and polyurethane film. A total of 460 patients with second degree burns, skin donor sites, meshed skin grafts and losses of skin substance were included in the study. Each patient acted as his, or her, own control. Two similar lesions in terms of site, depth and surface area were compared, one being treated with Inerpan, the other one with a control dressing. The following parameters were studied: healing time, intensity of pain, local safety, and frequency of dressing changes. Analysis of the results showed that healing time and importance of local events such as exudate and suppuration did not differ significantly. Intensity of pain experienced by the patient and frequency of dressing renewals were significantly lower with Inerpan then with control dressings&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guilbaud J, Honde C</AU>
<TI>Multicentre comparative clinical study of a new wound dressing: PA286 (Inerpan)</TI>
<SO>European Journal of Plastic Surgery</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>2</NO>
<PG>73-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hadjiiski-1999" NAME="Hadjiiski 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Hadjiiski OG and Lesseva MI&lt;br&gt;Article Title:          Comparison of four drugs for local treatment of burn wounds&lt;br&gt;Journal Detail:      European Journal of  Emergency Medicine  99  6  1  41-7&lt;br&gt;Design:                   CCT&lt;br&gt;Trial Cross Reference: &lt;br&gt;Notes:                     / SR-HANDSRCH /&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hadjiiski OG, Lesseva MI</AU>
<TI>Comparison of four drugs for local treatment of burn wounds</TI>
<SO>European Journal of Emergency Medicine</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>1</NO>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2007" MODIFIED="2008-11-04 18:47:54 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-04 18:47:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Huang Y, Li X, Liao Z, Zhang G, Liu Q, Tang J, Peng Y, Liu X, and Luo Q&lt;br&gt;Article Title:          A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis&lt;br&gt;Journal Detail:      Burns  2007  33  2  161-166&lt;/p&gt;" NOTES_MODIFIED="2008-11-04 18:47:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Y, Li X, Liao Z, Zhang G, Liu Q, Tang J, et al</AU>
<TI>A randomized comparative trial between Acticoat and SD-Ag in the treatment of residual burn wounds, including safety analysis</TI>
<SO>Burns</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>161-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jorgensen-2006" MODIFIED="2009-12-10 14:42:47 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Jorgensen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-12-10 14:42:47 +0000" MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ivins N, Harding KG, Price P, Jurgensen B, Lohmann M, Gottrup F, et al</AU>
<TI>Safety and efficacy in long-term use of a sustained silver-releasing foam dressing: a randomized, controlled trial on venous leg ulcers</TI>
<SO>SAWC 2006 April 30-May 3, 2006 San Antonio, Texas</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-06-24 20:11:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen B, Bech Thomsen N, Grenov B, Gottrup F</AU>
<TI>Effect of a new silver dressing on chronic venous leg ulcers with signs of critical colonisation</TI>
<SO>International Wound Journal</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>1</NO>
<PG>64-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lanzara-2008" MODIFIED="2009-09-17 17:28:54 +0100" MODIFIED_BY="[Empty name]" NAME="Lanzara 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-17 17:28:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lanzara S, Tacconi G, Gianesini S, Menegatti E, Federici F, Liboni A, et al</AU>
<TI>A pilot randomized trial to determine the effects of a new active dressing on wound healing of venous leg ulcers [Abstract no. 114]</TI>
<SO>EWMA Journal</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>2</NO>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molnar-2004" MODIFIED="2009-12-10 14:46:01 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Molnar 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-12-10 14:46:01 +0000" MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Molnar JA, Heimbach DM, Tredgett EE, Mozingo DW</AU>
<TI>Prospective, randomized, controlled, multicenter trial applying subatmospheric pressure to acute hand burns: an interim report</TI>
<SO>2nd World Union of Wound Healing Societies Meeting, 8-13 July, Paris</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munster-1980" MODIFIED="2009-01-23 10:45:52 +0000" MODIFIED_BY="[Empty name]" NAME="Munster 1980" YEAR="1980">
<REFERENCE MODIFIED="2009-01-23 10:45:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Helvig EI, Munster AM, Su CT, Oppel W</AU>
<TI>Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective, randomized study</TI>
<SO>American Surgeon</SO>
<YR>1979</YR>
<VL>45</VL>
<NO>4</NO>
<PG>270-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-01-23 10:45:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munster AM, Helvig E, Rowland S</AU>
<TI>Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation</TI>
<SO>Surgery</SO>
<YR>1980</YR>
<VL>88</VL>
<NO>5</NO>
<PG>658-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00fc_nter-2006" MODIFIED="2008-11-04 18:47:38 +0000" MODIFIED_BY="[Empty name]" NAME="Münter 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-04 18:47:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Münter KC, Beele H,  Russell L, Crespi A, Grochenig E, Basse P, et al</AU>
<TI>Effect of a sustained silver-releasing dressing on ulcers with delayed healing: the CONTOP study</TI>
<SO>Journal of Wound Care</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>5</NO>
<PG>199-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Planinsek-2007" MODIFIED="2009-12-10 14:46:44 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Planinsek 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-10 14:46:44 +0000" MODIFIED_BY="Elizabeth Royle" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Planinsek Rucigaj T</AU>
<TI>Comparative effects of honey based and silver/charcoal based dressings on the healing of venous leg ulcers: a randomized clinical study [Oral presentation no: 78]</TI>
<SO>17th Conference of the European Wound Management Association; 2007, 2-4 May; Glasgow, Scotland</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riesinger-2006" MODIFIED="2009-09-17 17:29:30 +0100" MODIFIED_BY="[Empty name]" NAME="Riesinger 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-09-17 17:29:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riesinger T, Gubish ER</AU>
<TI>Clinical evaluation of the efficacy and safety of an innovative moist wound dressing (IWD), containing a nanolayer of metallic silver in patients following an extensive surgical procedure for pectus excavatum</TI>
<SO>SAWC April 30 - May 3, 2006 San Antonio, Texas</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-2007" MODIFIED="2008-11-04 22:30:39 +0000" MODIFIED_BY="[Empty name]" NAME="Silver 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-04 22:30:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver GM, Robertson SW, Halerz MM, Conrad P, Supple KG, Gamelli RL</AU>
<TI>A silver-coated antimicrobial barrier dressing used postoperatively on meshed autografts: A dressing comparison study</TI>
<SO>Journal of Burn Care and Research</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>5</NO>
<PG>715-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stair-1986" NAME="Stair 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Stair TO, D'Orta J, Altieri MF, and Lippe MS&lt;br&gt;Article Title:          Polyurethane and silver sulfadiazene dressings in treatment of partial-thickness burns and abrasions&lt;br&gt;Journal Detail:      American Journal of Emergency Medicine  86  4  3  214-7&lt;br&gt;Design:                   RCT&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stair TO, D'Orta J, Altieri MF, Lippe MS</AU>
<TI>Polyurethane and silver sulfadiazene dressings in treatment of partial-thickness burns and abrasions</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>3</NO>
<PG>214-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Subrahmanyam-1991" NAME="Subrahmanyam 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Author, Analytic:  Subrahmanyam M&lt;br&gt;Article Title:          Topical application of honey in treatment of burns&lt;br&gt;Journal Detail:      British Journal of Surgery  91  78  4  497-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Subrahmanyam M</AU>
<TI>Topical application of honey in treatment of burns</TI>
<SO>British Journal of Surgery</SO>
<YR>1991</YR>
<VL>78</VL>
<NO>4</NO>
<PG>497-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terrill-1991" MODIFIED="2009-09-17 17:11:47 +0100" MODIFIED_BY="[Empty name]" NAME="Terrill 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-09-17 17:11:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terrill PJ, Kedwards SM, Lawrence JC</AU>
<TI>The use of Gore-Tex bags for hand burns</TI>
<SO>Burns</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>161-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verd_x00fa_-2004" MODIFIED="2008-10-30 22:33:49 +0000" MODIFIED_BY="[Empty name]" NAME="Verdú 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-30 22:33:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verdú SJ, Rueda LJ, Martinez CF, Soldevilla AJ</AU>
<TI>Effects of an activated charcoal silver dressing on chronic wounds with no clinical signs of infection</TI>
<SO>Journal of Wound Care</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>10</NO>
<PG>419, 421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yue-Seng-2005" MODIFIED="2009-09-17 17:31:33 +0100" MODIFIED_BY="[Empty name]" NAME="Yue Seng 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-17 17:31:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yue Seng C, Bin Sofiyan M, Bin Mohd Hashim AS</AU>
<TI>The role of nanocrystalline silver in complicated wounds in the orthopaedic ward</TI>
<SO>European Wound Management Association Conference; 2005, 15-17 September; Stuttgart, Germany</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-09-17 17:12:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" NAME="Chen 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen J, Han CM, Lin XW, Tang ZJ, Su SJ</AU>
<TI>Effect of silver nanoparticle dressing on second degree burn wound</TI>
<SO>Chung-Hua Wai Ko Tsa Chih</SO>
<YR>2006</YR>
<VL>44</VL>
<NO>1</NO>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hirsch-2008" MODIFIED="2009-09-17 17:12:27 +0100" MODIFIED_BY="[Empty name]" NAME="Hirsch 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-17 17:12:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch T, Ashkar W, Schumacher O, Steinstraesser L, Ingianni G, Cedidi CC</AU>
<TI>Moist Exposed Burn Ointment (MEBO) in partial thickness burns - a randomized, comparative open mono-center study on the efficacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy</TI>
<SO>European Journal of Medical Research</SO>
<YR>2008</YR>
<VL>13(11)</VL>
<PG>505-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2006" MODIFIED="2009-04-28 16:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-04-28 16:07:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li XL, Huang YS, Peng YZ , Liao ZJ , Zhang GA, Liu Q, et al</AU>
<TI>Multi-center clinical study of acticoat (nanocrystalline silver dressing) for the management of residual burn wounds</TI>
<SO>Zhonghua Shao Shang Za Zhi [Chinese Journal of Burns]</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>1</NO>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2008" MODIFIED="2008-11-01 21:57:36 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-11-01 21:57:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J-W, Teng Y-J</AU>
<TI>Efficacy of ionic silver dressing and gel in local treatment of dog bite III wounds: A randomized control study</TI>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>14</NO>
<PG>2659-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-09-17 17:41:00 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Serena-2008" MODIFIED="2009-09-17 17:41:00 +0100" MODIFIED_BY="[Empty name]" NAME="Serena 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-17 17:27:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hanft J, Serena T, Snyder R</AU>
<TI>Evaluation of the clinical effectiveness of a collagen-orc antimicrobial matrix in venous leg ulcers</TI>
<SO>16th Conference of the European Wound Management Association May 2006 Prague</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-09-17 17:41:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Serena TE, Hanft JR, Snyder R</AU>
<TI>The lack of reliability of clinical examination in the diagnosis of wound infection: preliminary communication</TI>
<SO>The International Journal of Lower Extremity Wounds</SO>
<YR>2008</YR>
<VL>7(1)</VL>
<PG>32-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-02-10 17:09:14 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-02-10 17:09:14 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abedon-1998" MODIFIED="2010-02-10 15:01:32 +0000" MODIFIED_BY="[Empty name]" NAME="Abedon 1998" TYPE="OTHER">
<AU>Abedon ST</AU>
<TI>Supplemental lecture, 1998</TI>
<SO>Available from: http://www.mansfield.ohio-state.edu/~sabedon/biol2007.htm</SO>
<YR>(accessed 10 January 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adeyemo-2005" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Adeyemo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Adeyemo WL, Ogunlewe MO, Ladeinde AL, Bamgbose BO</AU>
<TI>Are sterile gloves necessary in nonsurgical dental extractions?</TI>
<SO>Journal of Oral Maxillofacial Surgery</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>7</NO>
<PG>936-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arrowsmith-2001" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Arrowsmith 2001" TYPE="COCHRANE_REVIEW">
<AU>Arrowsmith VA, Maunder JA, Sargent RJ, Taylor R</AU>
<TI>Removal of nail polish and finger rings to prevent surgical infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:14:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:14:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003325"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Atiyeh-2007" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Atiyeh 2007" TYPE="JOURNAL_ARTICLE">
<AU>Atiyeh BS, Costagliola M, Hayek SN, Dibo SA</AU>
<TI>Effect of silver on burn wound infection control and healing: review of the literature</TI>
<SO>Burns</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>139-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-2002" MODIFIED="2009-05-08 13:36:45 +0100" MODIFIED_BY="[Empty name]" NAME="Ballard 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ballard K, McGregor F</AU>
<TI>Product Focus. Avance: silver hydropolymer dressing for critically colonised wounds</TI>
<SO>British Journal of Nursing</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>3</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balthazar-1982" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Balthazar 1982" TYPE="JOURNAL_ARTICLE">
<AU>Balthazar ER, Colt JD, Nichols RL</AU>
<TI>Preoperative hair removal: a random prospective study of shaving versus clipping</TI>
<SO>Southern Medical Journal</SO>
<YR>1982</YR>
<VL>75</VL>
<NO>7</NO>
<PG>799-801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergin-2006" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Bergin 2006" TYPE="COCHRANE_REVIEW">
<AU>Bergin S, Wraight P</AU>
<TI>Silver based wound dressings and topical agents for treating diabetic foot ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:14:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-10 22:11:56 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brett-2006" MODIFIED="2009-09-17 17:42:12 +0100" MODIFIED_BY="[Empty name]" NAME="Brett 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brett DW</AU>
<TI>A discussion of silver as an antimicrobial agent: alleviating the confusion</TI>
<SO>Ostomy Wound Manage</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>1</NO>
<PG>34-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2001" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Brooks 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brooks RA, Hollinghurst D, Ribbans WJ, Severn M</AU>
<TI>Bacterial recolonization during foot surgery: a prospective randomized study of toe preparation techniques</TI>
<SO>Foot &amp; Ankle International</SO>
<YR>2001</YR>
<VL>22</VL>
<NO>4</NO>
<PG>347-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooper-2004" MODIFIED="2008-11-01 22:09:51 +0000" MODIFIED_BY="[Empty name]" NAME="Cooper 2004" TYPE="CONFERENCE_PROC">
<AU>Cooper R</AU>
<TI>A review of the evidence for the use of topical antimicrobials agents in wound care</TI>
<SO>World Wide Wounds</SO>
<YR>2004:http://www.worldwidewounds.com/2004/february/Cooper/Topical&#8211;Antimicrobial-Agents.html (accessed October 19, 2008)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cutting-2005" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Cutting 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cutting KF, White RJ</AU>
<TI>Criteria for identifying wound infection-revisited</TI>
<SO>Ostomy Wound Management</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>1</NO>
<PG>28-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dowsett-2004" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Dowsett 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dowsett C</AU>
<TI>The use of silver-based dressings in wound care</TI>
<SO>Nursing Standard</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>7</NO>
<PG>56-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dunn-2004" MODIFIED="2009-09-17 17:42:51 +0100" MODIFIED_BY="[Empty name]" NAME="Dunn 2004" TYPE="JOURNAL_ARTICLE">
<AU>Dunn K, Edwards-Jones V</AU>
<TI>The role of Acticoat with nanocrystalline silver in the management of burns</TI>
<SO>Burns</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>Suppl 1</NO>
<PG>S1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Edwards-2004" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Edwards 2004" TYPE="COCHRANE_REVIEW">
<AU>Edwards PS, Lipp A, Holmes A</AU>
<TI>Preoperative skin antiseptics for preventing surgical wound infections after clean surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:30:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:30:03 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003949.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-01-27 14:32:54 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fernandez-2008" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Fernandez 2008" TYPE="COCHRANE_REVIEW">
<AU>Fernandez R, Griffiths R, Ussia C</AU>
<TI>Water for wound cleansing</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:16:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:16:17 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD003861.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fuller-1994" MODIFIED="2008-11-04 18:48:52 +0000" MODIFIED_BY="[Empty name]" NAME="Fuller 1994" TYPE="JOURNAL_ARTICLE">
<AU>Fuller FW, Parrish M, Nance FC</AU>
<TI>A review of the dosimetry of 1% silver sulfadiazine cream in burn wound treatment</TI>
<SO>Journal of Burn Care and Rehabilitation</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>3</NO>
<PG>213-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartford-1981" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Hartford 1981" TYPE="JOURNAL_ARTICLE">
<AU>Hartford CE</AU>
<TI>The bequests of Moncrief and Moyer: An appraisal of topical therapy of burns--1981 American burn association presidential address</TI>
<SO>The Journal of Trauma</SO>
<YR>1981</YR>
<VL>21</VL>
<NO>10</NO>
<PG>827-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-01-27 14:34:17 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-09-17 17:43:57 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008)</SO>
<YR>The Cochrane Collaboration, 2008</YR>
<PB>Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hussain-2006" MODIFIED="2010-01-27 14:36:48 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Hussain 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hussain S, Ferguson C</AU>
<TI>Best evidence topic report. Silver sulphadiazine cream in burns</TI>
<SO>Emergency Medicine Journal</SO>
<YR>2006</YR>
<VL>23</VL>
<NO>12</NO>
<PG>929-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-1993" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Jakobsen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen BW, Bach A, Kristensen K, Sorensen TS, Staehr H</AU>
<TI>Finger tip injuries. A comparative study of silver sulfadiazine and fucidin gauze</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1993</YR>
<VL>155</VL>
<NO>45</NO>
<PG>3654-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kac-2005" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kac 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kac G, Podglajen I, Gueneret M, Vaupré S, Bissery A, Meyer G</AU>
<TI>Microbiological evaluation of two hand hygiene procedures achieved by healthcare workers during routine patient care: a randomized study</TI>
<SO>The Journal of Hospital Infection</SO>
<YR>2005</YR>
<VL>60</VL>
<NO>1</NO>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karlsmark-2003" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Karlsmark 2003" TYPE="JOURNAL_ARTICLE">
<AU>Karlsmark T, Agerslev RH, Bendz SH, Larsen JR, Roed-Petersen J, Andersen KE</AU>
<TI>Clinical performance of a new silver dressing, Contreet Foam, for chronic exuding venous leg ulcers</TI>
<SO>Journal of Wound Care</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>9</NO>
<PG>351-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kucan-1981" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kucan 1981" TYPE="JOURNAL_ARTICLE">
<AU>Kucan JO, Robson MC, Heggers JP, Ko F</AU>
<TI>Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1981</YR>
<VL>29</VL>
<NO>5</NO>
<PG>232-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lammers-1990" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lammers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Lammers RL, Fourré M, Callaham ML, Boone T</AU>
<TI>Effect of povidone-iodine and saline soaking on bacterial counts in acute, traumatic, contaminated wounds</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>6</NO>
<PG>709-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lansdown-2002" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lansdown 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lansdown AB</AU>
<TI>Silver. I: Its antibacterial properties and mechanism of action</TI>
<SO>Journal of Wound Care</SO>
<YR>2002</YR>
<VL>11</VL>
<NO>4</NO>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawson-2003" MODIFIED="2010-02-10 15:04:17 +0000" MODIFIED_BY="[Empty name]" NAME="Lawson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lawson C, Juliano L, Ratliff CR</AU>
<TI>Does sterile or nonsterile technique make a difference in wounds healing by secondary intention?</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>4</NO>
<PG>56-8, 60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2008-10-21 20:38:23 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6.4.11: Search filters</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008)</SO>
<YR>The Cochrane Collaboration, 2008</YR>
<PB>Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lethaby-2008" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lethaby 2008" TYPE="COCHRANE_REVIEW">
<AU>Lethaby A, Temple J, Santy J</AU>
<TI>Pin site care for preventing infections associated with external bone fixators and pins</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:21:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:21:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD004551.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mangram-1999" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Mangram 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR</AU>
<TI>Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee</TI>
<SO>Infection Control and Hospital Epidemiology</SO>
<YR>1999</YR>
<VL>20</VL>
<NO>4</NO>
<PG>250-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLaws-2000" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="McLaws 2000" TYPE="JOURNAL_ARTICLE">
<AU>McLaws ML, Caelli M</AU>
<TI>Pilot testing standardized surveillance: Hospital Infection Standardised Surveillance (HISS)</TI>
<SO>American Journal of Infection Control</SO>
<YR>2000</YR>
<VL>28</VL>
<NO>6</NO>
<PG>401-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2005" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2005" TYPE="COCHRANE_REVIEW">
<AU>Moore ZE, Cowman S</AU>
<TI>Wound cleansing for pressure ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:18:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:18:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD004983.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moralejo-2003" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Moralejo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moralejo D, Jull A</AU>
<TI>Handrubbing with an aqueous alcohol solution was as effective as handscrubbing with an antiseptic soap for preventing surgical site infections</TI>
<SO>Evidence Based Nursing</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>2</NO>
<PG>54-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagl-2003" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Nagl 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nagl M, Nguyen VA, Gottardi W, Ulmer H, Höpfl R</AU>
<TI>Tolerability and efficacy of N-chlorotaurine in comparison with chloramine T for the treatment of chronic leg ulcers with a purulent coating: a randomized phase II study</TI>
<SO>British Journal of Dermatology</SO>
<YR>2003</YR>
<VL>149</VL>
<NO>3</NO>
<PG>590-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2001" MODIFIED="2009-09-17 17:45:05 +0100" MODIFIED_BY="[Empty name]" NAME="O'Meara 2001" TYPE="JOURNAL_ARTICLE">
<AU>O'Meara SM, Cullum NA, Majid M, Sheldon TA</AU>
<TI>Systematic review of antimicrobial agents used for chronic wounds</TI>
<SO>British Journal of Surgery</SO>
<YR>2001</YR>
<VL>88</VL>
<NO>1</NO>
<PG>4-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Meara-2008" MODIFIED="2009-09-17 17:45:12 +0100" MODIFIED_BY="[Empty name]" NAME="O'Meara 2008" TYPE="COCHRANE_REVIEW">
<AU>O'Meara S, Ovington L</AU>
<TI>Antibiotics and antiseptics for venous leg ulcers</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="DOI: 10.1002/14651858.CD003557.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ovington-2001" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Ovington 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ovington LG</AU>
<TI>Nanocrystalline Silver: Where the old and familiar meets a new frontier</TI>
<SO>Wounds: A compendium of clinical practice and research</SO>
<YR>2001</YR>
<VL>13</VL>
<NO>2</NO>
<PG>4-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ovington-2003" MODIFIED="2010-02-10 15:05:00 +0000" MODIFIED_BY="[Empty name]" NAME="Ovington 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ovington LG</AU>
<TI>Bacterial toxins and wound healing</TI>
<SO>Ostomy/Wound Management</SO>
<YR>2003</YR>
<VL>49</VL>
<NO>Suppl 7A</NO>
<PG>8-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peinemann-2008" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Peinemann 2008" TYPE="JOURNAL_ARTICLE">
<AU>Peinemann F, McGauran N, Sauerland S, Lange S</AU>
<TI>Negative pressure wound therapy: potential publication bias caused by lack of access to unpublished study results data</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perelman-2004" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Perelman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Perelman VS, Francis GJ, Rutledge T, Foote J, Martino F, Dranitsaris G</AU>
<TI>Sterile versus nonsterile gloves for repair of uncomplicated lacerations in the emergency department: a randomized controlled trial</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>3</NO>
<PG>362-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossoff-1995" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rossoff 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rossoff LJ, Borenstein M, Isenberg HD</AU>
<TI>Is hand washing really needed in an intensive care unit?</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>7</NO>
<PG>1211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rotter-1997" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rotter 1997" TYPE="BOOK_SECTION">
<AU>Rotter ML</AU>
<TI>Hand washing, hand disinfection, and skin disinfection</TI>
<SO>Prevention and control of nosocomial infections</SO>
<YR>1997</YR>
<PG>691&#8211;709</PG>
<EN>3th</EN>
<ED>RP Wenzel</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibbald-2005" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Sibbald 2005" TYPE="OTHER">
<AU>Sibbald RG, Meaume S, Kirsner RS, Münter K</AU>
<TI>Review of the clinical RCT evidence and cost-effectiveness data of a sustained-release silver foam dressing in the healing of critically colonised wounds</TI>
<SO>World Wide Wounds</SO>
<YR>2005</YR>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SIGN-2008" MODIFIED="2008-10-21 20:42:07 +0100" MODIFIED_BY="[Empty name]" NAME="SIGN 2008" TYPE="OTHER">
<AU>Scottish Intercollegiate Guidelines Network (SIGN)</AU>
<TI>Search filters</TI>
<SO>http://www.sign.ac.uk/methodology/filters.html#random (accessed 19 October 2008)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stotts-1997" MODIFIED="2009-04-28 16:14:40 +0100" MODIFIED_BY="[Empty name]" NAME="Stotts 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stotts NA, Barbour S, Griggs K, Bouvier B, Buhlman L, Wipke-Tevis D, et al</AU>
<TI>Sterile versus clean technique in postoperative wound care of patients with open surgical wounds: a pilot study</TI>
<SO>Journal of Wound, Ostomy, and Continence Nursing</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>1</NO>
<PG>10-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tang-2001" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Tang K, Yeh JS, Sgouros S</AU>
<TI>The Influence of hair shave on the infection rate in neurosurgery. A prospective study</TI>
<SO>Pediatric Neurosurgery</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tanner-2006" MODIFIED="2009-10-28 15:49:54 +0000" MODIFIED_BY="[Empty name]" NAME="Tanner 2006" TYPE="COCHRANE_REVIEW">
<AU>Tanner J, Woodings D, Moncaster K</AU>
<TI>Preoperative hair removal to reduce surgical site infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-10-28 15:49:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:49:54 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004122.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tanner-2008" MODIFIED="2010-01-27 14:46:30 +0000" MODIFIED_BY="Elizabeth Royle" NAME="Tanner 2008" TYPE="COCHRANE_REVIEW">
<AU>Tanner J, Swarbrook S, Stuart J</AU>
<TI>Surgical hand antisepsis to reduce surgical site infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-10-28 15:47:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-28 15:47:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004288.pub2 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-2007" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Vermeulen 2007" TYPE="COCHRANE_REVIEW">
<AU>Vermeulen H, van Hattem JM, Storm-Versloot MN, Ubbink DT</AU>
<TI>Topical silver for treating infected wounds</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-13 15:31:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 15:31:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005486.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vogt-2001" MODIFIED="2009-04-28 16:14:28 +0100" MODIFIED_BY="[Empty name]" NAME="Vogt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Vogt PM, Hauser J, Rossbach O, Bosse B, Fleischer W, Steinau HU, et al</AU>
<TI>Polyvinyl pyrrolidone-iodine liposome hydrogel improves epithelialization by combining moisture and antisepis. A new concept in wound therapy</TI>
<SO>Wound Repair and Regeneration</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>2</NO>
<PG>116-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasiak-2006" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Wasiak 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wasiak J, Cleland H</AU>
<TI>Burns (minor thermal)</TI>
<SO>BMJ Clinical Evidence</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>1903</NO>
<PG>1-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasiak-2008" MODIFIED="2008-10-21 19:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Wasiak 2008" TYPE="COCHRANE_REVIEW">
<AU>Wasiak J, Cleland H, Campbell F</AU>
<TI>Dressings for superficial and partial thickness burns</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-10-21 14:56:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 14:56:32 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002106.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1986" MODIFIED="2009-04-28 16:14:54 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 1986" TYPE="JOURNAL_ARTICLE">
<AU>Wilson GR, Fowler C, Ledger J, Thorley M</AU>
<TI>Evaluation of a new antiseptic dressing in minor burns</TI>
<SO>Burns Incl Therm Injury</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>7</NO>
<PG>518-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2004" MODIFIED="2009-09-17 17:46:46 +0100" MODIFIED_BY="[Empty name]" NAME="Wilson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wilson AP, Gibbons C, Reeves BC, Hodgson B, Liu M, Plummer D, Krukowski ZH, Bruce J, Wilson J, Pearson A</AU>
<TI>Surgical wound infection as a performance indicator: agreement of common definitions of wound infection in 4773 patients</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>329</VL>
<NO>7468</NO>
<PG>720</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-02-16 15:06:09 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-02-16 15:06:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Miscellaneous quality issues" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-02-03 13:06:40 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Afilalo-1992">
<CHAR_METHODS MODIFIED="2008-07-04 13:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Computer-generated random numbers table</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 11:47:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 48<BR/>Patients in Emergency Department with partial-thickness burns, &lt;15% TBSA<BR/>Duration of wound in both groups: &lt; 48 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-03 13:06:40 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) (n = 15)<BR/>Group 2: hydrocolloid dressing (Duoderm®) (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 11:52:30 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain; patient satisfaction</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 11:52:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-16 21:42:14 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Definition of infection: not reported<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-03 13:07:54 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Carneiro-2002">
<CHAR_METHODS>
<P>Randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-03 13:07:47 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 64<BR/>Patients with 2nd degree burns, &lt; 30% TBSA<BR/>Duration of wound: not reported for either group<BR/>Unit of allocation: patient<BR/>Period of follow-up: until discharge</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 11:54:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD/chlorhexidine (Silverex) (n = 32)<BR/>Group 2: Diphenyldantoin (phenytoin) (n = 32)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-03 13:07:54 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain; length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 11:54:44 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-16 21:50:37 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Tanzania<BR/>Definition of infection: cultures<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-03 13:08:36 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Caruso-2006">
<CHAR_METHODS>
<P>Stratified randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 11:55:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 84<BR/>Patients with superficial, mid-dermal or mixed partial-thickness burns of 5-40% TBSA<BR/>Duration of wound in both groups: &lt; 36 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: 3 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-03 13:08:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 40)<BR/>Group 2: hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 42)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 11:56:52 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; adverse effects; use of systemic antibiotics; pain; costs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 11:56:56 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-16 21:56:59 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: not reported<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Gracia-2001">
<CHAR_METHODS MODIFIED="2010-01-22 11:57:27 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients assigned consecutively according to a pre-established randomised sequence</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 11:57:46 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 60<BR/>Patients with moderate and severe burns, &gt;15% TBSA<BR/>Duration of wound in both groups: &lt; 24 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-03 13:10:21 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (Flamazine®) (n = 30)<BR/>Group 2 SSD/cerium-nitrate (Flammacerium®) (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 11:58:56 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; adverse effects; use of systemic antibiotics; length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 11:59:00 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:48 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Philippines<BR/>Definition of infection: cultures and clinical criteria<BR/>Concurrent illness: majority none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dire-1995">
<CHAR_METHODS MODIFIED="2009-09-17 16:28:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, opaque numbered vials</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 11:59:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 465<BR/>Patients with minor, uncomplicated soft-tissue wounds necessitating suturing<BR/>Duration of wound in both groups: &lt; 12 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:01:44 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 99)<BR/>Group 2: BAC (n = 109)<BR/>Group 3: neomycin sulfate (n = 110)<BR/>Group 4: petrolatum (n = 108)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infection rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:01:50 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:49 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Texas<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-22 12:04:31 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Fang-1987">
<CHAR_METHODS>
<P>Selected at random</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 12:03:49 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 27 (54 wound sites)<BR/>Patients with similar size and injury-matched areas of 2nd degree burns<BR/>Duration of wound: not reported in either group<BR/>Unit of allocation: wounds<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:04:24 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (1%) (n = 27)<BR/>Group 2: synthetic dressing containing silver (Hydron AgSD (1-3%)) (n = 27)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 12:04:26 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:04:31 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-16 22:12:25 +0000" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Definition of infection: cultures<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerding-1988">
<CHAR_METHODS MODIFIED="2010-01-22 12:06:58 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated codes within sealed, numbered envelopes that were opened sequentially</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 12:05:19 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 47 (50 wounds)<BR/>Inpatients with acute partial-thickness burns<BR/>Duration of wound in both groups: &lt; 6 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:05:54 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (1%) (n = 23)<BR/>Group 2: biosynthetic dressing (Biobrane®) (n = 27)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 12:06:06 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain; costs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:06:09 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:50 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: cultures and clinical criteria<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerding-1990">
<CHAR_METHODS MODIFIED="2010-01-22 12:06:48 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated codes within sealed, numbered envelopes that were opened sequentially</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 12:07:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 64 (analysed 56 wounds)<BR/>Outpatients with acute partial-thickness thermal burns, &lt; 10% TBSA<BR/>Duration of wound in both groups: &lt; 24 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:08:07 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (1%) (n = 26)<BR/>Group 2: biosynthetic dressing (Biobrane®) (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 12:08:17 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain; costs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:08:20 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:51 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: clinical criteria, but not described in detail<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-22 12:10:05 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Hansbrough-1995">
<CHAR_METHODS>
<P>Randomly assigned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-22 12:09:16 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 79 (158 wounds)<BR/>Patients with 2 similar partial-thickness burns of 1-25% TBSA<BR/>Duration of wound in both groups: &lt; 4 days<BR/>Unit of allocation: wounds<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:09:52 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (1%) (Silvadene) (n = 79)<BR/>Group 2: collagenase ointment applied with polymyxin B sulfate/bacitracin powder (Santyl®) (n = 79)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-22 12:10:02 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:10:05 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-16 22:21:24 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: not reported<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Homann-2007">
<CHAR_METHODS MODIFIED="2010-01-22 12:11:17 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated randomisation list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-03 13:16:10 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 47<BR/>Patients with 2 comparable partial-thickness burns (degree IIa) without wound infection, &lt; 50% TBSA<BR/>Duration of wound in both groups: &lt; 72 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: until healing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:13:50 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 43)<BR/>Group 2: liposome hydrogel with PVP-I (n = 43) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-03 13:16:18 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; adverse effects; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:52 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:52 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: not sufficiently reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 14:16:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hutchinson-1993">
<CHAR_METHODS MODIFIED="2010-01-22 12:17:03 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Prospective, controlled, randomised investigation </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-16 14:16:08 +0000" MODIFIED_BY="[Empty name]">
<P>n = 292<BR/>Patients with venous leg ulcers, partial-thickness burns or partial-thickness donor sites.<BR/>Duration of wound in both groups: not reported for burns or donor sites.<BR/>Duration of wound for leg ulcers: Group 1: 318 weeks; Group 2: 102 weeks; Group 3: 162 weeks.<BR/>Unit of allocation: patient.<BR/>Period of follow-up: for burns and donor sites 3 weeks; for leg ulcers 10 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-22 12:22:27 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream/hydrocolloid (n = 58)<BR/>Group 2: hydrocolloid (n = 108)<BR/>Group 3: non-occlusive paraffin impregnated gauze (n = 126)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infection rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:52 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA, United Kingdom, Netherlands<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inman-1984">
<CHAR_METHODS MODIFIED="2010-01-27 13:22:40 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomly assigned </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:24:20 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 121 <BR/>Patients with fresh full-thickness burns<BR/>Duration of wound in both groups: &lt; 24 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:25:01 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (Flamazine®) (n = 54)<BR/>Group 2: SSD/chlorhexidine digluconate cream (0.2%) (Silvazine®) (n = 67)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:25:11 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; use of systemic antibiotics; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:54 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Definition of infection: clinical criteria accompanied with cultures with &gt; 10<SUP>5 </SUP>organisms per gram of tissue<BR/>Concurrent illness: not sufficiently reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Innes-2001">
<CHAR_METHODS MODIFIED="2010-01-27 13:29:14 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomisation table assigned dressings to site A or site B</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:30:03 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 17 (32 wound sites)<BR/>Patients with burns who required split-thickness skin graft <BR/>Duration of wound in both groups: not reported<BR/>Unit of allocation: wounds<BR/>Period of follow-up: &gt; 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:30:48 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: nanocrystalline silver-coated dressing (Acticoat®) (n = 16)<BR/>Group 2: hydrophilic polyurethane dressing (Allevyn®) (n = 16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:31:00 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; costs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:30 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:54 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Definition of infection: cultures and clinical criteria<BR/>Concurrent illness: not sufficiently reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jacobs-2008">
<CHAR_METHODS MODIFIED="2009-01-17 17:43:25 +0000" MODIFIED_BY="[Empty name]">
<P>Randomly assigned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:23:18 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 40<BR/>Diabetic patients with Wagner grade 1 or 2 ulcers<BR/>Duration of wound in both groups: not reported<BR/>Unit of allocation: patients<BR/>Period of follow-up: 6 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-03 13:18:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 20)<BR/>Group 2: benzoic acid-6%, salicylic acid-3% and <I>Quercus rubra</I> extract-3% (Bensal HP) (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:34:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:30 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:55 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Definition of infection: cultures and clinical criteria<BR/>Concurrent illness: all patients had diabetes, patients with peripheral vascular disease were excluded. Additional co-morbid conditions were not evaluated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 15:05:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jude-2007">
<CHAR_METHODS MODIFIED="2009-02-04 21:08:28 +0000" MODIFIED_BY="[Empty name]">
<P>Randomly assigned to instructions in a sealed envelope </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-16 15:05:17 +0000" MODIFIED_BY="[Empty name]">
<P>n = 134<BR/>Patients with diabetic foot ulcers of Wagner grade 1 or 2 of non-ischaemic aetiology with area &#8805;1 cm<SUP>2</SUP>
<BR/>Duration of wound in both groups: not reported<BR/>Unit of allocation: patient<BR/>Period of follow-up: 8 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:38:30 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 67)<BR/>Group 2: calcium alginate dressing (Algosteril®) (n = 67)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:38:43 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:31 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:57 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United Kingdom, Germany, Sweden, France<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: DM, types 1 and 2</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jurczak-2007">
<CHAR_METHODS MODIFIED="2010-01-22 12:16:21 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated randomisation scheme with sealed envelopes opened sequentially</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:23:23 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 67<BR/>Patients with open surgical wounds or open traumatic wounds left to heal by secondary intent and requiring an antimicrobial dressing<BR/>Duration of wound in both groups: &lt; 12 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:42:12 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: Hydrofibre dressing containing ionic silver (Aquacel® Ag) (n = 35)<BR/>Group 2: povidone iodine gauze (n = 32)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:42:24 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; adverse effects; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:31 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:57 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain, Germany, France<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: not sufficiently reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 13:49:53 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Livingston-1990">
<CHAR_METHODS MODIFIED="2010-01-27 13:47:49 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomisation by labelling cards, shuffling and drawing in blinded fashion; because of resulting imbalance in group size, last 7 consecutive patients all placed in silver nitrate group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:48:28 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 52<BR/>Patients with thermal injury who required skin grafting<BR/>Duration of wound in both groups:<BR/>Group 1: mean 3-4 days to first graft;<BR/>Group 2: mean 4 days;<BR/>Group 3: 4-9 days<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:49:48 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: silver nitrate 0.5% (n = 19)<BR/>Group 2: Ringer's lactate (n = 15)<BR/>Group 3: neomycin (1 g/L) + bacitracin (50,000 Units/L) (n = 18)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:49:53 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:32 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-05-06 09:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: &gt; 10<SUP>5 </SUP>organisms per gram of tissue<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:56:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mashhood-2006">
<CHAR_METHODS>
<P>Randomly divided into two groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:50:52 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 50<BR/>Patients with superficial and partial-thickness burns, &lt; 15% TBSA<BR/>Duration of wound in both groups: not reported<BR/>Unit of allocation: patient<BR/>Period of follow-up: 6 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:51:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 25)<BR/>Group 2: honey (pure, unprocessed, and undiluted) (n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:51:44 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Wound healing rate; pain; costs</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:56:58 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Pakistan<BR/>Definition of infection: cultures and clinical criteria<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:57:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1990">
<CHAR_METHODS MODIFIED="2010-01-22 12:16:23 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:52:46 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 59<BR/>Patients with full-thickness burns, &lt; 40% TBSA<BR/>Duration of wound in both groups: &lt; 48 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: 2 weeks<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-16 13:57:01 +0000" MODIFIED_BY="[Empty name]">
<P>Group 1: SSD cream (Silvadene) (n = 51)<BR/>Group 2: Polyethylene glycol 400, poly-2-hydroxyethyl methacrylate, and dimethyl sulfoxide: Dimac-containing SSD (Sildimac®) (n = 51)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:55:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-17 15:51:43 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: &gt; 10<SUP>5 </SUP>organisms per gram of tissue<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:57:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muangman-2006">
<CHAR_METHODS>
<P>Randomised into two groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:57:24 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 50<BR/>Patients with partial-thickness burns, &lt; 25% TBSA<BR/>Duration of wound in both groups: not reported<BR/>Unit of allocation: patient<BR/>Period of follow-up: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:57:50 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 25)<BR/>Group 2: nanocrystalline silver-coated dressing (Acticoat®) (n = 25)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:57:58 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; pain; length of hospital stay</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:57:02 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Thailand<BR/>Definition of infection: swabs and clinical criteria<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 13:59:53 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Noordenbos-1999">
<CHAR_METHODS MODIFIED="2010-01-27 13:59:05 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomised, chosen wound sites</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:59:28 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 14<BR/>Patients with 2 comparable-sized, moderate to deep, partial-thickness burns of 2-30% TBSA<BR/>Duration of wound in both groups: &lt; 24 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: 12 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 13:59:48 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 14)<BR/>Group 2: biosynthetic dressing with skin substitute (Transcyte on Biobrane mesh) (n = 14)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 13:59:53 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:34 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-17 15:59:32 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: not reported<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-27 14:01:15 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Soroff-1994">
<CHAR_METHODS MODIFIED="2008-05-20 19:03:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:00:47 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 15<BR/>Patients with partial-thickness burns, &lt; 25% TBSA<BR/>Duration of wound in both groups: 1-10 days<BR/>Unit of allocation: wounds<BR/>Period of follow-up: till healing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:01:15 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 15)<BR/>Group 2: collagenase ointment applied with polymyxin B sulfate/Bacitracin spray (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-20 19:08:39 +0100" MODIFIED_BY="[Empty name]">
<P>Wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:34 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: approved the trial<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-17 16:09:32 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: not reported<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:57:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Subrahmanyam-1998">
<CHAR_METHODS>
<P>Randomly allocated to two groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:03:04 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 50<BR/>Patients with superficial thermal burns, &lt; 40% TBSA<BR/>Duration of wound in both groups: &lt; 6 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: &gt; 3 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:04:41 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 25)<BR/>Group 2: honey (pure, unprocessed, undiluted from the hive) (n = 25) </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 14:04:45 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:35 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:57:04 +0000" MODIFIED_BY="[Empty name]">
<P>Country: India<BR/>Definition of infection: clinical criteria<BR/>Concurrent illness: not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-03 13:25:14 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Tredget-1998">
<CHAR_METHODS MODIFIED="2010-01-22 12:16:25 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Computer-generated randomisation schedule</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:05:45 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 30 (60 wounds)<BR/>Patients with deep partial- and full-thickness burns<BR/>Duration of wound in both groups: &lt; 72 hours<BR/>Unit of allocation: wounds<BR/>Period of follow-up: mean 4 days (until first operative procedure)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-03 13:25:14 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: nanocrystalline silver-coated dressing (Acticoat®) (n = 30)<BR/>Group 2: fine-mesh gauze moistened with a 0.5% solution of silver nitrate (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 14:06:18 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-17 16:12:56 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Definition of infection: &gt; 10<SUP>5 </SUP>organisms per gram of tissue<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-03 13:25:44 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Wunderlich-1991">
<CHAR_METHODS>
<P>Randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-03 13:25:44 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 40<BR/>Patients with venous leg ulcers<BR/>Duration of wound in both groups: Group 1: 7.6 years; Group 2: 7.9 years<BR/>Unit of allocation: patient<BR/>Period of follow-up: 6 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:07:37 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: activated charcoal xerodressing silver-impregnated (SIAX) (Actisorb plus) (n = 19)<BR/>Group 2: conventional phase-adapted therapy using diverse topical modalities (n = 19)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 14:07:41 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:36 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: not reported</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-01-17 16:17:03 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Definition of infection: swabs<BR/>Concurrent illness: DM excluded, other ulcers excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-16 13:57:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wyatt-1990">
<CHAR_METHODS>
<P>Randomly assigned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:08:12 +0000" MODIFIED_BY="Elizabeth Royle">
<P>n = 50<BR/>Patients with minor second degree burns<BR/>Duration of wound in both groups: &lt; 48 hours<BR/>Unit of allocation: patient<BR/>Period of follow-up: until healing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:08:31 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (n = 20)<BR/>Group 2: hydrocolloid (Duoderm® Hydroactive) (n = 22)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-27 14:08:41 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Infection rate; wound healing rate; pain</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-22 12:14:37 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Medical Ethics Committee: not reported<BR/>Informed consent: yes</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-02-16 13:57:05 +0000" MODIFIED_BY="[Empty name]">
<P>Country: USA<BR/>Definition of infection: clinical criteria, but not described in detail<BR/>Concurrent illness: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Abbreviations</B>
</P>
<P>&lt; = less than<BR/>&gt; = more than<BR/>&#8805; = more than or equal to<BR/>BAC = bacitracin zinc ointment<BR/>DM = diabetes mellitus<BR/>ITT = intention-to-treat analysis<BR/>PVP-I = polyvinyl-pyrrolidone iodine<BR/>SSD = silver sulphadiazine<BR/>TBSA = total surface body area<BR/>vs = versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-02-16 13:57:40 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-10-30 22:34:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Boer-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 22:34:25 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-20 13:02:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ganai-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-20 13:02:07 +0100" MODIFIED_BY="[Empty name]">
<P>No comparison of dressings</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-17 17:19:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guilbaud-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-17 17:19:05 +0100" MODIFIED_BY="[Empty name]">
<P>Almost no silver used, and no separate figures reported on the effect of silver</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 22:34:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hadjiiski-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 22:34:28 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Wounds already infected at inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-24 20:18:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jorgensen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-24 20:18:06 +0100" MODIFIED_BY="[Empty name]">
<P>Wounds already infected at inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:12:34 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Lanzara-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:12:34 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Only abstract available; no response to attempts to contact investigator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:12:42 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Molnar-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:12:42 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Only abstract available; no response to attempts to contact investigator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-01-23 10:46:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Munster-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-01-23 10:46:12 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-06-24 21:02:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-M_x00fc_nter-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-06-24 21:02:32 +0100" MODIFIED_BY="[Empty name]">
<P>Wounds already infected at inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:12:50 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Planinsek-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:12:50 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Only abstract available; no response to attempts to contact investigator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:13:04 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Riesinger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:13:04 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Only abstract available; not able to retrieve contact information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 22:34:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silver-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 22:34:34 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:13:09 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Stair-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:13:09 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-03 13:27:04 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Subrahmanyam-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-03 13:27:04 +0000" MODIFIED_BY="Elizabeth Royle">
<P>The aim of the study was not prevention of infection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-16 13:57:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terrill-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-16 13:57:40 +0000" MODIFIED_BY="[Empty name]">
<P>Compared the bacteriological properties and clinical performance of polythene and polytetrafluoroethylene fabric bags, both containing SSD. The <BR/>
<BR/>silver-containing dressings were not compared.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-30 22:34:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verd_x00fa_-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-30 22:34:37 +0000" MODIFIED_BY="[Empty name]">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-27 14:13:30 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Yue-Seng-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-27 14:13:30 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Only abstract available; no response to attempts to contact investigator</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-01-27 14:17:38 +0000" MODIFIED_BY="Elizabeth Royle" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-01-27 14:15:29 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Chen-2006">
<CHAR_METHODS MODIFIED="2008-05-30 11:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomly divided</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:15:29 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients with superficial and deep burns (n = 191)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:15:00 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream<BR/>Group 2: silver nanoparticle dressing<BR/>Group 3: Vaseline gauze</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 17:21:12 +0100" MODIFIED_BY="[Empty name]">
<P>Infection rate; wound healing rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-02 12:18:51 +0100" MODIFIED_BY="Dirk T Ubbink">
<P>Article in Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-01-27 14:16:06 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Hirsch-2008">
<CHAR_METHODS MODIFIED="2010-01-27 14:15:18 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Single-centred randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:15:37 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients with second degree burns (n = 40)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:16:06 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream (Flamazine)<BR/>Group 2: moist exposed burn ointment (MEBO)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 17:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Infection rate; wound healing rate; pain </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-17 17:12:27 +0100" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-01-27 14:16:52 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Li-2006">
<CHAR_METHODS MODIFIED="2010-01-27 14:16:17 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Multi-centred randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:16:33 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients with residual burns (n = 98; 166 wounds)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:16:52 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: SSD cream<BR/>Group 2: nanocrystalline silver dressing (Acticoat)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-31 15:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>Wound healing time</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-31 15:39:04 +0000" MODIFIED_BY="[Empty name]">
<P>Article in Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-01-27 14:17:38 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Wang-2008">
<CHAR_METHODS MODIFIED="2010-01-27 14:17:00 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Randomised control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 14:17:24 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients with wounds from dog bites (n = 40)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:17:38 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Group 1: ionic silver dressing (Aquacel)<BR/>Group 2: Duoderm Hydroactive gel</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-31 15:42:02 +0000" MODIFIED_BY="[Empty name]">
<P>Wound healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-17 17:22:38 +0100" MODIFIED_BY="[Empty name]">
<P>Article in Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-27 14:18:09 +0000" MODIFIED_BY="Elizabeth Royle" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2010-01-27 14:18:09 +0000" MODIFIED_BY="Elizabeth Royle" STUDY_ID="STD-Serena-2008">
<CHAR_STUDY_NAME MODIFIED="2009-09-17 19:49:05 +0100" MODIFIED_BY="[Empty name]">
<P>The lack of reliability of clinical examination in the diagnosis of wound infection: preliminary communication</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-27 14:17:51 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Multicentred randomised clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-27 13:23:47 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Patients with chronic venous leg ulcers (n = 49)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-27 14:18:09 +0000" MODIFIED_BY="Elizabeth Royle">
<P>Collagen-ORC antimicrobial matrix compared with moist wound dressings</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 17:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction in wound area, number of wounds healed in 12 weeks, infection, healing rate, pain, quality of life, ease of use</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-09-17 17:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>August 2004 to October 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-09-17 17:27:30 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2009-09-17 17:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceedings and preliminary results</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-02-16 13:57:24 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-02-03 13:12:53 +0000" MODIFIED_BY="Elizabeth Royle" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-11 14:52:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Computer-generated random numbers table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:08:12 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Reported as "Randomised, controlled, prospective study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-18 18:34:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>Stratified randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:12:53 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>Patients were assigned consecutively according to a pre-established randomised sequence </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:28:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>Randomised, opaque numbered vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:15:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Selected at random</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:06:53 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Computer-generated codes within sealed, numbered envelopes that were opened sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:08:28 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Computer-generated codes within sealed, numbered envelopes that were opened sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-18 20:24:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:14:59 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>Computer-generated randomisation list using the program Rancode</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:22:36 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Prospective, controlled, randomised investigation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:32:48 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Randomisation table assigned dressings to either site A or B</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:35:26 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Drawing marbles of different colours out of a sock; marbles were not replaced (information retrieved from author)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 17:11:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Randomly assigned to instructions in a sealed envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:16:22 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Computer-generated randomisation scheme with sealed envelopes opened sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:50:10 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Randomisation by labelling cards, shuffling and drawing in blinded fashion</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:19:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Randomly divided into two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:16:30 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:20:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>Randomised into two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:00:01 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Randomised, chosen wound sites</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:22:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:22:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Randomly allocated to two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:16:25 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:23:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 11:23:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-02-03 13:20:47 +0000" MODIFIED_BY="Elizabeth Royle" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:19:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:02:28 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>Study agent in randomised opaque vials labelled with identification numbers, but not clear whether the person responsible for determining eligibility of participants had influence on the assignment sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:07:07 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Sequentially-opened sealed, numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:08:35 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Sequentially-opened sealed, numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:24:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:41:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>Not sufficiently reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-02 14:47:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:31:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:31:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:35:42 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Participants blindly drew a marble out of a sock. This technique has a high risk of subversion since there is no audit trail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:20:47 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Instructions in a sealed envelope, but not clear if the envelopes were sequentially numbered and opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:43:31 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Sequentially-opened, sealed, numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:33:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:34:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 08:26:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:35:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:37:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:37:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 10:11:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:38:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:39:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-02-03 13:24:27 +0000" MODIFIED_BY="Elizabeth Royle" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-05-05 16:24:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Participants, caregivers and outcome assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-03 13:08:50 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>Authors stated that the study treatment was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-04 14:32:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>Stated that double-blinding was not possible, but not explicitly reported for the outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-22 12:02:37 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>Reported as double-blinded: likely that the outcome assessor was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-10-30 15:14:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Not reported for participants and caregivers<BR/>Outcome assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:23:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:24:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Participants, caregivers and outcome assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-03 13:15:44 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Although a designated observer evaluated time to clean wound bed, not reported whether observer was blinded regarding treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-22 12:15:11 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>Participants and caregivers not blinded; outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:30:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:31:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-27 13:33:25 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Not reported for participants; caregivers not blinded. Although authors stated that 4 independent observers viewed standard images of wounds for re-epitheliailisation and that scar was rated by a blinded observer, they stated that the daily wound observer was an experienced burn surgeon. It is likely that he was not blinded to the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-01-17 19:42:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Not sufficiently reported. The authors stated that the study was blinded, but did not report who was blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-04 21:08:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Participants, caregivers and outcome assessors not blinded: open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-04 21:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Participants, caregivers and outcome assessors not blinded: open label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:33:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-17 17:01:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-09-17 17:02:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Not reported for outcome assessors. Blinding was not possible for participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-27 13:58:44 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>Not explicitly stated, but materials different, so participants and caregivers not blinded. Not reported for outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-17 12:59:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Non-blinded study: participants, caregivers and outcome assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-03 13:24:27 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Not explicitly stated, but materials were different, so participants and caregivers not blinded. Not reported for outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-27 14:05:06 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Not explicitly stated, but materials were different, so participants and caregivers not blinded. Not reported for outcome assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-04 13:38:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-06 10:24:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Open RCT: participants, caregivers and outcome assessors not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-27 14:08:55 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Participants, caregivers not blinded<BR/>Outcome assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-02-16 13:57:24 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>Drop out rate described and acceptable (&gt; 80%)</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>ITT analysis</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 12:59:54 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>18 dropouts were described: follow-up 62%<BR/>A reason for drop out was occurrence of infection (n = 3)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-03 13:07:27 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>ITT not reported, but patients were excluded from analysis when they would not comply with the protocol</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-22 11:47:36 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>No dropouts were reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-17 13:50:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Not stated, but evident from study assessment </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:09:00 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>2 dropouts described: follow-up 98%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 11:57:16 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>2 participants did not receive study treatment and, therefore, were not analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-04 16:42:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>11 dropouts were described, but only 1 patient was not included in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-17 13:51:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>One participant was not analysed due to poor compliance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:06 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>39 dropouts were described: follow-up 92%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 12:02:53 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>1 participant received the wrong study treatment and was excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-17 13:53:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-09-17 16:31:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:10 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>4 dropouts described: follow-up 91%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 12:06:33 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>1 participant excluded from analysis due to protocol violation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:20 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>12 dropouts described: follow-up 81%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 12:08:45 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>5 participants excluded from analysis due to protocol violations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-22 12:10:46 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>34 participants discontinued early and described. Follow-up 56%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 12:10:51 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Participants with incomplete data assigned censored values for missing data points</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-22 12:15:30 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>4 participants excluded due to protocol violations for inclusion criteria, and 4 participants did not complete the study: follow-up 91%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-22 12:15:37 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>4 participants excluded due to protocol violations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:30 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>70 dropouts, reasons not described: follow-up 76%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-01-17 15:24:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-27 13:27:46 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Reasons for drop out described, but number of excluded participants not reported. Unclear if follow-up was &gt; 80%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-27 13:28:21 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Not all participants included in the analysis according to randomisation group to which allocated. Patients excluded from analysis if they did not survive for 7 days, if all eschar excised before day 7, and if they were discharged before day 7</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:37 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>2 dropouts described: follow-up 88%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-04 20:16:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Not stated, but evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-17 18:34:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Stated, that there were no dropouts; follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-04 20:16:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Not stated, but evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-01-17 17:15:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>21 participants discontinued the study, but were included in the ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-05-05 16:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Stated as undertaken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:44 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>5 dropouts described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-27 13:43:45 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Dropouts included in the ITT analysis for primary endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:50 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>No dropouts reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-04 21:29:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:54 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>No dropouts reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-04 21:30:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:00:57 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>8 dropouts described; follow-up 86%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-03 13:23:09 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>ITT used for adverse effects, but 8 participants not analysed for infection rate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:02 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>No dropouts reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-27 13:58:55 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>All participants included in analysis, not likely that ITT was violated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:07 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>No dropouts reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-06 09:16:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:11 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>2 dropouts described: follow-up 87%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-27 14:01:59 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>1 cross-over not treated as randomised and, therefore, there was no ITT analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:15 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>No dropouts reported: follow-up 100%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-17 14:15:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:20 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>1 dropout described: follow-up 97%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-02-06 10:20:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:01:24 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>2 dropouts described: follow-up 95%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-05-06 09:52:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Evident from study assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-03 13:02:30 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>8 dropouts described: follow-up 84%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-02-16 13:57:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Four participants were wrongfully randomised and therefore excluded from analysis. Four other participants were lost to follow-up and not analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-01-07 11:04:55 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-12-17 15:28:52 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2010-01-27 14:00:17 +0000" MODIFIED_BY="Elizabeth Royle" NO="10">
<NAME>Financial support for trial or trialists?</NAME>
<DESCRIPTION>
<P>Was the trial free of financial support by a company with an interest in the product being investigated</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:27:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Supported, in part, by a grant from Convatec Division of Bristol-Meyers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:26:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Support for the trial from Dreyfus Health Foundation, New York</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:26:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>The trial was supported by a grant from Convatec, a Bristol-Myers Squibb company. Convatec supervised the design, data-analysis and the development of the manuscript of this study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:20:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:21:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:23:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:24:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:11:03 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Study sponsored by Knoll Pharmaceutical Company, Whyppany, NJ</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:26:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>The study was sponsored by Mundipharma GmbH</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:26:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Author works for ConvaTec Ltd</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:28:34 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Funding support for microbiological studies and statistical analysis by British Columbia Professional Firefighters Association, and Smith and Nephew</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:33:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-01-17 18:27:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:40:53 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Study supported by clinical grant from ConvaTec, a Bristol-Myers Squibb Company, Princeton, NJ, USA</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:44:25 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Study supported by grant from Convatec, a Bristol-Myers Squibb Company. Convatec monitored study design, study conduct, and data collection, and supervised data analysis and preparation of the manuscript</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:33:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:34:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:56:32 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Partly supported by grant from Marion Laboratories, Inc</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:00:17 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Non-sponsored, investigator-initiated investigational device exemption</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:23:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Supported by Knoll Pharmaceutical Company</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-20 10:23:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Supported by funding from the Westaim Corporation, Fort Saskatchewan, Alberta, Canada</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:39:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2010-02-03 13:15:19 +0000" MODIFIED_BY="Elizabeth Royle" NO="12">
<NAME>Groups similar at baseline?</NAME>
<DESCRIPTION>
<P>Were both groups comparable at baseline, or was adjustment for imbalance in the analysis made</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 16:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Authors stated no significant differences with respect to location, size and causative agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 13:48:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Authors stated no significant differences with respect to age, sex and extent of burn injury. Also no significant difference in positive bacterial cultures obtained on admission</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 14:04:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>Authors stated baseline characteristics were comparable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-17 13:51:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>No significant difference with respect to age. The extent of burn injury differed, but was compensated with multiple linear regression analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:03:09 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>No significant differences with respect to age, or wounds' depth and location</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-20 13:44:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Author reported the wounds as injury and size matched.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:32:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Author stated no differences for sex, race and burn agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:15:19 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Author stated no differences for sex, race and TBSA burned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 18:21:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>No significant differences for wound size and location</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 18:21:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>No significant difference for wound size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:22:55 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Groups statistically homogeneous</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:28:49 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="NO" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Groups comparable, except that scald burns more frequent in SSD group. No adjustment made in the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 20:15:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>No differences in wound size</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:36:11 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>Groups comparable for wound size, and authors stated that there were no differences between the two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:49:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>It seemed that at baseline there were larger ulcers in the control group and more frequent use of antibiotics in the hydrofibre-silver group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:46:51 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION>
<P>Only mean ulcer area was larger in the povidone iodine gauze group due to an outlier (976 mm<SUP>2</SUP> vs 1463 mm<SUP>2</SUP>), but median ulcer area was comparable (both 600 mm<SUP>2</SUP>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:50:32 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Average age and percentage TBSA similar, however, operative procedures and hospital stay not similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:34:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:56:54 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Participants with two comparable wound sites. No significant difference before treatment in number of positive biopsies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 08:58:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>No differences in baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-05 16:22:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Participants with two comparable-sized wound sites</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:02:32 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="UNKNOWN" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Although the author stated that groups were not statistically different, the mean burn size was larger in the collagenase group (182.7 cm<SUP>2</SUP> vs 163.7 cm<SUP>2</SUP>)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-06 09:51:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>No differences in baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-20 14:32:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Two comparable wounds</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:07:58 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Baseline characteristics similar</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-20 14:35:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>No significant differences for baseline characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2010-02-05 11:34:39 +0000" MODIFIED_BY="Elizabeth Royle" NO="13">
<NAME>Co interventions avoided or similar?</NAME>
<DESCRIPTION>
<P>Were groups under investigation treated the same apart from the intervention</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-27 20:48:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Afilalo-1992">
<DESCRIPTION>
<P>Same cleaning of the wound and instructions given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:23:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carneiro-2002">
<DESCRIPTION>
<P>Same cleaning of the wound, same wound assessment procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:18:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Caruso-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-03 13:13:25 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-De-Gracia-2001">
<DESCRIPTION>
<P>Cleansing of wounds and other treatments stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-04 15:21:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dire-1995">
<DESCRIPTION>
<P>Same wound treatment except for study agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:05:01 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Fang-1987">
<DESCRIPTION>
<P>Participants acted as their own control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:06:45 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Gerding-1988">
<DESCRIPTION>
<P>Same wound treatment except for study agent. 7 participants acted as their own control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:34:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gerding-1990">
<DESCRIPTION>
<P>Same cleaning of the wound and follow-up procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:11:14 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Hansbrough-1995">
<DESCRIPTION>
<P>Participants acted as their own control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-22 12:15:48 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Homann-2007">
<DESCRIPTION>
<P>Participants acted as their own control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:30:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hutchinson-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:45:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Inman-1984">
<DESCRIPTION>
<P>Same wound cleaning and same procedure when cultures were taken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:33:49 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Innes-2001">
<DESCRIPTION>
<P>Participants acted as their own controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-05 11:34:39 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Jacobs-2008">
<DESCRIPTION>
<P>All patients treated with off-loading, debridement, instructions for application, wound coverage</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 16:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jude-2007">
<DESCRIPTION>
<P>Same wound cleansing and treatment, except for study agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-21 22:04:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jurczak-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Livingston-1990">
<DESCRIPTION>
<P>Same nutritional support and antibiotic prophylaxis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:01:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mashhood-2006">
<DESCRIPTION>
<P>General management in wound care was the same</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 13:57:08 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Miller-1990">
<DESCRIPTION>
<P>Participants acted as their own controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-04 13:35:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Muangman-2006">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:00:33 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Noordenbos-1999">
<DESCRIPTION>
<P>Participants acted as their own controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:02:48 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Soroff-1994">
<DESCRIPTION>
<P>Participants acted as their own controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:07:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Subrahmanyam-1998">
<DESCRIPTION>
<P>Same wound assessment and same procedure when biopsies were taken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-27 14:06:43 +0000" MODIFIED_BY="Elizabeth Royle" RESULT="YES" STUDY_ID="STD-Tredget-1998">
<DESCRIPTION>
<P>Participants acted as their own controls</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:08:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wunderlich-1991">
<DESCRIPTION>
<P>Same wound care, except for study agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 17:09:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wyatt-1990">
<DESCRIPTION>
<P>Same wound assessment and follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2008-10-24 17:51:44 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-09-17 17:36:19 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-02-12 16:27:19 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-02-05 11:04:00 +0000" MODIFIED_BY="Elizabeth Royle" NO="1">
<NAME>Silver sulfadiazine (SSD) cream (1%) vs biosynthetic dressing (Biobrane®)</NAME>
<DICH_OUTCOME CHI2="0.15353105416725993" CI_END="0.12433722247500908" CI_START="-0.1244456588228729" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-5.4218173931900514E-5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.9053988384094743" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:00:40 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="0.6951837119340185" P_Q="0.0" P_Z="0.9993183797432921" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="57" WEIGHT="100.0" Z="8.542844078312243E-4">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Biobrane</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Biobrane</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2305833677795884" CI_START="-0.17905357711936296" EFFECT_SIZE="0.025764895330112725" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.10450114087047398" STUDY_ID="STD-Gerding-1988" TOTAL_1="23" TOTAL_2="27" VAR="0.010920488443230647" WEIGHT="47.137280416395576"/>
<DICH_DATA CI_END="0.12529891141739163" CI_START="-0.1714527575712378" EFFECT_SIZE="-0.023076923076923078" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.07570334744142461" STUDY_ID="STD-Gerding-1990" TOTAL_1="26" TOTAL_2="30" VAR="0.00573099681383705" WEIGHT="52.862719583604424"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.15148386598236746" CI_END="1.8295786286871212" CI_START="0.9938310358412329" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.411704832264177" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2010-02-05 11:03:45 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="0.6971214996097277" P_Q="1.0" P_Z="3.559217578876144E-11" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="57" UNITS="" WEIGHT="100.00000000000001" Z="6.62135470499443">
<NAME>Mean pain scores</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Biobrane</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Biobrane</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8220103704104336" CI_START="0.9779896295895661" EFFECT_SIZE="1.4" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="2.4" MODIFIED="2009-09-17 17:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="267" SD_1="0.82" SD_2="0.68" SE="0.2153153699451611" STUDY_ID="STD-Gerding-1988" TOTAL_1="23" TOTAL_2="27" WEIGHT="98.04919462263717"/>
<CONT_DATA CI_END="4.991838639008462" CI_START="-0.9918386390084617" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="1.6" MODIFIED="2009-09-17 17:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="268" SD_1="6.63" SD_2="4.38" SE="1.526476334569259" STUDY_ID="STD-Gerding-1990" TOTAL_1="26" TOTAL_2="30" WEIGHT="1.9508053773628369"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="124.45834354688539" CI_START="15.541656453114612" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="70.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-02-05 11:04:00 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.011758490126521201" Q="0.0" RANDOM="NO" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="2.519310540536088">
<NAME>Costs based on hospital charges (US dollars)</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Biobrane</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Biobrane</GRAPH_LABEL_2>
<CONT_DATA CI_END="124.45834354688539" CI_START="15.541656453114612" EFFECT_SIZE="70.0" ESTIMABLE="YES" MEAN_1="504.0" MEAN_2="434.0" MODIFIED="2009-09-17 17:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="269" SD_1="122.38" SD_2="76.68" SE="27.785379719446812" STUDY_ID="STD-Gerding-1990" TOTAL_1="26" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-02-05 11:01:01 +0000" MODIFIED_BY="Elizabeth Royle" NO="2">
<NAME>SSD cream (1%) vs biosynthetic dressing with skin substitute (Transcyte® on Biobrane® mesh)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.6952887439245014" CI_START="0.16185411321835574" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.15783480137958844" LOG_CI_START="-0.7908762593424323" LOG_EFFECT_SIZE="-0.36797678529459443" METHOD="MH" MODIFIED="2010-02-05 11:01:01 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.0016363747348138876" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="14" TOTAL_2="14" WEIGHT="100.0" Z="3.1493439550069433">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Transcyte</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Transcyte</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6952887439245014" CI_START="0.16185411321835574" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.13608276348795434" STUDY_ID="STD-Noordenbos-1999" TOTAL_1="14" TOTAL_2="14" VAR="0.01851851851851852" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-02-05 11:01:44 +0000" MODIFIED_BY="Elizabeth Royle" NO="3">
<NAME>SSD cream (1%) with chlorhexidine-impregnated gauze (Bactigras®) vs hydrocolloid (Duoderm® Hydroactive)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.09478179061656164" CI_START="-0.17811512394989495" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.041666666666666664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-1.0232750908724675" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:01:44 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5495026254873111" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.5985056016645798">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD/Bactigrass®</GROUP_LABEL_1>
<GROUP_LABEL_2>Duoderm® HD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD/Bactigras</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Duoderm HD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.09478179061656164" CI_START="-0.17811512394989495" EFFECT_SIZE="-0.041666666666666664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.06961783908251187" STUDY_ID="STD-Afilalo-1992" TOTAL_1="24" TOTAL_2="24" VAR="0.004846643518518518" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-02-05 11:03:21 +0000" MODIFIED_BY="Elizabeth Royle" NO="4">
<NAME>SSD cream (1%) vs hydrocolloid (Duoderm® Hydroactive)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.08833816911992041" CI_START="-0.08833816911992041" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-1.053851606089123" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 11:02:16 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.0">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Duoderm® HD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Duoderm HD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08833816911992041" CI_START="-0.08833816911992041" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.04507132264506931" STUDY_ID="STD-Wyatt-1990" TOTAL_1="20" TOTAL_2="22" VAR="0.002031424124975937" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.8178409929392507" CI_START="0.5621590070607487" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1899999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2010-02-05 11:03:21 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.0329605881702026E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" UNITS="" WEIGHT="99.99999999999999" Z="3.7148850868811296">
<NAME>Mean pain scores</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Duoderm® HD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Duoderm HD</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8178409929392507" CI_START="0.5621590070607487" EFFECT_SIZE="1.1899999999999997" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="1.09" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="273" SD_1="1.43" SD_2="0.09" SE="0.32033292340654246" STUDY_ID="STD-Wyatt-1990" TOTAL_1="20" TOTAL_2="22" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-02-05 11:05:12 +0000" MODIFIED_BY="Elizabeth Royle" NO="5">
<NAME>SSD cream (1%) vs honey</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 11:02:40 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="50" TOTAL_2="50" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients with clinical evidence of wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Honey</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Honey</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Day 7</NAME>
<DICH_DATA CI_END="0.15039451298583675" CI_START="-0.15039451298583675" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.07673330437300352" STUDY_ID="STD-Subrahmanyam-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.005888" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Day 21</NAME>
<DICH_DATA CI_END="0.36561891377969297" CI_START="0.034381086220307056" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.08450099853164333" STUDY_ID="STD-Subrahmanyam-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.007140418752844789" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 11:04:40 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="75" TOTAL_2="75" WEIGHT="0.0" Z="0.0">
<NAME>Number of wounds completely healed</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Honey</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="13" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 2</NAME>
<DICH_DATA CI_END="-0.06912460997887304" CI_START="-0.570875390021127" EFFECT_SIZE="-0.32" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.128" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.016384" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="25" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 4</NAME>
<DICH_DATA CI_END="-0.2041486229483549" CI_START="-0.5958513770516451" EFFECT_SIZE="-0.4" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.09992600812897369" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.009985207100591717" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 6</NAME>
<DICH_DATA CI_END="0.0746548727053014" CI_START="-0.0746548727053014" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.038089920679241815" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.0014508420573509332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.005298284856637553" CI_START="-0.31470171514336254" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:04:58 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.042653250498807804" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="2.0270895977837102">
<NAME>Number of patients with clinical evidence of wound healing (day 21)</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Honey</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.005298284856637553" CI_START="-0.31470171514336254" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.07893089687546805" STUDY_ID="STD-Subrahmanyam-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.006230086481565772" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="58" EVENTS_2="79" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 11:05:12 +0000" MODIFIED_BY="Elizabeth Royle" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="100" TOTAL_2="100" WEIGHT="0.0" Z="0.0">
<NAME>Number of patients reporting free of pain</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Honey</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Honey</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 1</NAME>
<DICH_DATA CI_END="0.03675845731793553" CI_START="-0.4367584573179355" EFFECT_SIZE="-0.19999999999999998" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.120797350964332" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.014592" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="20" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 2</NAME>
<DICH_DATA CI_END="-0.11010651351184905" CI_START="-0.609893486488151" EFFECT_SIZE="-0.36000000000000004" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.1274990196040738" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.016256" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="18" EVENTS_2="25" I2="0.0" ID="CMP-005.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 3</NAME>
<DICH_DATA CI_END="-0.09803226661541142" CI_START="-0.46196773338458863" EFFECT_SIZE="-0.28" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.0928423862988947" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.00861970869367319" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="25" I2="0.0" ID="CMP-005.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>week 4</NAME>
<DICH_DATA CI_END="0.0746548727053014" CI_START="-0.0746548727053014" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.038089920679241815" STUDY_ID="STD-Mashhood-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.0014508420573509332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-02-05 11:05:58 +0000" MODIFIED_BY="Elizabeth Royle" NO="6">
<NAME>SSD cream (1%) vs liposome hydrogel with polyvinyl-pyrrolidone iodine</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.04429081835636578" CI_START="-0.04429081835636578" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-1.3536862952318263" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 11:05:32 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.0">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Liposome HG PVP-I</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liposome</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.04429081835636578" CI_START="-0.04429081835636578" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.022597771543623302" STUDY_ID="STD-Homann-2007" TOTAL_1="43" TOTAL_2="43" VAR="5.106592787377911E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.10065853890619214" CI_START="-0.0541469109992154" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-0.9971493778290402" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6334684555795866" METHOD="MH" MODIFIED="2010-02-05 11:05:45 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.555944888655237" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.588875363339635">
<NAME>Number of patients with adverse effects</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Liposome HG PVP-I</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liposome</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.10065853890619214" CI_START="-0.0541469109992154" EFFECT_SIZE="0.023255813953488372" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.03949191187350716" STUDY_ID="STD-Homann-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.0015596111034248557" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.11783346554834072" CI_START="-0.16434509345531745" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.023255813953488372" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.9287313492864677" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:05:58 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.7466484336838392" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.3230618083878609">
<NAME>Number of patients reporting wound pain</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Liposome HG PVP-I</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Liposome</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.11783346554834072" CI_START="-0.16434509345531745" EFFECT_SIZE="-0.023255813953488372" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.07198564902963693" STUDY_ID="STD-Homann-2007" TOTAL_1="43" TOTAL_2="43" VAR="0.005181933666218069" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-02-05 11:06:37 +0000" MODIFIED_BY="Elizabeth Royle" NO="7">
<NAME>SSD cream (1%) vs collagenase ointment applied with polymyxin B sulfate/bacitrin (Santyl®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.09730647691259549" CI_START="-0.12262293260879804" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.012658227848101278" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-1.0118582512652325" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:06:16 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8215009879024785" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="0.22561485291458583">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Santyl® Collagenase</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Santyl</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.09730647691259549" CI_START="-0.12262293260879804" EFFECT_SIZE="-0.012658227848101278" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.05610547215565404" STUDY_ID="STD-Hansbrough-1995" TOTAL_1="79" TOTAL_2="79" VAR="0.003147824005808871" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.06661268082600487" CI_START="-0.31313415461703314" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.189873417721519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:06:37 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.00253468657720978" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="3.0191695241215952">
<NAME>Number of patients reporting pain</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Santyl® Collagenase</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Santyl</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.06661268082600487" CI_START="-0.31313415461703314" EFFECT_SIZE="-0.189873417721519" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.0628892866745405" STUDY_ID="STD-Hansbrough-1995" TOTAL_1="79" TOTAL_2="79" VAR="0.0039550623784325376" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2010-02-05 11:07:12 +0000" MODIFIED_BY="Elizabeth Royle" NO="8">
<NAME>SSD cream (1%)/chlorhexidine (0.2%) (Silverex) vs diphenyldantoin (Phenytoin)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5752332408185018" CI_START="0.17476675918149817" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-0.24015602546431114" LOG_CI_START="-0.7575411671070063" LOG_EFFECT_SIZE="-0.42596873227228116" METHOD="MH" MODIFIED="2010-02-05 11:06:51 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="2.4193279086905052E-4" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="3.6706517419289884">
<NAME>Number of patients with positive cultures (day 10)</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Phenytoin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5752332408185018" CI_START="0.17476675918149817" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.10216169398923454" STUDY_ID="STD-Carneiro-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.01043701171875" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.024602795082593165" CI_START="-0.33710279508259317" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.15625" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="-1.6090155506206" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:07:01 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.09039171456098617" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="1.6933350266692069">
<NAME>Number of wounds completely healed</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Phenytoin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.024602795082593165" CI_START="-0.33710279508259317" EFFECT_SIZE="-0.15625" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.0922735297735759" STUDY_ID="STD-Carneiro-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.008514404296875" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.5370211982420289" CI_START="0.0879788017579711" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="-0.27000857072905965" LOG_CI_START="-1.0556219572653265" LOG_EFFECT_SIZE="-0.505149978319906" METHOD="MH" MODIFIED="2010-02-05 11:07:12 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.006372398187648571" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.727977357881894">
<NAME>Number of patients reporting moderate to severe pain</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Phenytoin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Phenytoin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5370211982420289" CI_START="0.0879788017579711" EFFECT_SIZE="0.3125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.11455373670793109" STUDY_ID="STD-Carneiro-2002" TOTAL_1="32" TOTAL_2="32" VAR="0.01312255859375" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2010-02-05 10:54:05 +0000" MODIFIED_BY="Elizabeth Royle" NO="9">
<NAME>Nanocrystalline silver-coated dressing (Acticoat®) vs hydrophilic polyurethane dressing (Allevyn®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.11358387504551336" CI_START="-0.11358387504551336" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-0.9446833189403213" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-02-05 10:54:05 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Acticoat®</GROUP_LABEL_1>
<GROUP_LABEL_2>Allevyn®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acticoat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Allevyn</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.11358387504551336" CI_START="-0.11358387504551336" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.0579520215378693" STUDY_ID="STD-Innes-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.0033584368003256666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.45105630923014517" CI_START="-0.9239436907698548" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.6875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="1.2056411432955689E-8" Q="0.0" RANDOM="NO" SCALE="1.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="5.698926602710104">
<NAME>Number of wounds healed by day of discharge</NAME>
<GROUP_LABEL_1>Acticoat®</GROUP_LABEL_1>
<GROUP_LABEL_2>Allevyn®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Allevyn</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acticoat</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.45105630923014517" CI_START="-0.9239436907698548" EFFECT_SIZE="-0.6875" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.12063675283571153" STUDY_ID="STD-Innes-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.014553226134744555" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2010-02-05 10:53:57 +0000" MODIFIED_BY="Elizabeth Royle" NO="10">
<NAME>Silver nitrate (0.5%) vs Ringer's lactate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.14035184570735965" CI_START="-0.7157885051698334" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.4280701754385965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:53:57 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.003544893762169279" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="15" WEIGHT="100.0" Z="2.916053792954795">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Silver nitrate</GROUP_LABEL_1>
<GROUP_LABEL_2>Ringer's lactate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Silver nitrate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ringer's lactate</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.14035184570735965" CI_START="-0.7157885051698334" EFFECT_SIZE="-0.4280701754385965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.14679776363276179" STUDY_ID="STD-Livingston-1990" TOTAL_1="19" TOTAL_2="15" VAR="0.0215495834075802" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2010-02-05 10:53:50 +0000" MODIFIED_BY="Elizabeth Royle" NO="11">
<NAME>Silver nitrate (0.5%) vs neomycin with bacitracin</NAME>
<DICH_OUTCOME CHI2="4.452330105368631E-32" CI_END="0.02974272887336296" CI_START="-0.485883079750556" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.2280701754385965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="100.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-1.5266191877887092" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:53:50 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.08294440836198456" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="18" WEIGHT="99.99999999999999" Z="1.7338516510658808">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Silver nitrate</GROUP_LABEL_1>
<GROUP_LABEL_2>Neomycin/bacitracin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Silver nitrate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Neomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.02974272887336299" CI_START="-0.48588307975055595" EFFECT_SIZE="-0.22807017543859648" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.13153961314878984" STUDY_ID="STD-Livingston-1990" TOTAL_1="19" TOTAL_2="18" VAR="0.017302669827333285" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2010-02-05 10:53:40 +0000" MODIFIED_BY="Elizabeth Royle" NO="12">
<NAME>SSD/SILVER vs NO SILVER</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.03263879845618591" CI_START="-0.030646858466744788" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="9.959699947205618E-4" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="-1.486265837462697" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-3.0017537452345127" METHOD="MH" MODIFIED="2010-02-05 10:53:40 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.9508092196369885" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-01" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="308" TOTAL_2="313" WEIGHT="0.0" Z="0.0616906077695322">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD/SILVER</GROUP_LABEL_1>
<GROUP_LABEL_2>NO SILVER</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD/SILVER</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours NO-SILVER</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.04429081835636578" CI_START="-0.04429081835636578" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.022597771543623302" STUDY_ID="STD-Homann-2007" TOTAL_1="43" TOTAL_2="43" VAR="5.106592787377911E-4" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.2305833677795884" CI_START="-0.17905357711936296" EFFECT_SIZE="0.025764895330112725" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.10450114087047398" STUDY_ID="STD-Gerding-1988" TOTAL_1="23" TOTAL_2="27" VAR="0.010920488443230647" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.09478179061656164" CI_START="-0.17811512394989495" EFFECT_SIZE="-0.041666666666666664" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.06961783908251187" STUDY_ID="STD-Afilalo-1992" TOTAL_1="24" TOTAL_2="24" VAR="0.004846643518518518" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.12529891141739163" CI_START="-0.1714527575712378" EFFECT_SIZE="-0.023076923076923078" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.07570334744142461" STUDY_ID="STD-Gerding-1990" TOTAL_1="26" TOTAL_2="30" VAR="0.00573099681383705" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.02974272887336299" CI_START="-0.48588307975055595" EFFECT_SIZE="-0.22807017543859648" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.13153961314878984" STUDY_ID="STD-Livingston-1990" TOTAL_1="19" TOTAL_2="18" VAR="0.017302669827333285" WEIGHT="0.0"/>
<DICH_DATA CI_END="-0.14035184570735965" CI_START="-0.7157885051698334" EFFECT_SIZE="-0.4280701754385965" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.14679776363276179" STUDY_ID="STD-Livingston-1990" TOTAL_1="19" TOTAL_2="15" VAR="0.0215495834075802" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.6952887439245014" CI_START="0.16185411321835574" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.13608276348795434" STUDY_ID="STD-Noordenbos-1999" TOTAL_1="14" TOTAL_2="14" VAR="0.01851851851851852" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.36561891377969297" CI_START="0.034381086220307056" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.08450099853164333" STUDY_ID="STD-Subrahmanyam-1998" TOTAL_1="25" TOTAL_2="25" VAR="0.007140418752844789" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.11358387504551336" CI_START="-0.11358387504551336" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.0579520215378693" STUDY_ID="STD-Innes-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.0033584368003256666" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.08833816911992041" CI_START="-0.08833816911992041" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.04507132264506931" STUDY_ID="STD-Wyatt-1990" TOTAL_1="20" TOTAL_2="22" VAR="0.002031424124975937" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.09730647691259549" CI_START="-0.12262293260879804" EFFECT_SIZE="-0.012658227848101278" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.05610547215565404" STUDY_ID="STD-Hansbrough-1995" TOTAL_1="79" TOTAL_2="79" VAR="0.003147824005808871" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2010-02-05 11:08:22 +0000" MODIFIED_BY="Elizabeth Royle" NO="13">
<NAME>SSD cream (1%) vs nanocrystalline silver-coated dressing (Acticoat®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.23203646705421244" CI_START="-0.15203646705421242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.04000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="-0.6344437556442833" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3979400086720375" METHOD="MH" MODIFIED="2010-02-05 11:07:51 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6830913993406129" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.4082482904638631">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Acticoat®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acticoat</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.23203646705421244" CI_START="-0.15203646705421242" EFFECT_SIZE="0.04000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.09797958971132713" STUDY_ID="STD-Muangman-2006" TOTAL_1="25" TOTAL_2="25" VAR="0.009600000000000001" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3613995018031988" CI_START="0.6386004981968012" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.02" MODIFIED="2010-02-05 11:08:06 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="5.8521299537524194E-8" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="5.423261445466404">
<NAME>Mean background pain scores</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Acticoat®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acticoat</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3613995018031988" CI_START="0.6386004981968012" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="4.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="308" SD_1="0.7" SD_2="0.6" SE="0.18439088914585774" STUDY_ID="STD-Muangman-2006" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.429159891515282" CI_START="-6.429159891515282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-013.03" MODIFIED="2010-02-05 11:08:22 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="100.00000000000001" Z="0.0">
<NAME>Mean length of hospital stay</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Acticoat®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acticoat</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.429159891515282" CI_START="-6.429159891515282" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="21.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="309" SD_1="10.0" SD_2="13.0" SE="3.280243893371345" STUDY_ID="STD-Muangman-2006" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2010-02-05 11:09:20 +0000" MODIFIED_BY="Elizabeth Royle" NO="14">
<NAME>SSD cream (1%) vs hydrofibre dressing containing ionic silver (Aquacel® Ag)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.12184397272511333" CI_START="-0.20279635367749427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.04047619047619047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="-0.9141959492610874" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:08:37 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.6250278809905183" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="42" WEIGHT="99.99999999999999" Z="0.4887370367311167">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Aquacel® Ag</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12184397272511333" CI_START="-0.20279635367749427" EFFECT_SIZE="-0.04047619047619047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="0.08281793159551121" STUDY_ID="STD-Caruso-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.006858809793758773" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.06372048133432817" CI_START="-0.3399109575248045" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.13809523809523816" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-014.02" LOG_CI_END="-1.1957209522674357" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:08:49 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.17987732000266463" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="42" WEIGHT="99.99999999999999" Z="1.341132860553072">
<NAME>Number of patients with re-epithelialisation within 21 days</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Aquacel® Ag</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.06372048133432817" CI_START="-0.3399109575248045" EFFECT_SIZE="-0.13809523809523816" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="31" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.10296909587189508" STUDY_ID="STD-Caruso-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.01060263470467552" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.18964048271118594" CI_START="-0.24202143509213825" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.026190476190476153" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-014.03" LOG_CI_END="-0.72206894789781" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:08:58 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.8120082307685623" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="42" WEIGHT="99.99999999999999" Z="0.23783608400069872">
<NAME>Number of patients reporting adverse effects</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Aquacel® Ag</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.18964048271118594" CI_START="-0.24202143509213825" EFFECT_SIZE="-0.026190476190476153" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="0.11011985965257992" STUDY_ID="STD-Caruso-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.012126383489903898" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.12184397272511333" CI_START="-0.20279635367749427" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.04047619047619047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-014.04" LOG_CI_END="-0.9141959492610874" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:09:08 +0000" MODIFIED_BY="Elizabeth Royle" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.6250278809905183" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="42" WEIGHT="99.99999999999999" Z="0.4887370367311167">
<NAME>Number of patients using systemic antibiotics</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Aquacel® Ag</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12184397272511333" CI_START="-0.20279635367749427" EFFECT_SIZE="-0.04047619047619047" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="0.08281793159551121" STUDY_ID="STD-Caruso-2006" TOTAL_1="40" TOTAL_2="42" VAR="0.006858809793758773" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="497.71658433167875" CI_START="-216.11658433167884" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="140.79999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-014.05" MODIFIED="2010-02-05 11:09:20 +0000" MODIFIED_BY="Elizabeth Royle" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.4394122790430116" Q="0.0" RANDOM="NO" SCALE="1250.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="0.7731860640210267">
<NAME>Total costs of clinical care (USD)</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Aquacel® Ag</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<CONT_DATA CI_END="497.71658433167875" CI_START="-216.11658433167884" EFFECT_SIZE="140.79999999999995" ESTIMABLE="YES" MEAN_1="1180.8" MEAN_2="1040.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="314" SD_1="792.18" SD_2="856.66" SE="182.1036443256056" STUDY_ID="STD-Caruso-2006" TOTAL_1="40" TOTAL_2="42" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2010-02-05 11:09:33 +0000" MODIFIED_BY="Elizabeth Royle" NO="15">
<NAME>SSD cream (1%) vs synthetic dressing containing silver (Hydron AgSD (1-3%))</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.2784410573417415" CI_START="0.007273228372544321" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.1428571428571429" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="-0.5552667257343639" LOG_CI_START="-2.138272775775368" LOG_EFFECT_SIZE="-0.8450980400142567" METHOD="MH" MODIFIED="2010-02-05 11:09:33 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.03891318141930841" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="98" WEIGHT="100.0" Z="2.0651037846093394">
<NAME>Number of patients with positive cultures</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydron AgSD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hydron-AgSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2784410573417415" CI_START="0.007273228372544321" EFFECT_SIZE="0.1428571428571429" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="32" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.06917673771256369" STUDY_ID="STD-Fang-1987" TOTAL_1="98" TOTAL_2="98" VAR="0.004785421040552831" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2010-02-05 11:10:14 +0000" MODIFIED_BY="Elizabeth Royle" NO="16">
<NAME>SSD cream (1%) (Flamazine®) vs SSD (1%) with 0.2% chlorhexidine digluconate cream (Silvazine®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.1323530949969056" CI_START="-0.14451451014339536" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.006080707573244887" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="-0.8782658985306606" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:09:51 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.9313937142658784" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="54" WEIGHT="100.0" Z="0.08609145759786939">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Silvazine®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silvazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1323530949969056" CI_START="-0.14451451014339536" EFFECT_SIZE="-0.006080707573244887" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.07063078896454152" STUDY_ID="STD-Inman-1984" TOTAL_1="67" TOTAL_2="54" VAR="0.004988708349753599" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.23818555935674413" CI_START="-0.03254708506155346" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.10281923714759533" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-016.02" LOG_CI_END="-0.6230845723317904" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.9879256226418975" METHOD="MH" MODIFIED="2010-02-05 11:10:04 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.136562185505261" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="54" WEIGHT="100.0" Z="1.4887159408512745">
<NAME>Number of patients that received antibiotics</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Silvazine®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silvazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.23818555935674413" CI_START="-0.03254708506155346" EFFECT_SIZE="0.10281923714759533" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="42" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.06906571920550636" STUDY_ID="STD-Inman-1984" TOTAL_1="67" TOTAL_2="54" VAR="0.004770073569373851" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.029075949433355973" CI_START="-0.06611298647039301" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.018518518518518517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-016.03" LOG_CI_END="-1.5364660951056093" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:10:14 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.445700886828754" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="54" WEIGHT="100.0" Z="0.7626018507032148">
<NAME>Number of patients reporting extreme pain at application</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Silvazine®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silvazine</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.029075949433355973" CI_START="-0.06611298647039301" EFFECT_SIZE="-0.018518518518518517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.024283338024215537" STUDY_ID="STD-Inman-1984" TOTAL_1="67" TOTAL_2="54" VAR="5.896805055983122E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2010-02-05 11:11:02 +0000" MODIFIED_BY="Elizabeth Royle" NO="17">
<NAME>SSD cream (1%) (Flamazine®) vs SSD (1%) cerium nitrate (2.2%) (SSD-CN) (Flammacerium®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.2199065711209039" CI_START="-0.019906571120903868" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="-0.657761793108922" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0" METHOD="MH" MODIFIED="2010-02-05 11:10:25 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.10213797085317203" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.6345759587802646">
<NAME>Sepsis after 10 days</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>SSD-cerium nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD-cerium</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2199065711209039" CI_START="-0.019906571120903868" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.061177946159578236" STUDY_ID="STD-De-Gracia-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.003742741096304253" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.5288806564598357E-31" CI_END="-0.15031305077032667" CI_START="-0.5830202825630066" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.36666666666666664" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" I2="100.0" I2_Q="0.0" ID="CMP-017.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:10:37 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="8.94832027852482E-4" Q="0.0" RANDOM="NO" SCALE="3.54" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="3.3216614292332576">
<NAME>Number of patients reporting subjective stinging effect</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>SSD-cerium nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD-cerium</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.15031305077032672" CI_START="-0.5830202825630066" EFFECT_SIZE="-0.3666666666666667" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.11038652628462037" STUDY_ID="STD-De-Gracia-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.012185185185185184" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.1289044758678072" CI_START="-0.19557114253447386" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.033333333333333326" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-017.03" LOG_CI_END="-0.8897320026548006" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:10:47 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.6871736192999343" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.4026936331284145">
<NAME>Number of patients receiving systemic antibiotics for at least 7 days</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>SSD-cerium nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD-cerium</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1289044758678072" CI_START="-0.19557114253447386" EFFECT_SIZE="-0.033333333333333326" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.08277591347639633" STUDY_ID="STD-De-Gracia-2001" TOTAL_1="30" TOTAL_2="30" VAR="0.006851851851851852" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.48974019440395" CI_START="-1.6897401944039547" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="7.399999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-017.04" MODIFIED="2010-02-05 11:11:02 +0000" MODIFIED_BY="Elizabeth Royle" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.11057458758904565" Q="0.0" RANDOM="NO" SCALE="25.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.5956158454919909">
<NAME>Mean length of hospital stay</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>SSD-cerium nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD-cerium</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.48974019440395" CI_START="-1.6897401944039547" EFFECT_SIZE="7.399999999999999" ESTIMABLE="YES" MEAN_1="30.7" MEAN_2="23.3" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="322" SD_1="22.7" SD_2="11.4" SE="4.637707767133817" STUDY_ID="STD-De-Gracia-2001" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2010-02-05 11:11:27 +0000" MODIFIED_BY="Elizabeth Royle" NO="18">
<NAME>SSD cream (1%) (Silvadene®) vs Dimac containing SSD (Sildimac®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.08507503074811584" CI_START="-0.04585934447360604" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0196078431372549" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="-1.0701978852678906" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7075701760979363" METHOD="MH" MODIFIED="2010-02-05 11:11:18 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.5571890681319402" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="51" WEIGHT="100.0" Z="0.5870218007830669">
<NAME>Number of patients that developed clinical wound sepsis</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Sildimac®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sildimac</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08507503074811584" CI_START="-0.04585934447360604" EFFECT_SIZE="0.0196078431372549" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.033402240106072234" STUDY_ID="STD-Miller-1990" TOTAL_1="51" TOTAL_2="51" VAR="0.0011157096441037006" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.16349927205927908" CI_START="-0.09570266188978757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.033898305084745756" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-018.02" LOG_CI_END="-0.7864841765898848" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.469822015978163" METHOD="MH" MODIFIED="2010-02-05 11:11:27 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.6081987567662993" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="59" TOTAL_2="59" WEIGHT="100.0" Z="0.5126463069994537">
<NAME>Number of patients reporting local adverse effects</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Sildimac®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Sildimac</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.16349927205927908" CI_START="-0.09570266188978757" EFFECT_SIZE="0.033898305084745756" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.06612415738085456" STUDY_ID="STD-Miller-1990" TOTAL_1="59" TOTAL_2="59" VAR="0.004372404189328023" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2010-02-05 11:12:09 +0000" MODIFIED_BY="Elizabeth Royle" NO="19">
<NAME>Nanocrystalline silver-coated dressing (Acticoat®) vs fine-mesh gauze with silver nitrate (0.5%)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="-0.4032881231562494" CI_START="-0.890829523902574" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.6470588235294117" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:11:45 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="1.9664741039719099E-7" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="5.202479166098045">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Acticoat®</GROUP_LABEL_1>
<GROUP_LABEL_2>FM silver nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acticoat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silver nitrate</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.4032881231562494" CI_START="-0.890829523902574" EFFECT_SIZE="-0.6470588235294117" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.12437509173433514" STUDY_ID="STD-Tredget-1998" TOTAL_1="17" TOTAL_2="17" VAR="0.015469163443924282" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.008476582726103465" CI_START="-0.4790648180202211" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.23529411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-019.02" LOG_CI_END="-2.0717791951853894" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:11:57 +0000" MODIFIED_BY="Elizabeth Royle" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.05851621969782506" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0" Z="1.8918106058538346">
<NAME>Number of patients that developed bacteraemia</NAME>
<GROUP_LABEL_1>Acticoat®</GROUP_LABEL_1>
<GROUP_LABEL_2>FM silver nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acticoat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silver nitrate</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.008476582726103465" CI_START="-0.4790648180202211" EFFECT_SIZE="-0.23529411764705882" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.12437509173433514" STUDY_ID="STD-Tredget-1998" TOTAL_1="17" TOTAL_2="17" VAR="0.015469163443924282" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3704108318575061" CI_START="-0.9304108318575057" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2799999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-019.03" MODIFIED="2010-02-05 11:12:09 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3988041655765042" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="0.8437588809890014">
<NAME>Mean overall painscore</NAME>
<GROUP_LABEL_1>Acticoat®</GROUP_LABEL_1>
<GROUP_LABEL_2>FM silver nitrate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acticoat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Silver nitrate</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3704108318575061" CI_START="-0.9304108318575057" EFFECT_SIZE="-0.2799999999999998" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.48" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="327" SD_1="1.31" SD_2="1.26" SE="0.3318483589432579" STUDY_ID="STD-Tredget-1998" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2010-02-05 11:12:32 +0000" MODIFIED_BY="Elizabeth Royle" NO="20">
<NAME>SSD cream (1%) vs bacitracin zinc ointment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.14340888507457528" CI_START="-0.011076385769598907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06616624965248818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="-0.843423940583697" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.1793634807619993" METHOD="MH" MODIFIED="2010-02-05 11:12:32 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.09316950135761395" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="109" WEIGHT="100.0" Z="1.678910430778498">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Bacitracin zinc</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Bacitrin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14340888507457528" CI_START="-0.011076385769598907" EFFECT_SIZE="0.06616624965248818" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.03941023204067378" STUDY_ID="STD-Dire-1995" TOTAL_1="99" TOTAL_2="109" VAR="0.0015531663894997503" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2010-02-05 11:12:43 +0000" MODIFIED_BY="Elizabeth Royle" NO="21">
<NAME>SSD cream (1%) vs neomycin sulfate</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.15091388327769772" CI_START="6.012682374537809E-4" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07575757575757576" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="-0.8212708055951955" LOG_CI_START="-3.2209317375529642" LOG_EFFECT_SIZE="-1.1205739312058498" METHOD="MH" MODIFIED="2010-02-05 11:12:43 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.04819509340348533" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="110" WEIGHT="100.0" Z="1.975644160021557">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Neomycin sulfate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Neomycin</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.15091388327769772" CI_START="6.012682374537809E-4" EFFECT_SIZE="0.07575757575757576" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.038345759469533794" STUDY_ID="STD-Dire-1995" TOTAL_1="99" TOTAL_2="110" VAR="0.0014703972692953408" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2010-02-05 11:12:57 +0000" MODIFIED_BY="Elizabeth Royle" NO="22">
<NAME>SSD cream (1%) vs petrolatum</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.04167034755483212" CI_START="-0.15109795698244155" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.054713804713804715" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="-1.3801728772601138" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 11:12:57 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.2658799266798495" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="108" WEIGHT="100.0" Z="1.1126008184138978">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Petrolatum</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Petrolatum</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.04167034755483212" CI_START="-0.15109795698244155" EFFECT_SIZE="-0.054713804713804715" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.04917649152173342" STUDY_ID="STD-Dire-1995" TOTAL_1="99" TOTAL_2="108" VAR="0.0024183273183871192" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2010-02-05 10:51:32 +0000" MODIFIED_BY="Elizabeth Royle" NO="23">
<NAME>Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs povidone iodine gauze</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.14497764694402937" CI_START="-0.16640621837260083" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.010714285714285718" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="-0.8386989533320025" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:51:21 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.8927073304517058" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="0.13487926934633296">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Povidone iodine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Povidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14497764694402937" CI_START="-0.16640621837260083" EFFECT_SIZE="-0.010714285714285718" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.07943611917687937" STUDY_ID="STD-Jurczak-2007" TOTAL_1="35" TOTAL_2="32" VAR="0.006310097029883382" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.30672859673009856" CI_START="-0.037085739587241456" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.13482142857142856" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-023.02" LOG_CI_END="-0.5132457322564278" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.8702410753770122" METHOD="MH" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.12425937145223623" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="1.5371386032043854">
<NAME>Number of wounds completely healed at end of treatment</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Povidone iodine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Povidone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.30672859673009856" CI_START="-0.037085739587241456" EFFECT_SIZE="0.13482142857142856" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.08770935053636282" STUDY_ID="STD-Jurczak-2007" TOTAL_1="35" TOTAL_2="32" VAR="0.0076929301715105685" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.018045760730206917" CI_START="-0.20554576073020692" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.09375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-023.03" LOG_CI_END="-1.743624805266027" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:51:32 +0000" MODIFIED_BY="Elizabeth Royle" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.10026049722517957" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="32" WEIGHT="100.0" Z="1.6435920499173475">
<NAME>Number of patients that reported adverse effects</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Povidone iodine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Povidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.018045760730206917" CI_START="-0.20554576073020692" EFFECT_SIZE="-0.09375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.05703970155168034" STUDY_ID="STD-Jurczak-2007" TOTAL_1="35" TOTAL_2="32" VAR="0.0032535275531047647" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2010-02-05 10:46:13 +0000" MODIFIED_BY="Elizabeth Royle" NO="24">
<NAME>SSD cream (1%) vs benzoic acid, salicylic acid and <I>Quercus rubra</I> extract (Bensal HP)</NAME>
<DICH_OUTCOME CHI2="8.559688641721048E-33" CI_END="0.19399459768100807" CI_START="-0.39399459768100814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.10000000000000005" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="100.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="-0.7122103640388233" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.5049850793815285" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.666666666666667">
<NAME>Number of wounds healed (6 weeks)</NAME>
<GROUP_LABEL_1>SSD</GROUP_LABEL_1>
<GROUP_LABEL_2>Bensal HP</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Bensal HP</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours SSD</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.19399459768100807" CI_START="-0.39399459768100814" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.15" STUDY_ID="STD-Jacobs-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.0225" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-025" MODIFIED="2010-02-05 10:46:35 +0000" MODIFIED_BY="Elizabeth Royle" NO="25">
<NAME>Activated-charcoal dressing containing silver (Actisorb Plus®) vs conventional phase-adapted therapy using diverse topical modalities</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.4609795826593746" CI_START="-0.039926951080427264" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-025.01" LOG_CI_END="-0.33631830960977477" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.6766936096248666" METHOD="MH" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.09945347974540855" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.6475089420958278">
<NAME>Number of wounds healed (6 weeks)</NAME>
<GROUP_LABEL_1>Actisorb Plus® 25</GROUP_LABEL_1>
<GROUP_LABEL_2>Conventional</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Conventional</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Actisorb</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4609795826593746" CI_START="-0.039926951080427264" EFFECT_SIZE="0.21052631578947367" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.12778462708776506" STUDY_ID="STD-Wunderlich-1991" TOTAL_1="19" TOTAL_2="19" VAR="0.016328910919959177" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-026" MODIFIED="2010-02-05 10:52:05 +0000" MODIFIED_BY="Elizabeth Royle" NO="26">
<NAME>Hydrofibre dressing containing ionic silver (Aquacel® Ag) vs calcium alginate dressing (Algosteril®)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.16265889003673845" CI_START="-0.07310665123076829" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.04477611940298508" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-026.01" LOG_CI_END="-0.7887221955952236" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.3489535479811638" METHOD="MH" MODIFIED="2010-02-05 10:51:48 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.45659529302989255" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.7444648690008621">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Algosteril</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.16265889003673845" CI_START="-0.07310665123076829" EFFECT_SIZE="0.04477611940298508" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.06014537591690338" STUDY_ID="STD-Jude-2007" TOTAL_1="67" TOTAL_2="67" VAR="0.003617466244185621" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.507155320096088" CI_START="-5.6928446799039145" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.100000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.02" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="8.744608366001187E-64" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="16.860767516332235">
<NAME>Time to complete healing</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Algosteril</GRAPH_LABEL_2>
<CONT_DATA CI_END="-4.507155320096088" CI_START="-5.6928446799039145" EFFECT_SIZE="-5.100000000000001" ESTIMABLE="YES" MEAN_1="52.6" MEAN_2="57.7" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="337" SD_1="1.8" SD_2="1.7" SE="0.3024773335531653" STUDY_ID="STD-Jude-2007" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.23888600105325566" CI_START="-0.05978152344131535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08955223880597016" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-026.03" LOG_CI_END="-0.6218092995739276" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0479235523171828" METHOD="MH" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.23985547462950496" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="1.1753481607460285">
<NAME>Number of wounds completely healed during study</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Algosteril</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.23888600105325566" CI_START="-0.05978152344131535" EFFECT_SIZE="0.08955223880597016" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.07619209507175191" STUDY_ID="STD-Jude-2007" TOTAL_1="67" TOTAL_2="67" VAR="0.005805235351422881" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.91568660010504" CI_START="-18.715686600105037" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.04" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7731123639418842" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="100.0" Z="0.2883061974765956">
<NAME>Percentage ulcer area reduction in 8 weeks</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Algosteril</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.91568660010504" CI_START="-18.715686600105037" EFFECT_SIZE="-2.3999999999999986" ESTIMABLE="YES" MEAN_1="58.1" MEAN_2="60.5" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="339" SD_1="53.1" SD_2="42.7" SE="8.324482862338845" STUDY_ID="STD-Jude-2007" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.2901898924966865" CI_START="-0.05018989249668651" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.12" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-026.05" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.16698388535543654" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="50" UNITS="" WEIGHT="100.0" Z="1.3819603191146361">
<NAME>Ulcer depth reduction in 8 weeks (cm)</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Algosteril</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aquacel</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.2901898924966865" CI_START="-0.05018989249668651" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.25" MEAN_2="0.13" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="340" SD_1="0.49" SD_2="0.37" SE="0.08683317338436963" STUDY_ID="STD-Jude-2007" TOTAL_1="50" TOTAL_2="50" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.14947156274153595" CI_START="-0.17932230901019264" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.014925373134328346" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-026.06" LOG_CI_END="-0.825441424859127" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:52:05 +0000" MODIFIED_BY="Elizabeth Royle" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.8587681713750911" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" WEIGHT="100.0" Z="0.17794245156244443">
<NAME>Number of patients that experienced adverse effects</NAME>
<GROUP_LABEL_1>Aquacel® Ag</GROUP_LABEL_1>
<GROUP_LABEL_2>Algosteril®</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Aquacel</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Algosteril</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14947156274153595" CI_START="-0.17932230901019264" EFFECT_SIZE="-0.014925373134328346" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.08387752896104538" STUDY_ID="STD-Jude-2007" TOTAL_1="67" TOTAL_2="67" VAR="0.007035439864611006" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-027" MODIFIED="2010-02-05 10:52:13 +0000" MODIFIED_BY="Elizabeth Royle" NO="27">
<NAME>SSD cream (1%)/hydrocolloid vs hydrocolloid</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.018044843419758275" CI_START="-0.05508188045679531" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.018518518518518517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-027.01" LOG_CI_END="-1.7436468820849391" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:52:13 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.32086712140046747" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="108" WEIGHT="100.0" Z="0.9926775717343931">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD/HCD</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydrocolloid</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD/HCD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Hydrocolloid</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.018044843419758275" CI_START="-0.05508188045679531" EFFECT_SIZE="-0.018518518518518517" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.018655119291315515" STUDY_ID="STD-Hutchinson-1993" TOTAL_1="58" TOTAL_2="108" VAR="3.480134757732123E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-028" MODIFIED="2010-02-05 10:52:24 +0000" MODIFIED_BY="Elizabeth Royle" NO="28">
<NAME>SSD cream (1%)/hydrocolloid vs non-occlusive paraffin-impregnated gauze</NAME>
<DICH_OUTCOME CHI2="8.301996595436896E-32" CI_END="-0.008355005179258634" CI_START="-0.10275610593185246" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.055555555555555546" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" I2="100.0" I2_Q="0.0" ID="CMP-028.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-02-05 10:52:24 +0000" MODIFIED_BY="Elizabeth Royle" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.021060468349730677" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="58" TOTAL_2="126" WEIGHT="100.0" Z="2.30689869422971">
<NAME>Number of patients that developed wound infection</NAME>
<GROUP_LABEL_1>SSD/HCD</GROUP_LABEL_1>
<GROUP_LABEL_2>Paraffin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours SSD/HCD</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Paraffine</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.008355005179258641" CI_START="-0.10275610593185247" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-09-17 17:48:57 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.02408235597623672" STUDY_ID="STD-Hutchinson-1993" TOTAL_1="58" TOTAL_2="126" VAR="5.799598693661844E-4" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-02-16 13:57:25 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Complete Flowchart marja 15-09-09.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-09-17 17:53:36 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-02-16 13:57:25 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYAAAAUHCAIAAADcXyKbAABT+UlEQVR42u2dvW4jydWGG3DiYAIF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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-02-16 13:57:25 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwQAAAEZCAMAAAAe8hK8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-09-17 17:53:53 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Funnel plot of comparison: 12 SSD/SILVER vs NO SILVER, outcome: 12.1 Number of patients developed wound infection.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-02-16 13:57:44 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-05-08 13:19:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-04 18:35:22 +0000" MODIFIED_BY="[Empty name]">Ovid MEDLINE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-08 13:19:48 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Wound Infection/ <BR/>2 (wound$ adj5 infect$).mp. <BR/>3 or/1-2 <BR/>4 exp Skin Ulcer/ <BR/>5 exp Diabetic Foot/ <BR/>6 exp Pressure Ulcer/ <BR/>7 exp Wounds, Penetrating/ <BR/>8 exp Lacerations/ <BR/>9 exp Burns/ <BR/>10 exp "Bites and Stings"/ <BR/>11 exp Surgical Wound Dehiscence/ <BR/>12 exp Wound Healing/ <BR/>13 (skin ulcer$ or foot ulcer$ or (feet adj5 ulcer$) or diabetic foot or diabetic ulcer$ or leg ulcer$ or varicose ulcer$ or (varicose adj5 wound$) or venous ulcer$ or stasis ulcer$ or arterial ulcer$).mp. <BR/>14 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp. <BR/>15 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp. <BR/>16 surgical wound$.mp. <BR/>17 (gun or guns or gunshot).mp. <BR/>18 (stab or stabs or stabbing).mp. <BR/>19 (burn or burns or scald$).ti,ab. <BR/>20 (bite or bites or biting).mp. <BR/>21 laceration$.mp. <BR/>22 or/4-21 <BR/>23 (infect$ or swell$ or swollen or erythema$ or odour or odor or hypertherm$ or coloni$ or contamin$ or inflamm$ or purulent or exudat$ or devital$).mp. <BR/>24 (positive adj5 culture$).mp. <BR/>25 (pain$ adj5 wound$).mp. <BR/>26 (dirty adj5 wound$).mp. <BR/>27 or/23-26 <BR/>28 exp Silver/ <BR/>29 (silver$ or contreet or acticoat or aquacel or avance or argent$ or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina).mp. (49935)<BR/>30 or/28-29 <BR/>31 22 and 27 and 30 <BR/>32 3 and 30 <BR/>33 or/31-32</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-05-08 13:21:36 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-04 18:35:32 +0000" MODIFIED_BY="[Empty name]">Ovid EMBASE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-08 13:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>1 exp Wound Infection/ <BR/>2 (wound$ adj5 infect$).mp. <BR/>3 or/1-2 <BR/>4 exp Skin Ulcer/ <BR/>5 exp Diabetic Foot/ <BR/>6 exp Decubitus/ <BR/>7 exp Penetrating Trauma/ <BR/>8 exp Laceration/ <BR/>9 exp Burn/ <BR/>10 exp Bite Wound/ <BR/>11 exp Surgical Wound/ <BR/>12 exp Wound Healing/ <BR/>13 (skin ulcer$ or foot ulcer$ or (feet adj5 ulcer$) or diabetic foot or diabetic ulcer$ or leg ulcer$ or varicose ulcer$ or (varicose adj5 wound$) or venous ulcer$ or stasis ulcer$ or arterial ulcer$).mp. <BR/>14 ((ischaemic or ischemic) adj (wound$ or ulcer$)).mp. <BR/>15 (bed sore$ or pressure sore$ or pressure ulcer$ or decubitus ulcer$).mp. <BR/>16 surgical wound$.mp. <BR/>17 (gun or guns or gunshot).mp. <BR/>18 (stab or stabs or stabbing).mp. <BR/>19 (burn or burns or scald$).ti,ab. <BR/>20 (bite or bites or biting).mp. <BR/>21 laceration$.mp. <BR/>22 or/4-21 <BR/>23 (infect$ or swell$ or swollen or erythema$ or odour or odor or hypertherm$ or coloni$ or contamin$ or inflamm$ or purulent or exudat$ or devital$).mp. <BR/>24 (positive adj5 culture$).mp. <BR/>25 (pain$ adj5 wound$).mp. <BR/>26 (dirty adj5 wound$).mp. <BR/>27 or/23-26 <BR/>28 exp Silver/ <BR/>29 (silver$ or contreet or acticoat or aquacel or avance or argent$ or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina).mp. (41820)<BR/>30 or/28-29 <BR/>31 22 and 27 and 30 <BR/>32 3 and 30 <BR/>33 or/31-32</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-05-08 13:25:30 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-05-08 13:23:58 +0100" MODIFIED_BY="[Empty name]">EBSCO CINAHL Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-05-08 13:25:30 +0100" MODIFIED_BY="[Empty name]">
<P>S34 S32 or S33<BR/>S33 S3 and S31<BR/>S32 S22 and S27 and S31<BR/>S31 S28 or S29 or S30<BR/>S30 TI ( silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina ) or AB ( silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina )TI ( silver* or contreet or acticoat or aquacel or avance or argent* or CuNova or urgotul or actisorb or arglaes or efodil or gyrosan or Nova-T or sulphadiazine or sulfadiazine or nanocrystalline or hydron or katomed or katoxyn or simanite or silverlon or sildimac or dimac or silvadene or agsd or ssd or flammazine or flamazine or flammacerium or sulplata or sulfaplata or silvazine or siax or oligorhine or ultradina ) or AB ( silver* or contreet or acticoat or aquacel or avance or argent* or CuNo ...Show Less<BR/>S29 (MH "Silver Sulfadiazine")<BR/>S28 (MH "Silver")<BR/>S27 S23 or S24 or S25 or S26<BR/>S26 TI dirty N5 wound* or AB dirty N5 wound*<BR/>S25 TI pain* N5 wound* or AB pain* N5 wound*<BR/>S24 TI positive N5 culture* or AB positive N5 culture*<BR/>S23 TI ( infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital* ) or AB ( infect* or swell* or swollen or erythema* or odour or odor or hypertherm* or coloni* or contamin* or inflamm* or purulent or exudat* or devital* )<BR/>S22 S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21<BR/>S21 TI surgical wound* or AB surgical wound*<BR/>S20 TI laceration* or AB laceration*<BR/>S19 TI ( bite or bites or biting ) or AB ( bite or bites or biting )<BR/>S18 TI ( burn or burns or scald* ) or AB ( burn or burns or scald* )<BR/>S17 TI ( stab or stabs or stabbing ) or AB ( stab or stabs or stabbing )<BR/>S16 TI ( gun or guns or gunshot ) or AB ( gun or guns or gunshot )<BR/>S15 TI ( bed sore* or pressure sore* or pressure ulcer* or decubitus ) or AB ( bed sore* or pressure sore* or pressure ulcer* or decubitus )<BR/>S14 TI ( ischaemic wound* or ischemic wound* or ischaemic ulcer* or ischemic ulcer* ) or AB ( ischaemic wound* or ischemic wound* or ischaemic ulcer* or ischemic ulcer* )<BR/>S13 TI ( skin ulcer* or foot ulcer* or diabetic foot or diabetic ulcer* or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer* ) or AB ( skin ulcer* or foot ulcer* or diabetic foot or diabetic ulcer* or leg ulcer* or varicose ulcer* or venous ulcer* or stasis ulcer* or arterial ulcer* )<BR/>S12 (MH "Wound Healing+")<BR/>S11 (MH "Surgical Wound Care+")<BR/>S10 (MH "Surgical Wound Dehiscence")<BR/>S9 (MH "Surgical Wound")<BR/>S8 (MH "Bites and Stings+")<BR/>S7 (MH "Burns+")<BR/>S6 (MH "Tears and Lacerations")<BR/>S5 (MH "Wounds, Penetrating+")<BR/>S4 (MH "Skin Ulcer+")<BR/>S3 S1 or S2<BR/>S2 TI wound* N5 infect* or AB wound* N5 infect*<BR/>S1 (MH "Wound Infection+")</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-02-16 13:57:44 +0000" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;I have reformatted this, with particular respect to the headings, which means that &amp;quot;Unclear&amp;quot; now appears as a heading, and it would make sense to insert some kind of statement beneath it to make it look like the other sections. Please could the authors provide a statement for each 'empty' Unclear.&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;&lt;span modified=&quot;2010-02-12 16:49:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;u&gt;Note from Marja: I have added &lt;/u&gt;&lt;/span&gt;&lt;u&gt;&lt;span modified=&quot;2010-02-12 16:50:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;'&lt;/span&gt;&lt;span modified=&quot;2010-02-12 16:50:13 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Insufficient information provided to permit judgement&lt;/span&gt;&lt;span modified=&quot;2010-02-12 16:50:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;'&lt;/span&gt;&lt;span modified=&quot;2010-02-12 16:50:13 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;.&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;4. Incomplete outcome data: &lt;/b&gt;please check that I have understood what the authors intended in the &amp;quot;Yes, low risk of bias&amp;quot; section.&lt;/p&gt;&lt;p&gt;&lt;b&gt;&lt;span modified=&quot;2010-02-12 16:52:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;u&gt;Note from Marja: I&lt;/u&gt;&lt;/span&gt;&lt;u&gt;&lt;span modified=&quot;2010-02-12 16:53:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; agree &lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;&lt;span modified=&quot;2010-02-12 16:53:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;u&gt;May &lt;/u&gt;&lt;/span&gt;&lt;u&gt;&lt;span modified=&quot;2010-02-12 16:54:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;be &lt;/span&gt;&lt;span modified=&quot;2010-02-12 16:53:00 +0100&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;Sally can judge this better&lt;/span&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;4. ITT analysis:&lt;/b&gt; please could the authors rewrite the following sentence in the &amp;quot;No, high risk of bias&amp;quot; section, as it is not clear as it stands: &amp;quot;As-treated&amp;#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation;&amp;quot;&lt;/p&gt;&lt;p&gt;&lt;b&gt;5. Other sources of potential bias:&lt;/b&gt;&lt;/p&gt;&lt;h5&gt;a) &amp;quot;Was the trial free from sponsorship by a manufacturer who potentially had an interest in the results?&lt;/h5&gt;&lt;p&gt;Trials that state they received funding from a manufacturer or company with a direct interest in the intervention, or trialists funded or employed by a manufacturer or company with a direct interest in the intervention.&amp;quot; This sentence is incomplete and needs to state whether such trials will be deemed not to be free from bias or not.&lt;/p&gt;&lt;h5&gt;b) &amp;quot;Were the groups similar at baseline regarding the most important prognostic indicators?&lt;/h5&gt;&lt;p&gt;Groups should be similar at baseline for demographic factors, duration and severity of complaints, e.g. size and duration of ulcer. Alternatively, if there were imbalances at baseline that have been accounted for in the analysis of the study.&amp;quot; Once again the thought needs completion - will these unbalanced trials be considered to be free from bias if imbalances have been accounted for in the analysis? It needs to be clear to the reader.&lt;/p&gt;" NOTES_MODIFIED="2010-02-16 13:57:44 +0000" NOTES_MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-02-05 12:22:50 +0000" MODIFIED_BY="Elizabeth Royle">Risk of bias descriptors for the domains</TITLE>
<APPENDIX_BODY MODIFIED="2010-02-16 13:57:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f4&quot;&gt;&lt;span coll_flag=&quot;f4&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Title&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s0&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Review information&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s3&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s51&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Storm-Versloot, Marja&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s53&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vos, Cornelis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s55&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ubbink, Dirk&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s57&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Vermeulen, Hester&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s1&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contact person&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s6&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dates&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s10&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;What's new&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s11&quot;&gt;&lt;img src=&quot;expand.png&quot;&gt;&lt;/span&gt;History&lt;/h2&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s49&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Abstract&lt;/h1&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;A general thought: &lt;/b&gt;would it be easier to stop referring to &amp;quot;non silver-containing dressings&amp;quot;, and to use the term &amp;quot;non-silver dressings&amp;quot; instead? This would help with the word count in the Abstract, and would generally be easier to use throughout the review. I have not changed this phrase, but maybe the authors should consider it.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Length: &lt;/b&gt;abstract started at 680 words, but only 400 are permitted, so I've had to reduce this substantially. I have managed to reduce it to 388 words, so please check it over and make sure you are happy with my adjustments.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Presentation of results:&lt;/b&gt; please note that a maximum of six results should be included in the abstract, and these should be supported by statistics. The statistics will need to be inserted by the authors, and will easily use up the 12 words in hand, so you may need to shorten the abstract further.&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f211&quot;&gt;&lt;span coll_flag=&quot;f211&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f213&quot;&gt;&lt;span coll_flag=&quot;f213&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f215&quot;&gt;&lt;span coll_flag=&quot;f215&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f217&quot;&gt;&lt;span coll_flag=&quot;f217&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection criteria&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f219&quot;&gt;&lt;span coll_flag=&quot;f219&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f221&quot;&gt;&lt;span coll_flag=&quot;f221&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f223&quot;&gt;&lt;span coll_flag=&quot;f223&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s48&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language summary&lt;/h1&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;This section can contain up to 400 words. I have rewritten it almost entirely, starting with the headline, which needs to provide a &amp;quot;take-home&amp;quot; message. I have not expanded the text much, but have simplified it as far as possible for the non-scientifically literate reader. Please check that you are happy with my changes.&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f206&quot;&gt;&lt;span coll_flag=&quot;f206&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Plain language title&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f208&quot;&gt;&lt;span coll_flag=&quot;f208&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary text&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f236&quot;&gt;&lt;span coll_flag=&quot;f236&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Background&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f238&quot;&gt;&lt;span coll_flag=&quot;f238&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of the condition&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f240&quot;&gt;&lt;span coll_flag=&quot;f240&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of the intervention&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;3rd sentence:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;1. What does SSD stand for? I have assumed that it is sliver sulfadiazine cream, so have put it in brackets after the full name. Please check that this is correct.&lt;/p&gt;&lt;p&gt;2. Is the spelling in this review UK English or US English? If UK English, which I have assumed, then should the compound be &amp;quot;silver sulphadiazine&amp;quot;?&lt;/p&gt;&lt;p&gt;&lt;b&gt;Final sentence&lt;/b&gt; requires a word at the end - including metallic, nanocrystalline or ionic whats? Options? polymeric films and meshes?&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f242&quot;&gt;&lt;span coll_flag=&quot;f242&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;How the intervention might work&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f244&quot;&gt;&lt;span coll_flag=&quot;f244&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Why it is important to do this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f246&quot;&gt;&lt;span coll_flag=&quot;f246&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Objectives&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f248&quot;&gt;&lt;span coll_flag=&quot;f248&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Methods&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f250&quot;&gt;&lt;span coll_flag=&quot;f250&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Criteria for considering studies for this review&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f252&quot;&gt;&lt;span coll_flag=&quot;f252&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f254&quot;&gt;&lt;span coll_flag=&quot;f254&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of participants&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f256&quot;&gt;&lt;span coll_flag=&quot;f256&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of interventions&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;3rd comparison: &lt;/b&gt;&amp;quot;...between alternative topical preparations of silver (e.g. SSD cream). &amp;quot; Would it be possible to insert another example of a silver preparation? For example, (SSD cream vs silver nitrate dressings), or some appropriate comparison.&lt;/p&gt;&lt;p&gt;&lt;b&gt;4th comparison:&lt;/b&gt; includes dose comparisons - should the 3rd comparison also include these?&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f258&quot;&gt;&lt;span coll_flag=&quot;f258&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Types of outcome measures&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f260&quot;&gt;&lt;span coll_flag=&quot;f260&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Primary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f262&quot;&gt;&lt;span coll_flag=&quot;f262&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Secondary outcomes&lt;/h4&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f264&quot;&gt;&lt;span coll_flag=&quot;f264&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Search methods for identification of studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f266&quot;&gt;&lt;span coll_flag=&quot;f266&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Electronic searches&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Dates need to be given in full, i.e. with the month stated in words. The date 6/5/09 would be 6 May 2009 in the UK, but would be 5 June in the USA. I have adjusted it to the former here, as the Abstract states that the Register was consulted in that month.&lt;/p&gt;&lt;p&gt;List of databases searched includes the following two: &amp;quot; Ovide MEDLINE (1950 to April Week 4 2009); Ovid EMBASE (1980 to 2009 Week 18);...&amp;quot; I see that the end dates are presented in different formats - is that normal for these databases, or should they both have the year first or last? Please adjust if required.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f268&quot;&gt;&lt;span coll_flag=&quot;f268&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Searching other resources&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f270&quot;&gt;&lt;span coll_flag=&quot;f270&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data collection and analysis&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f272&quot;&gt;&lt;span coll_flag=&quot;f272&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Selection of studies&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f274&quot;&gt;&lt;span coll_flag=&quot;f274&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data extraction and management&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f276&quot;&gt;&lt;span coll_flag=&quot;f276&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Assessment of risk of bias in included studies&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;4. Re drop-out rate: do the authors actually mean &amp;quot;less than (&amp;lt;) 80%&amp;quot;, rather than the &amp;quot;more than&amp;quot; symbol that is stated? Please check and adjust if necessary.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f288&quot;&gt;&lt;span coll_flag=&quot;f288&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Data synthesis&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f290&quot;&gt;&lt;span coll_flag=&quot;f290&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subgroup analysis and investigation of heterogeneity&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f294&quot;&gt;&lt;span coll_flag=&quot;f294&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f296&quot;&gt;&lt;span coll_flag=&quot;f296&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Description of studies&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;It would be helpful to have a short paragraph summarising the reasons why the 18 excluded trials were excluded. All included and excluded trials should be cited within the text of the review, and this is the best way of doing that for this set of trials.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f298&quot;&gt;&lt;span coll_flag=&quot;f298&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Results of the search&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f300&quot;&gt;&lt;span coll_flag=&quot;f300&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Included studies&lt;/h3&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Please could the authors check the spelling of &amp;quot;hydrofibre/hydrofiber dressing&amp;quot;. It is spelled both ways in this review, and it needs to be consistent, and correct, all through the review (including in the Data and analyses section).&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f304&quot;&gt;&lt;span coll_flag=&quot;f304&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias in included studies&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;The authors are inconsistent in their provision of citations of trials in this section. For ITT analysis the 13 trials that did not conduct ITT analysis are listed, but for Financial support, the 12 trials that reported that they received support are not listed. I do appreciate that the authors do not want to be inserting citation lists of 20+ names every couple of words through the text, and that the information is included in the Characteristics of included studies table, but a balance has to be struck, and it needs to be more consistent.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f306&quot;&gt;&lt;span coll_flag=&quot;f306&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Allocation&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f308&quot;&gt;&lt;span coll_flag=&quot;f308&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Blinding&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f310&quot;&gt;&lt;span coll_flag=&quot;f310&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Incomplete outcome data&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f314&quot;&gt;&lt;span coll_flag=&quot;f314&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Other potential sources of bias&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f316&quot;&gt;&lt;span coll_flag=&quot;f316&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Effects of interventions&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Opening section, final sentence&lt;/b&gt; re assessment of publication bias for SSD/silver vs no silver - what did the funnel plot show? It would be helpful to state in the text whether publication bias was/was not identified.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Primary and Secondary outcome headings:&lt;/b&gt;I have had to reformat the Primary and Secondary outcome headings, as I ran out of options with the formats for headings (1. started at Heading 3; 1.1 was Heading 4; 1.1.1 was Heading 5, leaving Primary outcomes as Heading 6, with nothing to follow for infection rate etc). I have repeated &amp;quot;Primary/Secondary outcome&amp;quot; at each relevant point, and appended the particular outcome, in order to include all the outcomes in the hierachy.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.1 Primary outcome: infection rate, 2nd sentence: &lt;/b&gt;&amp;quot;In this trial...&amp;quot; , but two have just been introduced - which is meant? Please could the authors either be specific, or adjust this sentence.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.2:&lt;/b&gt; I have had to make significant changes to the text for this trial in order to make it clear what was going on. Please check it over to ensure that I have interpreted it correctly, and make adjustments where necessary.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.3:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;a. Primary outcome: infection rate, 3rd sentence:&lt;/b&gt; &amp;quot;There was no difference in the number of patients that developed a wound infection (&lt;b&gt;1/24&lt;/b&gt; SSD...&lt;b&gt;2/24&lt;/b&gt; hydrocolloid dressing)&amp;quot; - that looks like a difference to me! Could the authors rephrase this sentence - maybe they mean &amp;quot;no statistically significant difference&amp;quot;.&lt;/p&gt;&lt;p&gt;&lt;b&gt;b. Primary outcome: wound healing rate, final sentence:&lt;/b&gt; is the value of the calculation to which this sentence refers given in the preceeding paragraph, or not cited in the review? If a figure is stated to be inaccurate, it would be helpful to state the inaccurate value clearly in order to avoid ambiguity between it and the RevMan (MetaView) figures. Please could the authors sort this point out here, and for other instances mentioned in the review where data were analysed inappropriately.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.4:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;a.&lt;/b&gt; &lt;b&gt;Primary outcome: wound healing rate, final sentence:&lt;/b&gt; as for 1.1.3 above - need to give inaccurate figures clearly in order to avoid confusion.&lt;/p&gt;&lt;p&gt;&lt;b&gt;b. Secondary outcome: pain&lt;/b&gt; - if possible the mean pain scores should be given before saying whether or not they were significantly different. If the data are not available, then that should be stated before making statements about statistical significance. Please adjust appropriately.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.5:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;a.Secondary outcome: pain &lt;/b&gt;- this whole paragraph did not read well, so I have rephrased it. Please check that I have interpreted everything correctly.&lt;/p&gt;&lt;p&gt;&lt;b&gt;b. Secondary outcome: costs&lt;/b&gt; - is &amp;quot;per percentage&amp;quot; the same as &amp;quot;per one percent&amp;quot;? I have adjusted it and rephrased parts of the paragraph; please check it over.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.1.7: &lt;/b&gt;The authors keep writing about the &amp;quot;collagenase ointment applied with polymyxin B sulfate/bacitrin group&amp;quot;, which is an unweildy phrase. I have adjusted it to &amp;quot;Santyl group&amp;quot; throughout.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.2.1: &lt;/b&gt;As for 1.1.7 above, I have substituted the trade names for the dressings as these are so much shorter. Please check you are happy with the way I have done this - does the word &amp;quot;dressing&amp;quot; need to be inserted when one of these trade names is used? If so, please insert.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.2.3:&lt;/b&gt; states, &amp;quot;There was no difference in the number of patients who developed an infection (2/19 in the silver nitrate group and 6/18 in the neomycin with bacitracin group)&amp;quot; - do the authors mean that there was no &lt;b&gt;statistically significant &lt;/b&gt;difference? Please adjust appropriately.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.3.1: &lt;/b&gt;see point made for 1.2.3 above.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.3.2: Caruso 2006&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;a. Primary outcome: infection rate&lt;/b&gt; - see point for 1.2.3 above.&lt;/p&gt;&lt;p&gt;&lt;b&gt;b. Primary outcome: wound healing rate: &lt;/b&gt;how can there be three different definitions for healing in one trial? Also, there &lt;b&gt;were&lt;/b&gt; numerical differences between the groups' results, so the authors need to state whether these were statistically significant or not.&lt;/p&gt;&lt;p&gt;&lt;b&gt;c. Secondary outcome: costs &lt;/b&gt;- although $ are cited, the authors need to provide information concerning the type of dollar, e.g. USD etc. Also, &amp;quot;The average cost effectiveness, calculated by dividing the mean total cost of clinical care by the rate of full epithelialisation, was $1968 (95% CI $1483 to $2690) in the SSD group and $1409 (95% CI $1050 to $1858) in the hydrofibre dressing containing ionic silver group.&amp;quot; It strikes me that the reader would benefit from some units here, e.g. $1968/person/cm&lt;sup&gt;2&lt;/sup&gt; etc. Would it be possible to insert something to make this more straightforward?&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.3.4: infection rate &lt;/b&gt;see point for 1.2.3 above.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Summary for burns: &lt;/b&gt;SSD vs silver: point referring to pain says, &amp;quot;Pain was reported in three trials. One trial showed no statistically significant differences (&lt;a link_type=&quot;STUDY&quot; href=&quot;Inman 1984&quot; protected=&quot;true&quot;&gt;Inman 1984&lt;/a&gt;), while two trials showed a statistically significant difference in favour of &lt;b&gt;other silver-containing dressings&lt;/b&gt;&amp;quot; - would it be worth specifying what these other silver-containing dressings were? It's a bit vague as it stands.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1.4.1 infection rate&lt;/b&gt; - as for 1.2.3 above.&lt;/p&gt;&lt;p&gt;&lt;b&gt;2.2.1 Primary outcome: wound healing rate:&lt;/b&gt; states, &amp;quot;Healing was defined as epithelialisation, reduction in area size in mm&lt;sup&gt;2&lt;/sup&gt;, and reduction in wound depth in mm.&amp;quot; It is not clear how one trial could have three different definitions for healing - please could the authors make it clear. Also see point 1.2.3 above.&lt;/p&gt;&lt;p&gt;&lt;b&gt;3.2.2 Adverse effects &lt;/b&gt;- as for 1.2.3 above&lt;/p&gt;&lt;p&gt;&lt;b&gt;4.1.1 infection&lt;/b&gt; - as for 1.2.3&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f318&quot;&gt;&lt;span coll_flag=&quot;f318&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Discussion&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f330&quot;&gt;&lt;span coll_flag=&quot;f330&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Authors' conclusions&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f332&quot;&gt;&lt;span coll_flag=&quot;f332&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for practice&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f334&quot;&gt;&lt;span coll_flag=&quot;f334&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Implications for research&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f225&quot;&gt;&lt;span coll_flag=&quot;f225&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Acknowledgements&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f229&quot;&gt;&lt;span coll_flag=&quot;f229&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Contributions of authors&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f227&quot;&gt;&lt;span coll_flag=&quot;f227&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Declarations of interest&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f231&quot;&gt;&lt;span coll_flag=&quot;f231&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Differences between protocol and review&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot; id=&quot;f233&quot;&gt;&lt;span coll_flag=&quot;f233&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Published notes&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s19&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s20&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of included studies&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Inman 1984, Notes:&lt;/b&gt; states, &amp;quot;Definition of infection: cultures with &amp;gt; 10&lt;sup&gt;5 &lt;/sup&gt;organisms per gram of tissue, and clinical&amp;quot;, which looks like an incomplete statement. Would the authors like to add something here to finish the thought?&lt;/p&gt;&lt;p&gt;&lt;b&gt;Innes 2001, Notes:&lt;/b&gt; states, &amp;quot;Definition of infection: cultures and clinical&amp;quot; - once again something is required to complete the statement - &amp;quot;indications&amp;quot; maybe?&lt;/p&gt;&lt;p&gt;&lt;b&gt;Jacobs 2008, Notes:&lt;/b&gt; as for above two trials.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Also:&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Mashood 2006&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Muangman 2006&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Miller 1990, Interventions:&lt;/b&gt; what is Dimac? Could the authors provide some indication of the nature/basis of its properties?&lt;/p&gt;&lt;p&gt;&lt;b&gt;Wyatt 1990, Risk of bias table&lt;/b&gt; states, &amp;quot;Participants due to protocol violations for the inclusion criteria were appropriate excluded from analysis.&amp;quot; The meaning of this sentence is not clear, could the authors rewrite it, please?&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s475&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Afilalo 1992&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4350&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4350&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4352&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4352&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4354&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4354&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4356&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4356&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4360&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4360&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4358&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4358&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s68&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s759&quot; id=&quot;s759&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f5995&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5995&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s785&quot; id=&quot;s785&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6073&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6073&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s812&quot; id=&quot;s812&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6154&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6154&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s840&quot; id=&quot;s840&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6238&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6238&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s841&quot; id=&quot;s841&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6241&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6241&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s893&quot; id=&quot;s893&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6399&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6399&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s920&quot; id=&quot;s920&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6482&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6482&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s947&quot; id=&quot;s947&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6565&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6565&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s476&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Carneiro 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4363&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4363&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4365&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4365&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4367&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4367&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4369&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4369&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4373&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4373&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4371&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4371&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s74&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s760&quot; id=&quot;s760&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f5998&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f5998&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s786&quot; id=&quot;s786&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6076&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6076&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s813&quot; id=&quot;s813&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6157&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6157&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s842&quot; id=&quot;s842&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6244&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6244&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s843&quot; id=&quot;s843&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6247&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6247&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s894&quot; id=&quot;s894&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6402&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6402&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s921&quot; id=&quot;s921&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6485&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6485&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s948&quot; id=&quot;s948&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6568&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6568&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s477&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Caruso 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4376&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4376&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4378&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4378&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4380&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4380&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4382&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4382&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4386&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4386&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4384&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4384&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s80&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s761&quot; id=&quot;s761&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6001&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6001&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s787&quot; id=&quot;s787&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6079&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6079&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s814&quot; id=&quot;s814&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6160&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6160&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s844&quot; id=&quot;s844&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6250&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6250&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s845&quot; id=&quot;s845&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6253&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6253&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s895&quot; id=&quot;s895&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6405&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6405&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s922&quot; id=&quot;s922&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6488&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6488&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s949&quot; id=&quot;s949&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6571&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6571&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s478&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Gracia 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4389&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4389&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4391&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4391&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4393&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4393&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4395&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4395&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4399&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4399&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4397&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4397&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s86&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s762&quot; id=&quot;s762&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6004&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6004&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s788&quot; id=&quot;s788&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6082&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6082&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s815&quot; id=&quot;s815&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6163&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6163&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s846&quot; id=&quot;s846&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6256&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6256&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s847&quot; id=&quot;s847&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6259&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6259&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s896&quot; id=&quot;s896&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6408&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6408&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s923&quot; id=&quot;s923&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6491&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6491&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s950&quot; id=&quot;s950&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6574&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6574&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s479&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Dire 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4402&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4402&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4404&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4404&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4406&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4406&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4408&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4408&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4412&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4412&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4410&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4410&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s92&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s763&quot; id=&quot;s763&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6007&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6007&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s789&quot; id=&quot;s789&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6085&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6085&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s816&quot; id=&quot;s816&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6166&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6166&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s848&quot; id=&quot;s848&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6262&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6262&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s849&quot; id=&quot;s849&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6265&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6265&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s897&quot; id=&quot;s897&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6411&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6411&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s924&quot; id=&quot;s924&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6494&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6494&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s951&quot; id=&quot;s951&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6577&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6577&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s480&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Fang 1987&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4415&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4415&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4417&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4417&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4419&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4419&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4421&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4421&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4425&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4425&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4423&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4423&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s98&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s764&quot; id=&quot;s764&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6010&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6010&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s790&quot; id=&quot;s790&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6088&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6088&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s817&quot; id=&quot;s817&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6169&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6169&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s850&quot; id=&quot;s850&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6268&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6268&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s851&quot; id=&quot;s851&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6271&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6271&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s898&quot; id=&quot;s898&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6414&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6414&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s925&quot; id=&quot;s925&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6497&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6497&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s952&quot; id=&quot;s952&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6580&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6580&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s481&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gerding 1988&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4428&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4428&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4430&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4430&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4432&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4432&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4434&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4434&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4436&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4436&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s104&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s765&quot; id=&quot;s765&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6013&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6013&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s791&quot; id=&quot;s791&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6091&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6091&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s818&quot; id=&quot;s818&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6172&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6172&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s852&quot; id=&quot;s852&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6274&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6274&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s853&quot; id=&quot;s853&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6277&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6277&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s899&quot; id=&quot;s899&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6417&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6417&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s926&quot; id=&quot;s926&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6500&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6500&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s953&quot; id=&quot;s953&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6583&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6583&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s482&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Gerding 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4441&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4441&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4443&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4443&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4445&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4445&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4447&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4447&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4451&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4451&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4449&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4449&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s110&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s766&quot; id=&quot;s766&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6016&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6016&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s792&quot; id=&quot;s792&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6094&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6094&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s819&quot; id=&quot;s819&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6175&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6175&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s854&quot; id=&quot;s854&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6280&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6280&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s855&quot; id=&quot;s855&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6283&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6283&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s900&quot; id=&quot;s900&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6420&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6420&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s927&quot; id=&quot;s927&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6503&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6503&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s954&quot; id=&quot;s954&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6586&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6586&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s483&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hansbrough 1995&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4454&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4454&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4456&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4456&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4458&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4458&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4460&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4460&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4464&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4464&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4462&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4462&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s116&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s767&quot; id=&quot;s767&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6019&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6019&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s793&quot; id=&quot;s793&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6097&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6097&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s820&quot; id=&quot;s820&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6178&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6178&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s856&quot; id=&quot;s856&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6286&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6286&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s857&quot; id=&quot;s857&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6289&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6289&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s901&quot; id=&quot;s901&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6423&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6423&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s928&quot; id=&quot;s928&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6506&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6506&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s955&quot; id=&quot;s955&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6589&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6589&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s484&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Homann 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4467&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4467&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4469&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4469&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4471&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4471&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4473&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4473&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4477&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4477&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4475&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4475&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s126&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s768&quot; id=&quot;s768&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6022&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6022&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s794&quot; id=&quot;s794&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6100&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6100&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s821&quot; id=&quot;s821&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6181&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6181&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s858&quot; id=&quot;s858&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6292&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6292&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s859&quot; id=&quot;s859&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6295&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6295&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s902&quot; id=&quot;s902&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6426&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6426&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s929&quot; id=&quot;s929&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6509&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6509&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s956&quot; id=&quot;s956&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6592&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6592&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s485&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hutchinson 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4480&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4480&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4482&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4482&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4484&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4484&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4486&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4486&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4490&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4490&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4488&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4488&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s136&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s769&quot; id=&quot;s769&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6025&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6025&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s795&quot; id=&quot;s795&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6103&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6103&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s822&quot; id=&quot;s822&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6184&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6184&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s860&quot; id=&quot;s860&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6298&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6298&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s861&quot; id=&quot;s861&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6301&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6301&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s903&quot; id=&quot;s903&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6429&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6429&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s930&quot; id=&quot;s930&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6512&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6512&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s957&quot; id=&quot;s957&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6595&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6595&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s486&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Inman 1984&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4493&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4493&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4495&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4495&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4497&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4497&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4499&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4499&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4503&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4503&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4501&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4501&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s142&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s770&quot; id=&quot;s770&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6028&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6028&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s796&quot; id=&quot;s796&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6106&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6106&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s823&quot; id=&quot;s823&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6187&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6187&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s862&quot; id=&quot;s862&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6304&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6304&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s863&quot; id=&quot;s863&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6307&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6307&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s904&quot; id=&quot;s904&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6432&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6432&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s931&quot; id=&quot;s931&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6515&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6515&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s958&quot; id=&quot;s958&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6598&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6598&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s487&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Innes 2001&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4506&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4506&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4508&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4508&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4510&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4510&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4512&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4512&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4516&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4516&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4514&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4514&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s148&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s771&quot; id=&quot;s771&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6031&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6031&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s797&quot; id=&quot;s797&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6109&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6109&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s824&quot; id=&quot;s824&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6190&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6190&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s864&quot; id=&quot;s864&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6310&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6310&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s865&quot; id=&quot;s865&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6313&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6313&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s905&quot; id=&quot;s905&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6435&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6435&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s932&quot; id=&quot;s932&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6518&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6518&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s959&quot; id=&quot;s959&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s488&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jacobs 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4519&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4519&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4521&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4521&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4523&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4523&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4525&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4525&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4529&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4529&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4527&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4527&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s154&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s772&quot; id=&quot;s772&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6034&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6034&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s798&quot; id=&quot;s798&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6112&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6112&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s825&quot; id=&quot;s825&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6193&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6193&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s866&quot; id=&quot;s866&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6316&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6316&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s867&quot; id=&quot;s867&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6319&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6319&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s906&quot; id=&quot;s906&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6438&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6438&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s933&quot; id=&quot;s933&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6521&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6521&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s960&quot; id=&quot;s960&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6604&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6604&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s489&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jude 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4532&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4532&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4534&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4534&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4536&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4536&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4538&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4538&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4542&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4542&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4540&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4540&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s164&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s773&quot; id=&quot;s773&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6037&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6037&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s799&quot; id=&quot;s799&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6115&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6115&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s826&quot; id=&quot;s826&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6196&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6196&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s868&quot; id=&quot;s868&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6322&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6322&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s869&quot; id=&quot;s869&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6325&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6325&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s907&quot; id=&quot;s907&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6441&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6441&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s934&quot; id=&quot;s934&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6524&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6524&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s961&quot; id=&quot;s961&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6607&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6607&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s490&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jurczak 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4545&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4545&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4547&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4547&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4549&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4549&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4551&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4551&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4555&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4555&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4553&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4553&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s172&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s774&quot; id=&quot;s774&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6040&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6040&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s800&quot; id=&quot;s800&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6118&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6118&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s827&quot; id=&quot;s827&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6199&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6199&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s870&quot; id=&quot;s870&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6328&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6328&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s871&quot; id=&quot;s871&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6331&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6331&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s908&quot; id=&quot;s908&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6444&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6444&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s935&quot; id=&quot;s935&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6527&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6527&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s962&quot; id=&quot;s962&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6610&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6610&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s491&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Livingston 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4558&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4558&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4560&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4560&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4562&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4562&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4564&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4564&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4568&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4568&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4566&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4566&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s178&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s775&quot; id=&quot;s775&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6043&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6043&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s801&quot; id=&quot;s801&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6121&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6121&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s828&quot; id=&quot;s828&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6202&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6202&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s872&quot; id=&quot;s872&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6334&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6334&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s873&quot; id=&quot;s873&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6337&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6337&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s909&quot; id=&quot;s909&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6447&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6447&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s936&quot; id=&quot;s936&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6530&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6530&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s963&quot; id=&quot;s963&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6613&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6613&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s492&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Mashhood 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4571&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4571&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4573&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4573&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4575&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4575&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4577&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4577&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4581&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4581&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4579&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4579&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s184&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s776&quot; id=&quot;s776&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6046&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6046&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s802&quot; id=&quot;s802&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6124&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6124&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s829&quot; id=&quot;s829&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6205&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6205&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s874&quot; id=&quot;s874&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6340&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6340&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s875&quot; id=&quot;s875&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6343&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6343&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s910&quot; id=&quot;s910&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6450&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6450&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s937&quot; id=&quot;s937&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6533&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6533&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s964&quot; id=&quot;s964&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s493&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Miller 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4584&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4584&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4586&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4586&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4588&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4588&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4590&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4590&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4594&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4594&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4592&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4592&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s190&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s777&quot; id=&quot;s777&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6049&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6049&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s803&quot; id=&quot;s803&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6127&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6127&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s830&quot; id=&quot;s830&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6208&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6208&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s876&quot; id=&quot;s876&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6346&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6346&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s877&quot; id=&quot;s877&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6349&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6349&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s911&quot; id=&quot;s911&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6453&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6453&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s938&quot; id=&quot;s938&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6536&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6536&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s965&quot; id=&quot;s965&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6619&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6619&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s494&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Muangman 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4597&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4597&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4599&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4599&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4601&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4601&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4603&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4603&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4607&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4607&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4605&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4605&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s196&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s778&quot; id=&quot;s778&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6052&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6052&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s804&quot; id=&quot;s804&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6130&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6130&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s831&quot; id=&quot;s831&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6211&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6211&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s878&quot; id=&quot;s878&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6352&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6352&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s879&quot; id=&quot;s879&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6355&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6355&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s912&quot; id=&quot;s912&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6456&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6456&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s939&quot; id=&quot;s939&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6539&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6539&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s966&quot; id=&quot;s966&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6622&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6622&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s495&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Noordenbos 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4610&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4610&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4612&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4612&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4614&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4614&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4616&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4616&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4620&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4620&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4618&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4618&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s202&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s779&quot; id=&quot;s779&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6055&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6055&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s805&quot; id=&quot;s805&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6133&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6133&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s832&quot; id=&quot;s832&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6214&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6214&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s880&quot; id=&quot;s880&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6358&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6358&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s881&quot; id=&quot;s881&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6361&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6361&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s913&quot; id=&quot;s913&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6459&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6459&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s940&quot; id=&quot;s940&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6542&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6542&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s967&quot; id=&quot;s967&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s496&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Soroff 1994&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4623&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4623&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4625&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4625&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4627&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4627&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4629&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4629&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4633&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4633&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4631&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4631&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s208&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s780&quot; id=&quot;s780&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6058&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6058&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s806&quot; id=&quot;s806&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6136&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6136&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s833&quot; id=&quot;s833&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6217&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6217&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s882&quot; id=&quot;s882&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6364&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6364&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s883&quot; id=&quot;s883&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6367&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6367&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s914&quot; id=&quot;s914&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6462&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6462&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s941&quot; id=&quot;s941&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6545&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6545&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s968&quot; id=&quot;s968&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6628&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6628&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s497&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subrahmanyam 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4636&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4636&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4638&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4638&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4640&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4640&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4642&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4642&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4646&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4646&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4644&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4644&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s214&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s781&quot; id=&quot;s781&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6061&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6061&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s807&quot; id=&quot;s807&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6139&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6139&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s834&quot; id=&quot;s834&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6220&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6220&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s884&quot; id=&quot;s884&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6370&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6370&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s885&quot; id=&quot;s885&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6373&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6373&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s915&quot; id=&quot;s915&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6465&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6465&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s942&quot; id=&quot;s942&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6548&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6548&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s969&quot; id=&quot;s969&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6631&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6631&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s498&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Tredget 1998&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4649&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4649&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4651&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4651&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4653&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4653&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4655&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4655&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4659&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4659&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4657&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4657&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s220&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s782&quot; id=&quot;s782&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6064&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6064&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s808&quot; id=&quot;s808&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6142&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6142&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s835&quot; id=&quot;s835&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6223&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6223&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s886&quot; id=&quot;s886&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6376&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6376&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s887&quot; id=&quot;s887&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6379&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6379&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s916&quot; id=&quot;s916&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6468&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6468&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s943&quot; id=&quot;s943&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6551&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6551&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s970&quot; id=&quot;s970&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6634&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6634&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s499&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wunderlich 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4662&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4662&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4664&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4664&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4666&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4666&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4668&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4668&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4672&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4672&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4670&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4670&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s226&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s783&quot; id=&quot;s783&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6067&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6067&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s809&quot; id=&quot;s809&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6145&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6145&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s836&quot; id=&quot;s836&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6226&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6226&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s888&quot; id=&quot;s888&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6382&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6382&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s889&quot; id=&quot;s889&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6385&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6385&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s917&quot; id=&quot;s917&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6471&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6471&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s944&quot; id=&quot;s944&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6554&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6554&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s971&quot; id=&quot;s971&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6637&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6637&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s500&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wyatt 1990&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;7&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4675&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4675&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4677&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4677&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4679&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4679&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4681&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4681&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Miscellaneous quality issues&lt;/th&gt;&lt;td doc_fld_id=&quot;f4685&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4685&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4683&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4683&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h4 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s232&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Risk of bias table&lt;/h4&gt;&lt;table cols=&quot;3&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Item&lt;/th&gt;&lt;th class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s784&quot; id=&quot;s784&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f161&quot;&gt;Adequate sequence generation?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6070&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6070&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s810&quot; id=&quot;s810&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f166&quot;&gt;Allocation concealment?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6148&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6148&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s837&quot; id=&quot;s837&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f171&quot;&gt;Blinding? (All outcomes)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6229&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6229&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s890&quot; id=&quot;s890&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (Drop out rate described and acceptable (&amp;gt; 80%))&lt;/td&gt;&lt;td doc_fld_id=&quot;f6388&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6388&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s891&quot; id=&quot;s891&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f176&quot;&gt;Incomplete outcome data addressed? (ITT analysis)&lt;/td&gt;&lt;td doc_fld_id=&quot;f6391&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6391&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s918&quot; id=&quot;s918&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6398&quot;&gt;Financial support for trial or trialists?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6474&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6474&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s945&quot; id=&quot;s945&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6481&quot;&gt;Groups similar at baseline?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6557&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6557&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr doc_sec_id=&quot;s972&quot; id=&quot;s972&quot;&gt;&lt;td class=&quot;fixedcell&quot; readonly=&quot;true&quot; tooltip_fld=&quot;f6564&quot;&gt;Co interventions avoided or similar?&lt;/td&gt;&lt;td doc_fld_id=&quot;f6640&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f6640&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s21&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of excluded studies&lt;/h2&gt;&lt;p&gt;&lt;b&gt;Copy-editor's notes&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Terrill 1991: &lt;/b&gt;What are &amp;quot;bags&amp;quot;? Please provide a little more in the way of explanation here.&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s501&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;De Boer 1981&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4688&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4688&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s502&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Ganai 2002&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4691&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4691&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s503&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Guilbaud 1993&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4694&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4694&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s504&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hadjiiski 1999&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4697&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4697&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s505&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Huang 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4700&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4700&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s506&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Jorgensen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4703&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4703&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s507&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Lanzara 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4706&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4706&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s508&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Molnar 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4709&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4709&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s509&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Munster 1980&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4712&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4712&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s510&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;M&amp;#252;nter 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4715&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4715&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s511&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Planinsek 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4718&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4718&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s512&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Riesinger 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4721&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4721&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s513&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Silver 2007&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4724&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4724&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s514&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Stair 1986&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4727&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4727&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s515&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Subrahmanyam 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4730&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4730&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s516&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Terrill 1991&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4733&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4733&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s517&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Verd&amp;#250; 2004&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4736&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4736&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s518&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Yue Seng 2005&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;2&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Reason for exclusion&lt;/th&gt;&lt;td doc_fld_id=&quot;f4739&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4739&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s22&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of studies awaiting classification&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s519&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Chen 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4742&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4742&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4744&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4744&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4746&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4746&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4748&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4748&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4750&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4750&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s520&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Hirsch 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4753&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4753&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4755&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4755&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4757&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4757&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4759&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4759&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4761&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4761&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s521&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Li 2006&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4764&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4764&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4766&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4766&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4768&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4768&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4770&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4770&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4772&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4772&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s522&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Wang 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;6&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4775&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4775&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4777&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4777&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4779&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4779&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4781&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4781&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4783&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4783&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h2 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s23&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Characteristics of ongoing studies&lt;/h2&gt;&lt;p&gt;&lt;/p&gt;&lt;h3 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s523&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Serena 2008&lt;/h3&gt;&lt;p&gt;&lt;/p&gt;&lt;table cols=&quot;2&quot; width=&quot;100%&quot; rows=&quot;9&quot;&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Study name&lt;/th&gt;&lt;td doc_fld_id=&quot;f4786&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4786&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Methods&lt;/th&gt;&lt;td doc_fld_id=&quot;f4788&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4788&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Participants&lt;/th&gt;&lt;td doc_fld_id=&quot;f4790&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4790&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Interventions&lt;/th&gt;&lt;td doc_fld_id=&quot;f4792&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4792&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Outcomes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4794&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4794&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Starting date&lt;/th&gt;&lt;td doc_fld_id=&quot;f4796&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4796&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Contact information&lt;/th&gt;&lt;td doc_fld_id=&quot;f4798&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4798&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th width=&quot;25%&quot; class=&quot;fixedcell&quot; readonly=&quot;true&quot;&gt;Notes&lt;/th&gt;&lt;td doc_fld_id=&quot;f4800&quot; class=&quot;note&quot; doc_fld_cnt=&quot;f4800&quot;&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s31&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Summary of findings tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;&lt;h1 class=&quot;fixedtext&quot; readonly=&quot;true&quot;&gt;&lt;span coll_flag=&quot;s32&quot;&gt;&lt;img src=&quot;collapse.png&quot;&gt;&lt;/span&gt;Additional tables&lt;/h1&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-02-16 13:57:44 +0000" NOTES_MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Criteria for judgements</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Was the allocation sequence randomly generated?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Yes, low risk of bias</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">A random (unpredictable) assignment sequence.</HEADING>
<P>Examples of adequate methods of sequence generation include computer-generated random sequence, pre-ordered sealed envelopes, telephone call to a central office, coin toss (for studies with two groups), rolling a dice (for studies with two or more groups), and drawing of balls of different colours.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">No, high risk of bias</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Quasi-randomised approach</HEADING>
<P>Examples of inadequate methods include: alternation, birth date, social insurance/security number, date on which invited to participate in the study, and hospital registration number.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Non-random approaches</HEADING>
<P>Allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Insufficient information about the sequence generation process provided to permit judgement.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Was the treatment allocation adequately concealed?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Yes, low risk of bias</HEADING>
<P>Assignment must be generated independently by a person who is not responsible for determining the eligibility of the participants. This person has no information about the people included in the trial and has no influence on either the assignment sequence, or the decision about whether a person is eligible to enter the trial. Examples of adequate methods of allocation concealment include: central allocation - including telephone, web-based, and pharmacy-controlled randomization; sequentially-numbered drug containers of identical appearance; and sequentially-numbered, opaque, sealed envelopes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">No, high risk of bias</HEADING>
<P>Examples of inadequate methods of allocation concealment include: alternate medical record numbers, unsealed envelopes; dates of birth; case record numbers; alternation or rotation; an open list of random numbers; or any information in the study that indicates that investigators or participants could influence the intervention group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Unclear</HEADING>
<P>Randomisation stated but no available information on method of allocation used.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Blinding: was knowledge of the allocated interventions adequately prevented during the study?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Was the participant blinded to the intervention?</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Yes, low risk of bias</HEADING>
<P>The treatment and control groups were indistinguishable for the participants, or, if the participant was described as blinded, the method of blinding was described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">No, high risk of bias</HEADING>
<P>Blinding of study participants attempted, but likely that the blinding could have been broken; participants not blinded, and the nonblinding of others likely to introduce bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Unclear</HEADING>
<P>Insufficient information provided to permit judgement.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Was the care provider blinded to the intervention?</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Yes, low risk of bias</HEADING>
<P>The treatment and control groups were indistinguishable for the care/treatment providers, or, if the care provider was described as blinded, the method of blinding was described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">No, high risk of bias</HEADING>
<P>Blinding of care/treatment providers attempted, but likely that the blinding could have been broken; care/treatment providers not blinded, and the nonblinding of others likely to introduce bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Unclear</HEADING>
<P>Insufficient information provided to permit judgement</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Was the outcome assessor blinded to the intervention?</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Yes, low risk of bias</HEADING>
<P>Adequacy of blinding should be assessed for the primary outcomes. The outcome assessor was described as blinded and the method of blinding was described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">No, high risk of bias</HEADING>
<P>No blinding or incomplete blinding, and the outcome or outcome measurements were likely to be influenced by lack of blinding</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Unclear</HEADING>
<P>Insufficient information provided to permit judgement</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Were incomplete outcome data adequately addressed?</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Was the drop-out rate described and acceptable?</HEADING>
<P>The number of participants who were included in the study but did not complete the observation period or were not included in the analysis must be described and reasons given for their non-completion.</P>
<SUBSECTION>
<HEADING LEVEL="6">Yes, low risk of bias</HEADING>
<P>If the percentage of withdrawals and drop-outs does not exceed 20% for short-term follow-up and 30% for long-term follow-up, and does not lead to substantial bias (NB these percentages are arbitrary, i.e. not supported by literature); no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; and missing data have been imputed using appropriate methods.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">No, high risk of bias</HEADING>
<P>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Unclear</HEADING>
<P>Insufficient information provided to permit judgement</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Were all randomised participants analysed in the group to which they were allocated? (ITT analysis)</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Yes, low risk of bias</HEADING>
<P>Specifically reported by authors that intention-to-treat (ITT) analysis was undertaken and this was confirmed on study assessment, or not stated, but evident from study assessment that all randomised participants were reported/analysed in the group to which they were allocated for the most important time point of outcome measurement (minus missing values) irrespective of non-compliance and co-interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">No, high risk of bias</HEADING>
<P>Lack of ITT confirmed on study assessment (patients who were randomised were not included in the analysis because they did not receive the study intervention, withdrew from the study or violated the protocol) regardless of whether ITT reported or not.<BR/>&#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; or potentially inappropriate application of simple imputation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Unclear</HEADING>
<P>Described as ITT analysis, but unable to confirm on study assessment, or not reported, and unable to confirm by study assessment.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Other sources of potential bias:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Was the trial free from sponsorship by a manufacturer who potentially had an interest in the results?</HEADING>
<P>Trials that state they received funding from a manufacturer or company with a direct interest in the intervention, or trialists funded or employed by a manufacturer or company with a direct interest in the intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Were the groups similar at baseline regarding the most important prognostic indicators?</HEADING>
<P>Groups should be similar at baseline for demographic factors, duration and severity of complaints, e.g. size and duration of ulcer. Alternatively, if there were imbalances at baseline that have been accounted for in the analysis of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Were co-interventions avoided or similar?</HEADING>
<P>There were no co-interventions or there were co-interventions but they were similar between the treatment and control groups.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>